PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
26027838-3	2015	In this study, we evaluated the skin barrier function of hairless mice with colon carcinoma that was induced by azoxymethane (AOM) and dextran sodium sulfate (DSS).	Azoxymethane	112-124	lysine demethylase and nuclear receptor corepressor	Mus musculus	57-65
25277138-0	2014	Activation of intestinal human pregnane X receptor protects against azoxymethane/dextran sulfate sodium-induced colon cancer.	Azoxymethane	68-80	nuclear receptor subfamily 1 group I member 2	Homo sapiens	31-50
26397238-5	2015	QD655-VEGFR2 was applied to the colon of azoxymethane (AOM-) or saline-treated control mice in vivo via lavage.	Azoxymethane	41-53	kinase insert domain protein receptor	Mus musculus	6-12
26397238-5	2015	QD655-VEGFR2 was applied to the colon of azoxymethane (AOM-) or saline-treated control mice in vivo via lavage.	Azoxymethane	55-58	kinase insert domain protein receptor	Mus musculus	6-12
25218594-0	2014	Aldose reductase inhibition suppresses azoxymethane-induced colonic premalignant lesions in C57BL/KsJ-db/db mice.	Azoxymethane	39-51	aldo-keto reductase family 1, member B3 (aldose reductase)	Mus musculus	0-16
25218594-2	2014	In the present study, we examined the effects of polyol pathway enzyme aldose reductase (AR) inhibitor, fidarestat, on the development of azoxymethane (AOM)-induced colonic premalignant lesions in C57BL/KsJ-db/db obese mice.	Azoxymethane	138-150	aldo-keto reductase family 1, member B3 (aldose reductase)	Mus musculus	89-91
25216325-4	2014	METHODS: In vivo molecular imaging was performed to examine colon tumorigenesis in Lgr5-EGFP mice treated with azoxymethane and dextran sodium sulfate.	Azoxymethane	111-123	leucine rich repeat containing G protein coupled receptor 5	Mus musculus	83-87
25085247-5	2014	Similarly, Hur(IKO) mice subjected to an inflammatory colon carcinogenesis protocol [azoxymethane and dextran sodium sulfate (AOM-DSS) administration] exhibited a two-fold decrease in tumor burden.	Azoxymethane	85-97	ELAV (embryonic lethal, abnormal vision)-like 1 (Hu antigen R)	Mus musculus	11-14
25155760-4	2014	METHODS: FASN expression (IHC) in the colonic epithelium from azoxymethane and polyposis in rat colon (Pirc) models of colorectal cancer was studied.	Azoxymethane	62-74	fatty acid synthase	Rattus norvegicus	9-13
25155760-6	2014	RESULTS: FASN expression progressively increased from premalignant to malignant stage in the azoxymethane model (1.9- to 2.5-fold; P < 0.0001) and was also higher in the adenomas compared with adjacent uninvolved mucosa (1.8- to 3.4-fold; P < 0.001) in the Pirc model.	Azoxymethane	93-105	fatty acid synthase	Homo sapiens	9-13
25212605-1	2014	PURPOSE: We previously showed that EGF receptor (EGFR) promotes tumorigenesis in the azoxymethane/dextran sulfate sodium (AOM/DSS) model, whereas vitamin D suppresses tumorigenesis.	Azoxymethane	85-97	epidermal growth factor receptor	Mus musculus	35-47
25212605-1	2014	PURPOSE: We previously showed that EGF receptor (EGFR) promotes tumorigenesis in the azoxymethane/dextran sulfate sodium (AOM/DSS) model, whereas vitamin D suppresses tumorigenesis.	Azoxymethane	85-97	epidermal growth factor receptor	Mus musculus	49-53
25212605-1	2014	PURPOSE: We previously showed that EGF receptor (EGFR) promotes tumorigenesis in the azoxymethane/dextran sulfate sodium (AOM/DSS) model, whereas vitamin D suppresses tumorigenesis.	Azoxymethane	122-125	epidermal growth factor receptor	Mus musculus	35-47
25212605-1	2014	PURPOSE: We previously showed that EGF receptor (EGFR) promotes tumorigenesis in the azoxymethane/dextran sulfate sodium (AOM/DSS) model, whereas vitamin D suppresses tumorigenesis.	Azoxymethane	122-125	epidermal growth factor receptor	Mus musculus	49-53
24532706-0	2014	Luteolin inhibits matrix metalloproteinase 9 and 2 in azoxymethane-induced colon carcinogenesis.	Azoxymethane	54-66	matrix metallopeptidase 9	Mus musculus	18-50
24532706-1	2014	The present investigation deals with the antimetastatic role of luteolin (LUT) by inhibiting matrix metalloproteinase (MMP)-9 and -2 in azoxymethane (AOM)-induced colon carcinogenesis in Balb/C mice.	Azoxymethane	136-148	matrix metallopeptidase 9	Mus musculus	93-132
24532706-1	2014	The present investigation deals with the antimetastatic role of luteolin (LUT) by inhibiting matrix metalloproteinase (MMP)-9 and -2 in azoxymethane (AOM)-induced colon carcinogenesis in Balb/C mice.	Azoxymethane	150-153	matrix metallopeptidase 9	Mus musculus	93-132
25104409-3	2014	The resulting QD655-VEGFR2 contrast agent was applied in vivo to the colon of azoxymethane (AOM) treated mice via lavage and allowed to incubate.	Azoxymethane	78-90	kinase insert domain protein receptor	Mus musculus	20-26
24827115-3	2014	Specifically, decoloring of the azoxymethane-treated rat colon after scoring classical ACF (cACF) resulted in visualization of a subset of aberrant crypts that remained densely stained.	Azoxymethane	32-44	ATP-dependent chromatin assembly factor large subunit	Drosophila melanogaster	87-90
24710407-3	2014	Remarkably, imposing a modest 50% reduction in circulating prothrombin in fII+/- mice, a level that carries no significant bleeding risk, dramatically decreased adenoma formation following an azoxymethane/dextran sodium sulfate challenge.	Azoxymethane	192-204	coagulation factor II	Mus musculus	74-77
26484096-8	2014	Furthermore, we induced inflammation-driven colon tumors in Lgr5-EGFP-IRES-Cre-ERT2 mice via administration of azoxymethane and dextrane sodium sulfate.	Azoxymethane	111-123	leucine rich repeat containing G protein coupled receptor 5	Mus musculus	60-64
26484096-8	2014	Furthermore, we induced inflammation-driven colon tumors in Lgr5-EGFP-IRES-Cre-ERT2 mice via administration of azoxymethane and dextrane sodium sulfate.	Azoxymethane	111-123	mitogen-activated protein kinase 3	Mus musculus	79-83
24867956-4	2014	In a murine model of colorectal cancer induced by azoxymethane, NLRX1-/- mice developed fewer tumors than wild type mice.	Azoxymethane	50-62	NLR family member X1	Mus musculus	64-69
24867956-5	2014	In contrast, in a colitis-associated cancer model combining azoxymethane and dextran sulfate sodium, NLRX1-/- mice developed a more severe pathology likely due to the increased sensitivity to dextran sulfate sodium colitis.	Azoxymethane	60-72	NLR family member X1	Mus musculus	101-106
24694019-9	2014	RESULTS: Azoxymethane-treated Chrm3-/- mice had fewer and smaller colon tumors than wild-type mice.	Azoxymethane	9-21	cholinergic receptor, muscarinic 3, cardiac	Mus musculus	30-35
24686242-7	2014	Moreover, in the azoxymethane-dextran sodium sulfate model, CEA-specific CAR Tregs significantly decreased the subsequent colorectal tumor burden.	Azoxymethane	17-29	carcinoembryonic antigen gene family	Mus musculus	60-63
24366884-4	2014	Herein, we demonstrated that colonic epithelial cells (CEC) were a major cellular source of GM-CSF and its production was significantly augmented when CAC model was established by administration of azoxymethane and dextran sulfate sodium.	Azoxymethane	198-210	colony stimulating factor 2	Homo sapiens	92-98
24282287-4	2014	Additionally, we exposed Lgr5-EGFP-IRES-CreERT2 mice to azoxymethane/dextrane sodium sulfate (AOM/DSS), which induces inflammation-driven colon tumors.	Azoxymethane	56-68	leucine rich repeat containing G protein coupled receptor 5	Mus musculus	25-29
24282287-4	2014	Additionally, we exposed Lgr5-EGFP-IRES-CreERT2 mice to azoxymethane/dextrane sodium sulfate (AOM/DSS), which induces inflammation-driven colon tumors.	Azoxymethane	94-97	leucine rich repeat containing G protein coupled receptor 5	Mus musculus	25-29
24024667-0	2014	Luteolin, a bioflavonoid inhibits Azoxymethane-induced colorectal cancer through activation of Nrf2 signaling.	Azoxymethane	34-46	nuclear factor, erythroid derived 2, like 2	Mus musculus	95-99
24377586-7	2014	Mitochondrial enzymes such as isocitrate dehydrogenase (ICDH), alpha-keto dehydrogenase (alpha-KDH), succinate dehydrogenase (SDH) and the activities of respiratory chain enzymes NADH dehydrogenase and cytochrome c oxidase were found to be elevated in AOM-treated animals.	Azoxymethane	252-255	aminoadipate-semialdehyde synthase	Mus musculus	126-129
25036966-0	2014	Bovine milk-derived alpha-lactalbumin inhibits colon inflammation and carcinogenesis in azoxymethane and dextran sodium sulfate-treated mice.	Azoxymethane	88-100	lactalbumin, alpha	Mus musculus	20-37
24140386-0	2013	Repair and removal of azoxymethane-induced O6-methylguanine in rat colon by O6-methylguanine DNA methyltransferase and apoptosis.	Azoxymethane	22-34	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	76-114
24140386-4	2013	In rats given AOM (10 mg/kg), the formation of O(6)meG occurs within 2 h of exposure, accompanied by rapid depletion of MGMT activity and followed by the induction of an acute apoptotic response that peaks at 6-8 h. MGMT repair and apoptosis are dependent on AOM dose and O(6)meG load.	Azoxymethane	14-17	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	120-124
24140386-4	2013	In rats given AOM (10 mg/kg), the formation of O(6)meG occurs within 2 h of exposure, accompanied by rapid depletion of MGMT activity and followed by the induction of an acute apoptotic response that peaks at 6-8 h. MGMT repair and apoptosis are dependent on AOM dose and O(6)meG load.	Azoxymethane	14-17	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	216-220
24140386-4	2013	In rats given AOM (10 mg/kg), the formation of O(6)meG occurs within 2 h of exposure, accompanied by rapid depletion of MGMT activity and followed by the induction of an acute apoptotic response that peaks at 6-8 h. MGMT repair and apoptosis are dependent on AOM dose and O(6)meG load.	Azoxymethane	259-262	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	216-220
24140386-6	2013	AOM, 10 mg/kg, overwhelms MGMT repair for about 96 h and renewed MGMT activity is only observed once O(6)meG is no longer detectable.	Azoxymethane	0-3	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	26-30
24140386-6	2013	AOM, 10 mg/kg, overwhelms MGMT repair for about 96 h and renewed MGMT activity is only observed once O(6)meG is no longer detectable.	Azoxymethane	0-3	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	65-69
24025712-3	2013	EXPERIMENTAL DESIGN: The azoxymethane/dextran sodium sulfate mouse model of sporadic colon cancer represents an adequate source for the isolation of CAFs and normal fibroblasts.	Azoxymethane	25-37	T-box transcription factor 1	Homo sapiens	149-153
24617038-0	2013	Inhibition of beta-catenin and KRAS expressions by Piper betle in azoxymethane-induced colon cancer of male Fischer 344 rats.	Azoxymethane	66-78	catenin beta 1	Rattus norvegicus	14-26
24617038-0	2013	Inhibition of beta-catenin and KRAS expressions by Piper betle in azoxymethane-induced colon cancer of male Fischer 344 rats.	Azoxymethane	66-78	KRAS proto-oncogene, GTPase	Rattus norvegicus	31-35
24251703-4	2013	Other studies have investigated the effect of adiponectin under the normal and high-fat diet conditions in a mouse model of azoxymethane-induced colon cancer.	Azoxymethane	124-136	adiponectin, C1Q and collagen domain containing	Mus musculus	46-57
23784800-6	2013	Furthermore, dietary P40 at 10-30% significantly suppressed azoxymethane-induced formation of aberrant crypt foci in the colons of CF-1 mice in conjunction with, at least in part, a lesser proliferative PCNA and a greater apoptotic caspase-3 expression in the colon mucosal epithelial cells.	Azoxymethane	60-72	interleukin 9	Mus musculus	21-24
23784800-6	2013	Furthermore, dietary P40 at 10-30% significantly suppressed azoxymethane-induced formation of aberrant crypt foci in the colons of CF-1 mice in conjunction with, at least in part, a lesser proliferative PCNA and a greater apoptotic caspase-3 expression in the colon mucosal epithelial cells.	Azoxymethane	60-72	caspase 3	Mus musculus	232-241
23784081-2	2013	Azoxymethane-induced aberrant crypt focus (ACF; 6 weeks) and tumours (32 weeks) were analysed in wild-type (WT) BALB/c mice, as well as in IL-4Ralpha (-) (/-) , IL-13 (-/-) and "double-knockout" (DKO) animals.	Azoxymethane	0-12	interleukin 13	Mus musculus	161-166
23027128-2	2013	Disruption of Ptk6 decreases azoxymethane-induced colon tumorigenesis in mice by preventing signal transducer and activator of transcription 3 activation.	Azoxymethane	29-41	PTK6 protein tyrosine kinase 6	Mus musculus	14-18
23027128-2	2013	Disruption of Ptk6 decreases azoxymethane-induced colon tumorigenesis in mice by preventing signal transducer and activator of transcription 3 activation.	Azoxymethane	29-41	signal transducer and activator of transcription 3	Mus musculus	92-142
23977205-0	2013	Deletion of glutathione peroxidase-2 inhibits azoxymethane-induced colon cancer development.	Azoxymethane	46-58	glutathione peroxidase 2	Mus musculus	12-36
23824743-5	2013	Isorhamnetin inhibited AOM/DSS-induced oncogenic c-Src activation and beta-catenin nuclear translocation, while promoting the expression of C-terminal Src kinase (CSK), a negative regulator of Src family of tyrosine kinases.	Azoxymethane	23-26	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	49-54
23824743-5	2013	Isorhamnetin inhibited AOM/DSS-induced oncogenic c-Src activation and beta-catenin nuclear translocation, while promoting the expression of C-terminal Src kinase (CSK), a negative regulator of Src family of tyrosine kinases.	Azoxymethane	23-26	catenin beta 1	Homo sapiens	70-82
23824743-5	2013	Isorhamnetin inhibited AOM/DSS-induced oncogenic c-Src activation and beta-catenin nuclear translocation, while promoting the expression of C-terminal Src kinase (CSK), a negative regulator of Src family of tyrosine kinases.	Azoxymethane	23-26	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	51-54
22986531-5	2013	Immunohistochemistry revealed that HNF4alpha, unlike GATA6, exhibited a similar decrease to Cdx2 in genetic (Apc(min/+) and Apc(Delta14/+)) and chemically induced (Azoxymethane (AOM) treatment) models of intestinal tumors in mice.	Azoxymethane	164-176	hepatic nuclear factor 4, alpha	Mus musculus	35-44
23878224-6	2013	Here we demonstrate that azoxymethane (AOM) and dextran sulfate sodium (DSS)-induced inflammation-associated cancer is exacerbated in mice lacking Axl and Mer.	Azoxymethane	25-37	AXL receptor tyrosine kinase	Mus musculus	147-150
23878224-6	2013	Here we demonstrate that azoxymethane (AOM) and dextran sulfate sodium (DSS)-induced inflammation-associated cancer is exacerbated in mice lacking Axl and Mer.	Azoxymethane	39-42	AXL receptor tyrosine kinase	Mus musculus	147-150
23707755-0	2013	Effects of modulating M3 muscarinic receptor activity on azoxymethane-induced liver injury in mice.	Azoxymethane	57-69	cholinergic receptor, muscarinic 3, cardiac	Mus musculus	22-44
23598468-3	2013	We hypothesized that SPI and GEN induced epigenetic modifications on Sfrp2, Sfrp5 and Wnt5a genes, suppressing their gene expression induced by azoxymethane (AOM), a chemical carcinogen, to the similar level as that of pre-AOM period.	Azoxymethane	144-156	secreted frizzled-related protein 2	Rattus norvegicus	69-74
23598468-3	2013	We hypothesized that SPI and GEN induced epigenetic modifications on Sfrp2, Sfrp5 and Wnt5a genes, suppressing their gene expression induced by azoxymethane (AOM), a chemical carcinogen, to the similar level as that of pre-AOM period.	Azoxymethane	144-156	secreted frizzled-related protein 5	Rattus norvegicus	76-81
23598468-3	2013	We hypothesized that SPI and GEN induced epigenetic modifications on Sfrp2, Sfrp5 and Wnt5a genes, suppressing their gene expression induced by azoxymethane (AOM), a chemical carcinogen, to the similar level as that of pre-AOM period.	Azoxymethane	144-156	Wnt family member 5A	Rattus norvegicus	86-91
23660392-3	2013	MyD88 is also protective, for example in oncogenic virus carcinogenesis or, acting downstream of IL-18R to strengthen mucosal repair, in azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colon carcinogenesis.	Azoxymethane	137-149	MYD88 innate immune signal transduction adaptor	Homo sapiens	0-5
23660392-3	2013	MyD88 is also protective, for example in oncogenic virus carcinogenesis or, acting downstream of IL-18R to strengthen mucosal repair, in azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colon carcinogenesis.	Azoxymethane	151-154	MYD88 innate immune signal transduction adaptor	Homo sapiens	0-5
23922772-7	2013	Furthermore, FJX1 null mice develop significantly fewer colonic polyps than wild-type littermates after combined dextran sodium sulfate (DSS) and azoxymethane (AOM) treatment.	Azoxymethane	146-158	four jointed box 1	Mus musculus	13-17
23669411-9	2013	RESULTS: C57Bl6 mice given pharmacologic inhibitors of IDO1 and IDO1-/- mice had lower tumor burdens and reduced proliferation in the neoplastic epithelium after administration of dextran sodium sulfate and azoxymethane than control mice.	Azoxymethane	207-219	indoleamine 2,3-dioxygenase 1	Mus musculus	55-59
23669411-9	2013	RESULTS: C57Bl6 mice given pharmacologic inhibitors of IDO1 and IDO1-/- mice had lower tumor burdens and reduced proliferation in the neoplastic epithelium after administration of dextran sodium sulfate and azoxymethane than control mice.	Azoxymethane	207-219	indoleamine 2,3-dioxygenase 1	Mus musculus	64-68
23708609-2	2013	Previously, we showed that the selective iNOS inhibitor S,S"-1,4-phenylenebis(1,2-ethanediyl)bis-isothiourea (PBIT) caused significant inhibition of colon carcinogenesis induced by azoxymethane (AOM), although it did not completely abrogate NO production due to the exogenous bioavailability of NO and NO generation by eNOS in tumor tissues.	Azoxymethane	181-193	nitric oxide synthase 2	Rattus norvegicus	41-45
23708609-2	2013	Previously, we showed that the selective iNOS inhibitor S,S"-1,4-phenylenebis(1,2-ethanediyl)bis-isothiourea (PBIT) caused significant inhibition of colon carcinogenesis induced by azoxymethane (AOM), although it did not completely abrogate NO production due to the exogenous bioavailability of NO and NO generation by eNOS in tumor tissues.	Azoxymethane	195-198	nitric oxide synthase 2	Rattus norvegicus	41-45
23707755-1	2013	Previously, we reported that azoxymethane (AOM)-induced liver injury is robustly exacerbated in M3 muscarinic receptor (M3R)-deficient mice.	Azoxymethane	29-41	cholinergic receptor, muscarinic 3, cardiac	Mus musculus	96-118
23707755-1	2013	Previously, we reported that azoxymethane (AOM)-induced liver injury is robustly exacerbated in M3 muscarinic receptor (M3R)-deficient mice.	Azoxymethane	29-41	cholinergic receptor, muscarinic 3, cardiac	Mus musculus	120-123
23707755-1	2013	Previously, we reported that azoxymethane (AOM)-induced liver injury is robustly exacerbated in M3 muscarinic receptor (M3R)-deficient mice.	Azoxymethane	43-46	cholinergic receptor, muscarinic 3, cardiac	Mus musculus	96-118
23707755-1	2013	Previously, we reported that azoxymethane (AOM)-induced liver injury is robustly exacerbated in M3 muscarinic receptor (M3R)-deficient mice.	Azoxymethane	43-46	cholinergic receptor, muscarinic 3, cardiac	Mus musculus	120-123
23707755-3	2013	Initial experiments confirmed that giving a selective M3R antagonist, darifenacin, to AOM-treated mice mimicked M3R gene ablation.	Azoxymethane	86-89	cholinergic receptor, muscarinic 3, cardiac	Mus musculus	54-57
23707755-3	2013	Initial experiments confirmed that giving a selective M3R antagonist, darifenacin, to AOM-treated mice mimicked M3R gene ablation.	Azoxymethane	86-89	cholinergic receptor, muscarinic 3, cardiac	Mus musculus	112-115
23554136-0	2013	Yerba mate tea and mate saponins prevented azoxymethane-induced inflammation of rat colon through suppression of NF-kappaB p65ser(311) signaling via IkappaB-alpha and GSK-3beta reduced phosphorylation.	Azoxymethane	43-55	synaptotagmin 1	Rattus norvegicus	123-126
23554136-0	2013	Yerba mate tea and mate saponins prevented azoxymethane-induced inflammation of rat colon through suppression of NF-kappaB p65ser(311) signaling via IkappaB-alpha and GSK-3beta reduced phosphorylation.	Azoxymethane	43-55	NFKB inhibitor alpha	Rattus norvegicus	149-162
23554136-0	2013	Yerba mate tea and mate saponins prevented azoxymethane-induced inflammation of rat colon through suppression of NF-kappaB p65ser(311) signaling via IkappaB-alpha and GSK-3beta reduced phosphorylation.	Azoxymethane	43-55	glycogen synthase kinase 3 beta	Rattus norvegicus	167-176
23724067-6	2013	Furthermore, we observed that HDAC2 up-regulation is one of the earliest events in CRC carcinogenesis and observed this in human field carcinogenesis, the azoxymethane-treated rat model, and in more aggressive colon cancer cell lines.	Azoxymethane	155-167	histone deacetylase 2	Homo sapiens	30-35
23430954-6	2013	Compared with Gas6(+/+) mice, Gas6(-/-) mice exhibited enhanced azoxymethane/dextran sulfate sodium (DSS)-induced tumorigenesis and had a shorter survival.	Azoxymethane	64-76	growth arrest specific 6	Mus musculus	30-34
23393226-0	2013	Loss of sulfiredoxin renders mice resistant to azoxymethane/dextran sulfate sodium-induced colon carcinogenesis.	Azoxymethane	47-59	sulfiredoxin 1 homolog (S. cerevisiae)	Mus musculus	8-20
23338779-1	2013	The present study investigated whether a water-soluble extract from the culture medium of Ganoderma lucidum mycelia (Japanese: Reishi or Mannentake) (designated as MAK) exerted a protective effect against induction of aberrant crypt foci (ACF) by azoxymethane (AOM) and small-intestinal damage induced by the anticancer drug 5-FU.	Azoxymethane	247-259	male germ cell-associated kinase	Rattus norvegicus	164-167
22751125-4	2013	In mice, SMAC deficiency significantly increased the incidence and size of colon tumors induced by azoxymethane (AOM)/dextran sulfate sodium salt (DSS), and highly enriched beta-catenin hot spot mutations.	Azoxymethane	99-111	diablo, IAP-binding mitochondrial protein	Mus musculus	9-13
23567778-3	2013	METHODS: Colitis-associated cancer was induced by azoxymethane and dextran sodium sulfate in wild-type and in interleukin-1 receptor-associated kinase M (IRAK-M)-deficient mice with or without antibiotic (ATB) treatment.	Azoxymethane	50-62	interleukin-1 receptor-associated kinase 3	Mus musculus	154-160
22323126-3	2012	However, GLP-2 increases colonic dysplasia in murine azoxymethane (AOM)-induced colon cancer.	Azoxymethane	53-65	glucagon-like peptide 2 receptor	Mus musculus	9-14
23354397-0	2012	A chemoprotective fish oil/pectin diet enhances apoptosis via Bcl-2 promoter methylation in rat azoxymethane-induced carcinomas.	Azoxymethane	96-108	BCL2, apoptosis regulator	Rattus norvegicus	62-67
22859375-0	2012	Tomato powder impedes the development of azoxymethane-induced colorectal cancer in rats through suppression of COX-2 expression via NF-kappaB and regulating Nrf2/HO-1 pathway.	Azoxymethane	41-53	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	111-116
22859375-0	2012	Tomato powder impedes the development of azoxymethane-induced colorectal cancer in rats through suppression of COX-2 expression via NF-kappaB and regulating Nrf2/HO-1 pathway.	Azoxymethane	41-53	heme oxygenase 1	Rattus norvegicus	162-166
21986945-4	2012	Genetic deletion of mPGES-1 significantly reduced both the total number and size of colorectal polyps at 18 weeks after azoxymethane administration with reduced nuclear translocation of beta-catenin, altered expression profiles of chemokines/cytokines and increased production of antitumorigenic PGs, prostaglandin D(2) and prostacyclin in tumor tissues.	Azoxymethane	120-132	prostaglandin E synthase	Mus musculus	20-27
22550081-2	2012	The present study shows reduced inflammatory responses and colorectal cancer in IEX-1 knockout (KO) mice treated with azoxymethane/dextran sulfate sodium (DSS).	Azoxymethane	118-130	immediate early response 3	Mus musculus	80-85
22550081-5	2012	In accordance with this, T-helper 17 (T(H)17) cell differentiation was compromised in the absence of Galphai2, and deletion of Galphai2 in T cells alone aggravated colon inflammation and colorectal cancer development after azoxymethane/DSS treatment.	Azoxymethane	223-235	guanine nucleotide binding protein (G protein), alpha inhibiting 2	Mus musculus	127-135
21630261-4	2012	In mice treated with azoxymethane (AOM) to model sporadic cancer, NTR-1 had a significant effect on tumor development with Ntsr1(+/+) mice developing over twofold more tumors than Ntsr1(-) (/-) mice (p = 0.04).	Azoxymethane	21-33	neurotensin receptor 1	Mus musculus	66-71
23545937-0	2013	Extracellular calcium-sensing receptor/PTH knockout mice colons have increased Wnt/beta-catenin signaling, reduced non-canonical Wnt signaling, and increased susceptibility to azoxymethane-induced aberrant crypt foci.	Azoxymethane	176-188	calcium-sensing receptor	Mus musculus	0-38
23545937-2	2013	To understand a role of the colonic extracellular calcium-sensing receptor (CaSR) in calcium-mediated chemoprevention of colon cancer, we induced formation of aberrant crypt foci (ACF) caused by azoxymethane (AOM) injection in "rescued" CaSR-/PTH- (C-/P-) double knockout colons compared with colons from control CaSR+/PTH+ (C+/P+) mice.	Azoxymethane	195-207	calcium-sensing receptor	Mus musculus	76-80
23545937-2	2013	To understand a role of the colonic extracellular calcium-sensing receptor (CaSR) in calcium-mediated chemoprevention of colon cancer, we induced formation of aberrant crypt foci (ACF) caused by azoxymethane (AOM) injection in "rescued" CaSR-/PTH- (C-/P-) double knockout colons compared with colons from control CaSR+/PTH+ (C+/P+) mice.	Azoxymethane	209-212	calcium-sensing receptor	Mus musculus	76-80
23545937-9	2013	The loss of the colonic CaSR increased the number of ACF/cm(2) in response to AOM injection, suggesting colonic CaSR may mediate the chemoprotective effect of increased dietary calcium against colorectal cancer observed in humans.	Azoxymethane	78-81	calcium sensing receptor	Homo sapiens	24-28
23545937-9	2013	The loss of the colonic CaSR increased the number of ACF/cm(2) in response to AOM injection, suggesting colonic CaSR may mediate the chemoprotective effect of increased dietary calcium against colorectal cancer observed in humans.	Azoxymethane	78-81	calcium sensing receptor	Homo sapiens	112-116
23447577-4	2013	The membranous Hai-1/Spint1 immunoreactivity was decreased in murine Apc(Min/+) tumors and also in carcinogen (azoxymethane treatment followed by dextran sodium sulfate administration)-induced colon tumors compared with the adjacent non-neoplastic epithelium.	Azoxymethane	111-123	serine protease inhibitor, Kunitz type 1	Mus musculus	15-20
23447577-4	2013	The membranous Hai-1/Spint1 immunoreactivity was decreased in murine Apc(Min/+) tumors and also in carcinogen (azoxymethane treatment followed by dextran sodium sulfate administration)-induced colon tumors compared with the adjacent non-neoplastic epithelium.	Azoxymethane	111-123	serine protease inhibitor, Kunitz type 1	Mus musculus	21-27
22716201-0	2013	Genistein, a soya isoflavone, prevents azoxymethane-induced up-regulation of WNT/beta-catenin signalling and reduces colon pre-neoplasia in rats.	Azoxymethane	39-51	Wnt family member 2	Rattus norvegicus	77-80
22716201-0	2013	Genistein, a soya isoflavone, prevents azoxymethane-induced up-regulation of WNT/beta-catenin signalling and reduces colon pre-neoplasia in rats.	Azoxymethane	39-51	catenin beta 1	Rattus norvegicus	81-93
22716201-7	2013	AOM injection induced aberrant nuclear accumulation of beta-catenin in the CTL group but not in the SPI or GEN group.	Azoxymethane	0-3	catenin beta 1	Rattus norvegicus	55-67
23803085-0	2013	Suppression of beta-catenin and cyclooxygenase-2 expression and cell proliferation in azoxymethane-induced colonic cancer in rats by rice bran phytic acid (PA).	Azoxymethane	86-98	catenin beta 1	Rattus norvegicus	15-27
23803085-0	2013	Suppression of beta-catenin and cyclooxygenase-2 expression and cell proliferation in azoxymethane-induced colonic cancer in rats by rice bran phytic acid (PA).	Azoxymethane	86-98	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	32-48
23555575-6	2013	Although Ptp4a3 is normally associated with late-stage cancer and metastasis, we observed increased Ptp4a3 expression in the colon of wildtype mice immediately following treatment with the carcinogen azoxymethane.	Azoxymethane	200-212	protein tyrosine phosphatase 4a3	Mus musculus	100-106
23555575-10	2013	Ptp4a3-null mice developed 50% fewer colon tumors than wildtype mice after exposure to azoxymethane and dextran sodium sulfate.	Azoxymethane	87-99	protein tyrosine phosphatase 4a3	Mus musculus	0-6
22916810-3	2012	The present study shows the results of molecular changes involved in the Tp53 pathway at an early stage in the distal colon tissue of azoxymethane (AOM)-induced colon cancer in rats evaluated by PCR array after exposure to diets containing the non-digestible fraction (NDF) of cooked bean (cultivar Bayo Madero).	Azoxymethane	134-146	tumor protein p53	Rattus norvegicus	73-77
22320717-0	2012	Suppression of azoxymethane-induced colonic preneoplastic lesions in rats by 1-methyltryptophan, an inhibitor of indoleamine 2,3-dioxygenase.	Azoxymethane	15-27	indoleamine 2,3-dioxygenase 1	Rattus norvegicus	113-140
22323126-3	2012	However, GLP-2 increases colonic dysplasia in murine azoxymethane (AOM)-induced colon cancer.	Azoxymethane	67-70	glucagon-like peptide 2 receptor	Mus musculus	9-14
22432057-9	2012	Six months following treatment with the alkylating carcinogen azoxymethane (AOM) at 10 mg/kg once a week for 6 weeks, XRCC1tp mice had a decrease in average colon tumor volume of 14+-3 mm(3) compared to 34+-4 mm(3) in WT littermates (p <= 0.03, N= 20/genotype).	Azoxymethane	62-74	X-ray repair complementing defective repair in Chinese hamster cells 1	Mus musculus	118-123
22262168-8	2012	Enhanced CIN observed in SGO1-deficient mice resulted in an increase in formation of aberrant crypt foci (ACF) and accelerated development of tumors after exposure to azoxymethane (AOM), a colon carcinogen.	Azoxymethane	167-179	shugoshin 1	Mus musculus	25-29
22262168-8	2012	Enhanced CIN observed in SGO1-deficient mice resulted in an increase in formation of aberrant crypt foci (ACF) and accelerated development of tumors after exposure to azoxymethane (AOM), a colon carcinogen.	Azoxymethane	181-184	shugoshin 1	Mus musculus	25-29
22432057-9	2012	Six months following treatment with the alkylating carcinogen azoxymethane (AOM) at 10 mg/kg once a week for 6 weeks, XRCC1tp mice had a decrease in average colon tumor volume of 14+-3 mm(3) compared to 34+-4 mm(3) in WT littermates (p <= 0.03, N= 20/genotype).	Azoxymethane	76-79	X-ray repair complementing defective repair in Chinese hamster cells 1	Mus musculus	118-123
21994466-2	2011	TNF receptor (TNFR) 2 expression is increased in inflammatory bowel diseases, the azoxymethane/dextran sodium sulfate (AOM/DSS) model of colitis-associated cancer, and by combined interleukin (IL) 6 and TNFalpha.	Azoxymethane	82-94	TNF receptor superfamily member 1A	Homo sapiens	0-12
23098518-3	2012	In the present study, we investigated the effect of pioglitazone on the development of azoxymethane-induced colon aberrant crypt foci (ACF) in KK-Ay obesity and diabetes model mice, and tried to clarify mechanisms by which the PPARgamma ligand inhibits ACF development.	Azoxymethane	87-99	peroxisome proliferator activated receptor gamma	Mus musculus	227-236
22199291-4	2011	MATERIALS AND METHODS: CD133 was evaluated by immunohistochemistry in a mouse model of colitis-related colon tumorigenesis induced by a combined treatment with azoxymethane (AOM) and dextran sodium sulphate (DSS).	Azoxymethane	160-172	prominin 1	Mus musculus	23-28
21042865-4	2011	In this study, a novel single chain (sc)VEGF-based molecular probe is utilized in the azoxymethane (AOM)-treated mouse model of colorectal cancer to study delivery route and specificity for disease.	Azoxymethane	86-98	vascular endothelial growth factor A	Mus musculus	40-44
21042865-4	2011	In this study, a novel single chain (sc)VEGF-based molecular probe is utilized in the azoxymethane (AOM)-treated mouse model of colorectal cancer to study delivery route and specificity for disease.	Azoxymethane	100-103	vascular endothelial growth factor A	Mus musculus	40-44
21994466-2	2011	TNF receptor (TNFR) 2 expression is increased in inflammatory bowel diseases, the azoxymethane/dextran sodium sulfate (AOM/DSS) model of colitis-associated cancer, and by combined interleukin (IL) 6 and TNFalpha.	Azoxymethane	82-94	TNF receptor superfamily member 1A	Homo sapiens	14-18
21994466-2	2011	TNF receptor (TNFR) 2 expression is increased in inflammatory bowel diseases, the azoxymethane/dextran sodium sulfate (AOM/DSS) model of colitis-associated cancer, and by combined interleukin (IL) 6 and TNFalpha.	Azoxymethane	119-122	TNF receptor superfamily member 1A	Homo sapiens	0-12
21994466-2	2011	TNF receptor (TNFR) 2 expression is increased in inflammatory bowel diseases, the azoxymethane/dextran sodium sulfate (AOM/DSS) model of colitis-associated cancer, and by combined interleukin (IL) 6 and TNFalpha.	Azoxymethane	119-122	TNF receptor superfamily member 1A	Homo sapiens	14-18
21517784-4	2011	Consistent with the notion that PTPRT is a tumour suppressor, PTPRT knockout mice are hypersensitive to AOM (azoxymethane)-induced colon cancer.	Azoxymethane	109-121	protein tyrosine phosphatase, receptor type, T	Mus musculus	62-67
21987656-3	2011	IL-21 was increased in the gut of patients with UC-associated colon cancer, and in mice with CAC induced by azoxymethane (AOM) and dextran sulfate sodium (DSS).	Azoxymethane	108-120	interleukin 21	Homo sapiens	0-5
21914785-6	2011	Using Pgc1alpha(-/-) and Pgc1alpha(+/+) mice, we show that loss of PGC1alpha protects mice from azoxymethane-induced colon carcinogenesis.	Azoxymethane	96-108	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	67-76
21567095-4	2011	Although HGF stimulated proliferation of colonic epithelial cells in normal mucosa, the development of colorectal cancer induced by repeated injection of azoxymethane (AOM) was significantly inhibited by HGF treatment.	Azoxymethane	154-166	hepatocyte growth factor	Mus musculus	204-207
21741923-0	2011	Disruption of the mouse protein tyrosine kinase 6 gene prevents STAT3 activation and confers resistance to azoxymethane.	Azoxymethane	107-119	PTK6 protein tyrosine kinase 6	Mus musculus	24-49
21741923-5	2011	METHODS: Ptk6+/+ and Ptk6-/- mice were injected with azoxymethane alone or in combination with dextran sodium sulfate; formation of aberrant crypt foci and colon tumors was examined.	Azoxymethane	53-65	PTK6 protein tyrosine kinase 6	Mus musculus	9-13
21741923-5	2011	METHODS: Ptk6+/+ and Ptk6-/- mice were injected with azoxymethane alone or in combination with dextran sodium sulfate; formation of aberrant crypt foci and colon tumors was examined.	Azoxymethane	53-65	PTK6 protein tyrosine kinase 6	Mus musculus	21-25
21741923-8	2011	RESULTS: Ptk6-/- mice developed fewer azoxymethane-induced aberrant crypt foci and tumors.	Azoxymethane	38-50	PTK6 protein tyrosine kinase 6	Mus musculus	9-13
21741923-9	2011	Induction of PTK6 increased apoptosis, proliferation, and STAT3 activation in Ptk6+/+ mice injected with azoxymethane.	Azoxymethane	105-117	PTK6 protein tyrosine kinase 6	Mus musculus	13-17
21741923-9	2011	Induction of PTK6 increased apoptosis, proliferation, and STAT3 activation in Ptk6+/+ mice injected with azoxymethane.	Azoxymethane	105-117	signal transducer and activator of transcription 3	Mus musculus	58-63
21741923-9	2011	Induction of PTK6 increased apoptosis, proliferation, and STAT3 activation in Ptk6+/+ mice injected with azoxymethane.	Azoxymethane	105-117	PTK6 protein tyrosine kinase 6	Mus musculus	78-82
21741923-10	2011	Disruption of Ptk6 impaired STAT3 activation following azoxymethane injection, and reduced active STAT3 levels in Ptk6-/- tumors.	Azoxymethane	55-67	PTK6 protein tyrosine kinase 6	Mus musculus	14-18
21741923-13	2011	CONCLUSIONS: PTK6 promotes STAT3 activation in the colon following injection of the carcinogen azoxymethane and regulates STAT3 activity in mouse colon tumors and in the HCT116 and young adult mouse colon cell lines.	Azoxymethane	95-107	PTK6 protein tyrosine kinase 6	Mus musculus	13-17
21741923-13	2011	CONCLUSIONS: PTK6 promotes STAT3 activation in the colon following injection of the carcinogen azoxymethane and regulates STAT3 activity in mouse colon tumors and in the HCT116 and young adult mouse colon cell lines.	Azoxymethane	95-107	signal transducer and activator of transcription 3	Mus musculus	27-32
21741923-14	2011	Disruption of Ptk6 decreases azoxymethane-induced colon tumorigenesis in mice.	Azoxymethane	29-41	PTK6 protein tyrosine kinase 6	Mus musculus	14-18
21576350-7	2011	mPGES-1 gene deletion results in an about 80% decrease in tumor multiplicity and up to a 90% reduction in tumor load in the distal colon of azoxymethane (AOM)-treated mice.	Azoxymethane	140-152	prostaglandin E synthase	Mus musculus	0-7
21576350-7	2011	mPGES-1 gene deletion results in an about 80% decrease in tumor multiplicity and up to a 90% reduction in tumor load in the distal colon of azoxymethane (AOM)-treated mice.	Azoxymethane	154-157	prostaglandin E synthase	Mus musculus	0-7
21567095-4	2011	Although HGF stimulated proliferation of colonic epithelial cells in normal mucosa, the development of colorectal cancer induced by repeated injection of azoxymethane (AOM) was significantly inhibited by HGF treatment.	Azoxymethane	168-171	hepatocyte growth factor	Mus musculus	204-207
21640075-3	2011	In the present study, we examined the effects of an angiotensin-converting enzyme (ACE) inhibitor and angiotensin-II type 1 receptor blocker (ARB), both of which inhibit the RAS, on the development of azoxymethane (AOM)-initiated colonic premalignant lesions in C57BL/KsJ-db/db (db/db) obese mice.	Azoxymethane	201-213	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	83-86
21653642-8	2011	These miRNAs were downregulated in azoxymethane and inflammation-associated colonic tumors from Egfr(wt) mice but upregulated in Egfr(wa2) tumors.	Azoxymethane	35-47	epidermal growth factor receptor	Mus musculus	96-100
21519141-3	2011	In this model, the induction of tumors using azoxymethane was accompanied by the coappearance of F4/80+CD11b(high)Gr1(low) M2 macrophages, cells that undergo polarization by IL-13 and are absent in tumors that lack high level IL-13 production.	Azoxymethane	45-57	adhesion G protein-coupled receptor E1	Mus musculus	97-102
21370285-0	2011	Accumulation of K-Ras codon 12 mutations in the F344 rat distal colon following azoxymethane exposure.	Azoxymethane	80-92	KRAS proto-oncogene, GTPase	Rattus norvegicus	16-21
21519141-3	2011	In this model, the induction of tumors using azoxymethane was accompanied by the coappearance of F4/80+CD11b(high)Gr1(low) M2 macrophages, cells that undergo polarization by IL-13 and are absent in tumors that lack high level IL-13 production.	Azoxymethane	45-57	integrin subunit alpha M	Homo sapiens	103-108
21519141-3	2011	In this model, the induction of tumors using azoxymethane was accompanied by the coappearance of F4/80+CD11b(high)Gr1(low) M2 macrophages, cells that undergo polarization by IL-13 and are absent in tumors that lack high level IL-13 production.	Azoxymethane	45-57	interleukin 13	Homo sapiens	174-179
21519141-3	2011	In this model, the induction of tumors using azoxymethane was accompanied by the coappearance of F4/80+CD11b(high)Gr1(low) M2 macrophages, cells that undergo polarization by IL-13 and are absent in tumors that lack high level IL-13 production.	Azoxymethane	45-57	interleukin 13	Homo sapiens	226-231
20013030-0	2011	Luteolin inhibits cell proliferation during Azoxymethane-induced experimental colon carcinogenesis via Wnt/ beta-catenin pathway.	Azoxymethane	44-56	catenin (cadherin associated protein), beta 1	Mus musculus	108-120
21355597-0	2011	Pterostilbene is more potent than resveratrol in preventing azoxymethane (AOM)-induced colon tumorigenesis via activation of the NF-E2-related factor 2 (Nrf2)-mediated antioxidant signaling pathway.	Azoxymethane	60-72	nuclear factor, erythroid derived 2, like 2	Mus musculus	129-151
21355597-0	2011	Pterostilbene is more potent than resveratrol in preventing azoxymethane (AOM)-induced colon tumorigenesis via activation of the NF-E2-related factor 2 (Nrf2)-mediated antioxidant signaling pathway.	Azoxymethane	60-72	nuclear factor, erythroid derived 2, like 2	Mus musculus	153-157
21355597-0	2011	Pterostilbene is more potent than resveratrol in preventing azoxymethane (AOM)-induced colon tumorigenesis via activation of the NF-E2-related factor 2 (Nrf2)-mediated antioxidant signaling pathway.	Azoxymethane	74-77	nuclear factor, erythroid derived 2, like 2	Mus musculus	129-151
21355597-0	2011	Pterostilbene is more potent than resveratrol in preventing azoxymethane (AOM)-induced colon tumorigenesis via activation of the NF-E2-related factor 2 (Nrf2)-mediated antioxidant signaling pathway.	Azoxymethane	74-77	nuclear factor, erythroid derived 2, like 2	Mus musculus	153-157
21355597-11	2011	This is also the first study to demonstrate that PS is a Nrf2 inducer and AR inhibitor in the AOM-treated colon carcinogenesis model.	Azoxymethane	94-97	aldo-keto reductase family 1, member B3 (aldose reductase)	Mus musculus	74-76
21425406-7	2011	Mice with Ets2-deficient intestinal cells develop more colon tumors in response to treatment with azoxymethane and dextran sulfate sodium.	Azoxymethane	98-110	E26 avian leukemia oncogene 2, 3' domain	Mus musculus	10-14
22523637-6	2011	We have also shown that in peripheral blood mononuclear cells (PBMC) and bone marrow (BM) cells collected from colon cancer patients and from azoxymethane-induced rats the expression and localization of NMT is altered.	Azoxymethane	142-154	N-myristoyltransferase 1	Homo sapiens	203-206
21118981-3	2010	Using the azoxymethane and dextran sodium sulfate colitis-associated colorectal cancer model, we show that caspase-1-deficient (Casp1(-/-)) mice have enhanced tumor formation.	Azoxymethane	10-22	caspase 1	Mus musculus	107-116
21303973-6	2011	We report that Mtgr1(-/-) mice were protected from tumorigenesis when injected with azoxymethane (AOM) and then subjected to repeated cycles of dextran sodium sulfate (DSS).	Azoxymethane	84-96	CBFA2/RUNX1 translocation partner 2	Mus musculus	15-20
21721157-2	2011	It has been shown that ACA inhibited the development of azoxymethane-induced colon carcinogenesis through its suppression of cell proliferation in the colonic mucosa and its induction of glutathione S-transferase and quinone oxidoreductase 1 in vivo.	Azoxymethane	56-68	hematopoietic prostaglandin D synthase	Rattus norvegicus	187-212
21717373-8	2011	In contrast to these results obtained from DSS colitis, expression of claudin-1 was significantly downregulated, while expression of claudin-15 was upregulated in colitis-associated cancer tissues in the azoxymethane (AOM)/DSS model (Fig.	Azoxymethane	204-216	claudin 15	Rattus norvegicus	133-143
21717373-8	2011	In contrast to these results obtained from DSS colitis, expression of claudin-1 was significantly downregulated, while expression of claudin-15 was upregulated in colitis-associated cancer tissues in the azoxymethane (AOM)/DSS model (Fig.	Azoxymethane	218-221	claudin 1	Rattus norvegicus	70-79
21717373-8	2011	In contrast to these results obtained from DSS colitis, expression of claudin-1 was significantly downregulated, while expression of claudin-15 was upregulated in colitis-associated cancer tissues in the azoxymethane (AOM)/DSS model (Fig.	Azoxymethane	218-221	claudin 15	Rattus norvegicus	133-143
21118981-3	2010	Using the azoxymethane and dextran sodium sulfate colitis-associated colorectal cancer model, we show that caspase-1-deficient (Casp1(-/-)) mice have enhanced tumor formation.	Azoxymethane	10-22	caspase 1	Mus musculus	128-133
20855874-5	2010	In this study, we showed that mice deficient for Nlrp3 or the inflammasome effector caspase-1 were highly susceptible to azoxymethane/dextran sodium sulfate-induced inflammation and suffered from dramatically increased tumor burdens in the colon.	Azoxymethane	121-133	NLR family, pyrin domain containing 3	Mus musculus	49-54
20732909-9	2010	With a single low dose of AOM (3 mg/kg) Aag-null mice showed an even stronger tumor response than Mgmt-null mice.	Azoxymethane	26-29	N-methylpurine-DNA glycosylase	Mus musculus	40-43
20732909-9	2010	With a single low dose of AOM (3 mg/kg) Aag-null mice showed an even stronger tumor response than Mgmt-null mice.	Azoxymethane	26-29	O-6-methylguanine-DNA methyltransferase	Mus musculus	98-102
21120281-0	2010	The role of Fas ligand protein in the oxidative stress induced by azoxymethane on crypt colon of rats.	Azoxymethane	66-78	Fas ligand	Rattus norvegicus	12-22
21120281-1	2010	PURPOSE: To study the protein Fas ligand (FasL) on the expression of apoptosis, using a model of oxidative stress induced by azoxymethane (AOM), in the crypt of colon in rats.	Azoxymethane	125-137	Fas ligand	Rattus norvegicus	30-40
21120281-1	2010	PURPOSE: To study the protein Fas ligand (FasL) on the expression of apoptosis, using a model of oxidative stress induced by azoxymethane (AOM), in the crypt of colon in rats.	Azoxymethane	125-137	Fas ligand	Rattus norvegicus	42-46
21120281-1	2010	PURPOSE: To study the protein Fas ligand (FasL) on the expression of apoptosis, using a model of oxidative stress induced by azoxymethane (AOM), in the crypt of colon in rats.	Azoxymethane	139-142	Fas ligand	Rattus norvegicus	30-40
21120281-1	2010	PURPOSE: To study the protein Fas ligand (FasL) on the expression of apoptosis, using a model of oxidative stress induced by azoxymethane (AOM), in the crypt of colon in rats.	Azoxymethane	139-142	Fas ligand	Rattus norvegicus	42-46
21120281-11	2010	CONCLUSION: Azoxymethane induce the oxidative stress and the significantly decrease of FasL expression, although there is no significant difference between basal and top of colon crypt linked to consumption-activation of Fas ligand.	Azoxymethane	12-24	Fas ligand	Rattus norvegicus	87-91
20855874-5	2010	In this study, we showed that mice deficient for Nlrp3 or the inflammasome effector caspase-1 were highly susceptible to azoxymethane/dextran sodium sulfate-induced inflammation and suffered from dramatically increased tumor burdens in the colon.	Azoxymethane	121-133	caspase 1	Mus musculus	84-93
20823143-10	2010	Moreover, azoxymethane reduced insulin-like growth factor binding protein-3 protein level, which was enhanced by silibinin.	Azoxymethane	10-22	insulin-like growth factor binding protein 3	Mus musculus	31-75
20518744-2	2010	We demonstrated previously that NEU3 is markedly up-regulated in various human cancers and showed that NEU3 transgenic mice developed a diabetic phenotype and were susceptible to azoxymethane-induced aberrant crypt foci in their colon tissues.	Azoxymethane	179-191	neuraminidase 3	Homo sapiens	32-36
20518744-2	2010	We demonstrated previously that NEU3 is markedly up-regulated in various human cancers and showed that NEU3 transgenic mice developed a diabetic phenotype and were susceptible to azoxymethane-induced aberrant crypt foci in their colon tissues.	Azoxymethane	179-191	neuraminidase 3	Homo sapiens	103-107
20624890-2	2010	In contrast, MyD88 signaling has a protective role in the development of azoxymethane (AOM)/dextran sodium sulfate (DSS) colitis-associated cancer (CAC).	Azoxymethane	73-85	myeloid differentiation primary response gene 88	Mus musculus	13-18
20681671-8	2010	Furthermore, pterostilbene markedly inhibited AOM-induced activation of Ras, phosphatidylinositol 3 kinase/Akt, and EGFR signaling pathways.	Azoxymethane	46-49	thymoma viral proto-oncogene 1	Mus musculus	107-110
20624890-2	2010	In contrast, MyD88 signaling has a protective role in the development of azoxymethane (AOM)/dextran sodium sulfate (DSS) colitis-associated cancer (CAC).	Azoxymethane	87-90	myeloid differentiation primary response gene 88	Mus musculus	13-18
20133777-4	2010	PTPRT knockout mice that we generated exhibit increased levels of colonic paxillin phosphorylation at residue Y88 and are highly susceptible to carcinogen azoxymethane-induced colon tumor, providing critical in vivo evidence that PTPRT normally functions as a tumor suppressor.	Azoxymethane	155-167	protein tyrosine phosphatase, receptor type, T	Mus musculus	0-5
20197374-11	2010	Only AOM-treated Chrm3(-/-) mice developed ascites and had reduced survival compared with AOM-treated wild-type controls.	Azoxymethane	5-8	cholinergic receptor, muscarinic 3, cardiac	Mus musculus	17-22
20176658-8	2010	Mice null for IL4Ra and wild-type controls were treated with azoxymethane and dextran sulfate sodium to induce tumor formation.	Azoxymethane	61-73	interleukin 4 receptor, alpha	Mus musculus	14-19
20226691-6	2010	Together with their increased inflammatory response, the enhanced repair response of Casp12(-/-) mice rendered them more susceptible to colorectal cancer induced by azoxymethane (AOM)+DSS.	Azoxymethane	165-177	caspase 12	Mus musculus	85-91
20226691-6	2010	Together with their increased inflammatory response, the enhanced repair response of Casp12(-/-) mice rendered them more susceptible to colorectal cancer induced by azoxymethane (AOM)+DSS.	Azoxymethane	179-182	caspase 12	Mus musculus	85-91
19788889-3	2010	We observed that Nutlin-3 triggered a DNA damage response in azoxymethane-induced mouse AJ02-NM(0) colon cancer cells, characterized by the phosphorylation of H2AX (at Ser-139) and p53 (at Ser-15).	Azoxymethane	61-73	H2A.X variant histone	Mus musculus	159-163
19788889-3	2010	We observed that Nutlin-3 triggered a DNA damage response in azoxymethane-induced mouse AJ02-NM(0) colon cancer cells, characterized by the phosphorylation of H2AX (at Ser-139) and p53 (at Ser-15).	Azoxymethane	61-73	transformation related protein 53, pseudogene	Mus musculus	181-184
19931517-2	2010	We previously demonstrated that serum leptin levels are profoundly increased in mice which received azoxymethane (AOM) and dextran sulfate sodium (DSS) as tumor-initiator and -promoter, respectively, in a colon carcinogenesis model.	Azoxymethane	100-112	leptin	Mus musculus	38-44
19931517-2	2010	We previously demonstrated that serum leptin levels are profoundly increased in mice which received azoxymethane (AOM) and dextran sulfate sodium (DSS) as tumor-initiator and -promoter, respectively, in a colon carcinogenesis model.	Azoxymethane	114-117	leptin	Mus musculus	38-44
21189690-11	2010	In addition, mice heterozygous for a SF1 knockout allele show enhanced susceptibility to azoxymethane-induced colon tumorigenesis adding BBP/SF1 to the growing list of RNA processing factors implicated in genetic disease.	Azoxymethane	89-101	splicing factor 1	Mus musculus	37-40
21189690-11	2010	In addition, mice heterozygous for a SF1 knockout allele show enhanced susceptibility to azoxymethane-induced colon tumorigenesis adding BBP/SF1 to the growing list of RNA processing factors implicated in genetic disease.	Azoxymethane	89-101	splicing factor 1	Mus musculus	137-140
21189690-11	2010	In addition, mice heterozygous for a SF1 knockout allele show enhanced susceptibility to azoxymethane-induced colon tumorigenesis adding BBP/SF1 to the growing list of RNA processing factors implicated in genetic disease.	Azoxymethane	89-101	splicing factor 1	Mus musculus	141-144
19931338-5	2010	Significant increases in interleukin-1beta and tumor necrosis factor-alpha mRNA were observed in the frontal cortex of azoxymethane-treated wild-type mice at coma stages of encephalopathy.	Azoxymethane	119-131	interleukin 1 beta	Mus musculus	25-42
19737566-11	2010	Intestinal tumorigenesis increased after administration of azoxymethane to Gucy2c(-/-) mice, compared with wild-type mice, but was eliminated in Gucy2c(-/-)Akt1(-/-) mice.	Azoxymethane	59-71	guanylate cyclase 2c	Mus musculus	75-81
19931338-5	2010	Significant increases in interleukin-1beta and tumor necrosis factor-alpha mRNA were observed in the frontal cortex of azoxymethane-treated wild-type mice at coma stages of encephalopathy.	Azoxymethane	119-131	tumor necrosis factor	Mus musculus	47-74
19931338-9	2010	These results demonstrate that toxic liver injury resulting from exposure to azoxymethane is associated with selective induction of proinflammatory cytokines in the brain and that deletion of tumor necrosis factor receptor-1 or interlukin-1 type 1 receptor delays the onset of coma and brain edema in this model of acute liver failure.	Azoxymethane	77-89	tumor necrosis factor receptor superfamily, member 1a	Mus musculus	192-224
19903783-0	2009	Epidermal growth factor receptor is required for colonic tumor promotion by dietary fat in the azoxymethane/dextran sulfate sodium model: roles of transforming growth factor-{alpha} and PTGS2.	Azoxymethane	95-107	epidermal growth factor receptor	Mus musculus	0-32
20574917-0	2010	Freeze-dried ham promotes azoxymethane-induced mucin-depleted foci and aberrant crypt foci in rat colon.	Azoxymethane	26-38	solute carrier family 13 member 2	Rattus norvegicus	47-52
20616616-0	2010	Dietary linoleic acid and glucose enhances azoxymethane-induced colon cancer and metastases via the expression of high-mobility group box 1.	Azoxymethane	43-55	high mobility group box 1	Rattus norvegicus	114-139
20616616-2	2010	METHODS: We examined the significance of HMGB1 in causing colon carcinogenesis induced by azoxymethane (AOM) injection in Fischer 344 rats fed on a control diet (group C), a 15% linoleic acid (LA) diet (group L), a control diet with 10% glucose drink (group G), and a 15% LA diet with a 10% glucose drink (group L+G).	Azoxymethane	90-102	high mobility group box 1	Rattus norvegicus	41-46
20616616-2	2010	METHODS: We examined the significance of HMGB1 in causing colon carcinogenesis induced by azoxymethane (AOM) injection in Fischer 344 rats fed on a control diet (group C), a 15% linoleic acid (LA) diet (group L), a control diet with 10% glucose drink (group G), and a 15% LA diet with a 10% glucose drink (group L+G).	Azoxymethane	104-107	high mobility group box 1	Rattus norvegicus	41-46
19760669-0	2009	Genetic reduction of circulating insulin-like growth factor-1 inhibits azoxymethane-induced colon tumorigenesis in mice.	Azoxymethane	71-83	insulin-like growth factor 1	Mus musculus	33-61
19760669-6	2009	We conducted a pilot study to assess the impact of liver-specific IGF-1 deficiency on azoxymethane (AOM)-induced colon tumors.	Azoxymethane	86-98	insulin-like growth factor 1	Mus musculus	66-71
19760669-6	2009	We conducted a pilot study to assess the impact of liver-specific IGF-1 deficiency on azoxymethane (AOM)-induced colon tumors.	Azoxymethane	100-103	insulin-like growth factor 1	Mus musculus	66-71
19903783-4	2009	Although we showed that epidermal growth factor receptors (EGFR) controlled azoxymethane tumorigenesis in standard fat conditions, the role of EGFR in tumor promotion by high dietary fat has not been examined.	Azoxymethane	76-88	epidermal growth factor receptor	Mus musculus	59-63
19652364-7	2009	Furthermore, in the azoxymethane mouse model of colorectal carcinogenesis, Cck2r deletion in human progastrin-overexpressing mice resulted in markedly decreased aberrant crypt foci formation and substantially reduced tumor size and multiplicity.	Azoxymethane	20-32	cholecystokinin B receptor	Mus musculus	75-80
19787264-8	2009	Normal-appearing rat colonic mucosa and azoxymethane (AOM)-induced colorectal adenocarcinoma tissue expressed a barely detectable amount of BRD8 protein, but aggressive colon tumors induced with AOM and dextran sodium sulfate expressed BRD8 at a significantly higher level, suggesting that BRD8 expression is associated with tumor progression toward advanced stages and may aid to gain growth advantage.	Azoxymethane	40-52	bromodomain containing 8	Rattus norvegicus	140-144
19787264-8	2009	Normal-appearing rat colonic mucosa and azoxymethane (AOM)-induced colorectal adenocarcinoma tissue expressed a barely detectable amount of BRD8 protein, but aggressive colon tumors induced with AOM and dextran sodium sulfate expressed BRD8 at a significantly higher level, suggesting that BRD8 expression is associated with tumor progression toward advanced stages and may aid to gain growth advantage.	Azoxymethane	40-52	bromodomain containing 8	Rattus norvegicus	236-240
19787264-8	2009	Normal-appearing rat colonic mucosa and azoxymethane (AOM)-induced colorectal adenocarcinoma tissue expressed a barely detectable amount of BRD8 protein, but aggressive colon tumors induced with AOM and dextran sodium sulfate expressed BRD8 at a significantly higher level, suggesting that BRD8 expression is associated with tumor progression toward advanced stages and may aid to gain growth advantage.	Azoxymethane	40-52	bromodomain containing 8	Rattus norvegicus	236-240
19826045-2	2009	The present study explores the effects of p53-modulating agent CP-31398 alone and combined with celecoxib on azoxymethane-induced aberrant crypt foci (ACF) and colon adenocarcinomas in F344 rats.	Azoxymethane	109-121	tumor protein p53	Rattus norvegicus	42-45
19614672-0	2009	Co-treatment with deoxycholic acid and azoxymethane accelerates secretion of HMGB1 in IEC6 intestinal epithelial cells.	Azoxymethane	39-51	high mobility group box 1	Rattus norvegicus	77-82
19378291-0	2009	Epigenetic modulation of the retinoid X receptor alpha by green tea in the azoxymethane-Apc Min/+ mouse model of intestinal cancer.	Azoxymethane	75-87	retinoid X receptor alpha	Mus musculus	29-54
19694754-1	2009	To establish an efficient rat model for colitis-associated colorectal cancer, azoxymethane and dextran sodium sulfate (AOM/DSS)-induced colon carcinogenesis was applied to a novel adenomatous polyposis coli (Apc) mutant, the Kyoto Apc Delta (KAD) rat.	Azoxymethane	78-90	APC regulator of WNT signaling pathway	Rattus norvegicus	208-211
19694754-1	2009	To establish an efficient rat model for colitis-associated colorectal cancer, azoxymethane and dextran sodium sulfate (AOM/DSS)-induced colon carcinogenesis was applied to a novel adenomatous polyposis coli (Apc) mutant, the Kyoto Apc Delta (KAD) rat.	Azoxymethane	78-90	APC regulator of WNT signaling pathway	Rattus norvegicus	231-234
20021465-4	2009	Further, mice deficient in GCC signaling are more susceptible to colon cancer induced by Apc mutations or the carcinogen azoxymethane.	Azoxymethane	121-133	guanylate cyclase 2c	Mus musculus	27-30
19343039-6	2009	In vivo, pharmacological blockade of p38alpha inhibits CRC growth in xenografted nude mice and azoxymethane-treated Apc(Min) mice, achieving both a cytostatic and cytotoxic effect, associated with high nuclear expression of FoxO3A and increased expression of its target genes p21 and PTEN.	Azoxymethane	95-107	mitogen-activated protein kinase 14	Mus musculus	37-45
19497974-0	2009	Carcinogenic effects of exogenous and endogenous glucagon-like peptide-2 in azoxymethane-treated mice.	Azoxymethane	76-88	glucagon-like peptide 2 receptor	Mus musculus	49-72
19497974-8	2009	At 10 or 46 wk after azoxymethane treatment, the numbers of aberrant crypt foci increased with h(Gly(2))GLP-2[1-33] (P < 0.001) and decreased with hGLP-2[3-33] (P < 0.01-0.05) treatment.	Azoxymethane	21-33	glucagon-like peptide 2 receptor	Mus musculus	104-109
19442760-0	2009	Detection of K-ras mutations in azoxymethane-induced aberrant crypt foci in mice using LNA-mediated real-time PCR clamping and mutant-specific probes.	Azoxymethane	32-44	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	13-18
19627619-0	2009	Cyclophilin C-associated protein (CyCAP) knock-out mice spontaneously develop colonic mucosal hyperplasia and exaggerated tumorigenesis after treatment with carcinogen azoxymethane.	Azoxymethane	168-180	lectin, galactoside-binding, soluble, 3 binding protein	Mus musculus	0-32
19627619-0	2009	Cyclophilin C-associated protein (CyCAP) knock-out mice spontaneously develop colonic mucosal hyperplasia and exaggerated tumorigenesis after treatment with carcinogen azoxymethane.	Azoxymethane	168-180	lectin, galactoside-binding, soluble, 3 binding protein	Mus musculus	34-39
19627619-11	2009	The hyperplasia was even more pronounced in CyCAP-/- mice than in WT after challenge with azoxymethane (p = 0.005, T-test).	Azoxymethane	90-102	lectin, galactoside-binding, soluble, 3 binding protein	Mus musculus	44-49
19173288-0	2009	Fatty acid synthase is over-expressed in large aberrant crypt foci in rats treated with azoxymethane.	Azoxymethane	88-100	fatty acid synthase	Rattus norvegicus	0-19
19442760-1	2009	Azoxymethane, a rodent colon-specific carcinogen, induce DNA damage, and causes proto-oncogene K-ras point mutations and subsequent tumor formation if DNA damage is not repaired or removed.	Azoxymethane	0-12	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	95-100
19442760-2	2009	The present study was designed to detect and characterize K-ras mutations in azoxymethane (AOM)-induced aberrant crypt foci (ACF) in mice, and determine whether dietary supplementation of selenium influences K-ras mutations frequency in ACF using a new PCR technique of locked nucleic acid-mediated real-time PCR clamping combined with mutant-specific probes.	Azoxymethane	77-89	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	58-63
19442760-2	2009	The present study was designed to detect and characterize K-ras mutations in azoxymethane (AOM)-induced aberrant crypt foci (ACF) in mice, and determine whether dietary supplementation of selenium influences K-ras mutations frequency in ACF using a new PCR technique of locked nucleic acid-mediated real-time PCR clamping combined with mutant-specific probes.	Azoxymethane	91-94	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	58-63
19141699-0	2009	Soy isoflavones modulate azoxymethane-induced rat colon carcinogenesis exposed pre- and postnatally and inhibit growth of DLD-1 human colon adenocarcinoma cells by increasing the expression of estrogen receptor-beta.	Azoxymethane	25-37	estrogen receptor 2	Homo sapiens	193-215
19215228-0	2009	Plasma membrane-associated sialidase (NEU3) promotes formation of colonic aberrant crypt foci in azoxymethane-treated transgenic mice.	Azoxymethane	97-109	neuraminidase 3	Mus musculus	0-42
19215228-3	2009	Mice were injected with azoxymethane (i.p., 15 mg/kg/week) for 6 weeks, and 4 weeks later ACF had formed in the NEU3 transgenic mice significantly more than in the control wild-type mice.	Azoxymethane	24-36	neuraminidase 3	Mus musculus	112-116
19215228-7	2009	The results of this study provide the first evidence that NEU3 essentially increases azoxymethane-induced ACF formation in colon mucosa by suppression of apoptosis, possibly via activation of the EGF signaling pathway, and thus indicate that up-regulation of NEU3 is important to the promotion stage of colorectal carcinogenesis in vivo.	Azoxymethane	85-97	neuraminidase 3	Mus musculus	58-62
19215228-7	2009	The results of this study provide the first evidence that NEU3 essentially increases azoxymethane-induced ACF formation in colon mucosa by suppression of apoptosis, possibly via activation of the EGF signaling pathway, and thus indicate that up-regulation of NEU3 is important to the promotion stage of colorectal carcinogenesis in vivo.	Azoxymethane	85-97	neuraminidase 3	Mus musculus	259-263
18824518-7	2009	In the azoxymethane (AOM) murine model of colon cancer, SphK1 and S1P were significantly elevated in colon cancer tissues compared to normal mucosa.	Azoxymethane	7-19	sphingosine kinase 1	Mus musculus	56-61
19221092-5	2009	We find that enzastaurin potently reduces azoxymethane-induced colon tumor initiation and progression by inhibiting PKCbetaII-mediated tumor cell proliferation and beta-catenin accumulation.	Azoxymethane	42-54	protein kinase C, beta	Mus musculus	116-125
19221092-5	2009	We find that enzastaurin potently reduces azoxymethane-induced colon tumor initiation and progression by inhibiting PKCbetaII-mediated tumor cell proliferation and beta-catenin accumulation.	Azoxymethane	42-54	catenin (cadherin associated protein), beta 1	Mus musculus	164-176
18824518-7	2009	In the azoxymethane (AOM) murine model of colon cancer, SphK1 and S1P were significantly elevated in colon cancer tissues compared to normal mucosa.	Azoxymethane	7-19	sphingosine-1-phosphate receptor 1	Mus musculus	66-69
19139018-0	2009	Estrogen receptor-beta as a potential target for colon cancer prevention: chemoprevention of azoxymethane-induced colon carcinogenesis by raloxifene in F344 rats.	Azoxymethane	93-105	estrogen receptor 2	Rattus norvegicus	0-22
18790560-2	2009	But when treated with azoxymethane, a colon carcinogen, COX-2 mice had a higher tumor load compared to wild-type mice.	Azoxymethane	22-34	cytochrome c oxidase II, mitochondrial	Mus musculus	56-61
18790788-3	2008	We report herein the role of epidermal growth factor receptor (EGFR), a known mediator of Snail and overexpressed in approximately 80% of human colorectal cancers, on PEG-mediated antiproliferative and hence antineoplastic effects in azoxymethane (AOM) rats and HT-29 colon cancer cells.	Azoxymethane	234-246	epidermal growth factor receptor	Homo sapiens	29-61
19759415-0	2009	Pla2g2a attenuates colon tumorigenesis in azoxymethane-treated C57BL/6 mice; expression studies reveal Pla2g2a target genes and pathways.	Azoxymethane	42-54	phospholipase A2, group IIA (platelets, synovial fluid)	Mus musculus	0-7
19759415-4	2009	RESULTS: Pla2g2a strongly inhibited colon tumorigenesis in mice following treatment with the DNA alkylating agent azoxymethane (AOM).	Azoxymethane	114-126	phospholipase A2, group IIA (platelets, synovial fluid)	Mus musculus	9-16
19030198-0	2008	Adiponectin deficiency enhances colorectal carcinogenesis and liver tumor formation induced by azoxymethane in mice.	Azoxymethane	95-107	adiponectin, C1Q and collagen domain containing	Mus musculus	0-11
19138982-9	2008	Silibinin dose-dependently decreased AOM-induced colonic cell proliferation, evidenced by proliferative cell nuclear antigen and cyclin D1 immunohistochemical staining, and induced apoptosis in these colon tissues, evidenced by terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling staining and cleaved poly(ADP-ribose) polymerase.	Azoxymethane	37-40	cyclin D1	Rattus norvegicus	129-138
19138982-9	2008	Silibinin dose-dependently decreased AOM-induced colonic cell proliferation, evidenced by proliferative cell nuclear antigen and cyclin D1 immunohistochemical staining, and induced apoptosis in these colon tissues, evidenced by terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling staining and cleaved poly(ADP-ribose) polymerase.	Azoxymethane	37-40	poly (ADP-ribose) polymerase 1	Rattus norvegicus	323-350
19138982-10	2008	Furthermore, silibinin significantly decreased AOM-induced inducible nitric oxide synthase- and cyclooxygenase-2-positive cells in colon tissues.	Azoxymethane	47-50	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	96-112
18521082-1	2008	Mice overexpressing progastrin (PG) in intestinal mucosa (fatty acid-binding protein (Fabp)-PG mice) are at an increased risk of proximal colon carcinogenesis in response to azoxymethane.	Azoxymethane	174-186	glutamatic-oxaloacetic transaminase 2, mitochondrial	Mus musculus	58-84
18521082-1	2008	Mice overexpressing progastrin (PG) in intestinal mucosa (fatty acid-binding protein (Fabp)-PG mice) are at an increased risk of proximal colon carcinogenesis in response to azoxymethane.	Azoxymethane	174-186	glutamatic-oxaloacetic transaminase 2, mitochondrial	Mus musculus	86-90
19727435-4	2008	In addition, in colons of mice carrying mutations in Apc (Apc(Min) (/+)) or exposed to the carcinogen azoxymethane, elimination of GCC increased tumor initiation and promotion by disrupting genomic integrity and releasing cell cycle restriction.	Azoxymethane	102-114	guanylate cyclase 2c	Mus musculus	131-134
18790788-3	2008	We report herein the role of epidermal growth factor receptor (EGFR), a known mediator of Snail and overexpressed in approximately 80% of human colorectal cancers, on PEG-mediated antiproliferative and hence antineoplastic effects in azoxymethane (AOM) rats and HT-29 colon cancer cells.	Azoxymethane	234-246	epidermal growth factor receptor	Homo sapiens	63-67
18790788-3	2008	We report herein the role of epidermal growth factor receptor (EGFR), a known mediator of Snail and overexpressed in approximately 80% of human colorectal cancers, on PEG-mediated antiproliferative and hence antineoplastic effects in azoxymethane (AOM) rats and HT-29 colon cancer cells.	Azoxymethane	234-246	snail family transcriptional repressor 1	Homo sapiens	90-95
21479479-0	2008	Effects of synthetic and natural in vivo inhibitors of beta-glucuronidase on azoxymethane-induced colon carcinogenesis in rats.	Azoxymethane	77-89	glucuronidase, beta	Rattus norvegicus	55-73
19138955-4	2008	Azoxymethane/DSS-treated Nrf2 knockout mice had increased incidence, multiplicity, and size of all colorectal tumors, including adenomas, versus treated wild-type (WT) mice, and the proportion of tumors that were adenocarcinoma was much higher in knockout (80%) versus WT (29%) mice.	Azoxymethane	0-12	nuclear factor, erythroid derived 2, like 2	Mus musculus	25-29
18271008-4	2008	Transgenic mice in which an oncogenic K-ras(G12D) allele is activated in the colonic epithelium by sporadic recombination (K-rasLA2 mice) develop spontaneous ACF that are morphologically indistinguishable from those induced by the colon carcinogen azoxymethane (AOM).	Azoxymethane	248-260	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	38-43
18681964-0	2008	Dark Aberrant Crypt Foci with activated Wnt pathway are related to tumorigenesis in the colon of AOM-treated rat.	Azoxymethane	97-100	Wnt family member 2	Rattus norvegicus	40-43
18543083-1	2008	We previously demonstrated that angiotensin II (Ang II) receptor signaling is involved in azoxymethane-induced mouse colon tumorigenesis.	Azoxymethane	90-102	angiotensinogen	Rattus norvegicus	32-46
18543083-1	2008	We previously demonstrated that angiotensin II (Ang II) receptor signaling is involved in azoxymethane-induced mouse colon tumorigenesis.	Azoxymethane	90-102	angiotensinogen	Rattus norvegicus	48-54
18326560-8	2008	Following azoxymethane and dextran sodium sulfate (DSS) treatment, fewer total tumours were observed in the ILK knockout animals, which were mosaic with respect to ILK expression.	Azoxymethane	10-22	integrin linked kinase	Mus musculus	108-111
18644992-3	2008	In the azoxymethane-treated rat model of experimental colon carcinogenesis, sulindac treatment markedly induced Csk with a corresponding increase in inhibitory phosphorylation of Src (Tyr(527)).	Azoxymethane	7-19	C-terminal Src kinase	Rattus norvegicus	112-115
18644992-3	2008	In the azoxymethane-treated rat model of experimental colon carcinogenesis, sulindac treatment markedly induced Csk with a corresponding increase in inhibitory phosphorylation of Src (Tyr(527)).	Azoxymethane	7-19	SRC proto-oncogene, non-receptor tyrosine kinase	Rattus norvegicus	179-182
18413814-0	2008	Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model.	Azoxymethane	130-142	epidermal growth factor receptor	Rattus norvegicus	0-32
18220315-3	2008	Therefore, we investigated the effect of deletion of the IL-4R alpha gene on azoxymethane-induced colorectal aberrant crypt focus (ACF) multiplicity and size in Balb/c mice.	Azoxymethane	77-89	interleukin 4 receptor, alpha	Mus musculus	57-68
18307533-0	2008	Susceptibility of Snark-deficient mice to azoxymethane-induced colorectal tumorigenesis and the formation of aberrant crypt foci.	Azoxymethane	42-54	NUAK family, SNF1-like kinase, 2	Mus musculus	18-23
18239060-3	2008	Here, we show that colonic FASN levels are reduced with dietary intake of soy protein isolate (SPI), compared with a control casein diet, in male Sprague-Dawley rats administered the colon carcinogen azoxymethane.	Azoxymethane	200-212	fatty acid synthase	Rattus norvegicus	27-31
18239060-4	2008	SPI consumption resulted in decreased serum insulin levels and decreased azoxymethane-induced tumor suppressor p53 phosphorylation in colon crypt epithelium.	Azoxymethane	73-85	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	111-114
18220315-5	2008	There were significantly higher levels of IL-4 in serum from azoxymethane- and sham-treated IL-4R alpha(-/-) mice than WT animals, but no difference in serum IL-13 levels.	Azoxymethane	61-73	interleukin 4	Mus musculus	42-46
18220315-8	2008	In summary, IL-4R alpha-dependent signalling has a protective, anti-neoplastic role during the post-initiation phase of azoxymethane-induced colorectal carcinogenesis in Balb/c mice.	Azoxymethane	120-132	interleukin 4 receptor, alpha	Mus musculus	12-23
18087038-5	2007	We exploited this increased IGF-II sensitivity to develop an in vivo chemopreventive strategy using the azoxymethane (AOM) mutagenesis model.	Azoxymethane	104-116	insulin-like growth factor 2	Mus musculus	28-34
17900258-0	2007	Increased susceptibility of Sf1(+/-) mice to azoxymethane-induced colon tumorigenesis.	Azoxymethane	45-57	splicing factor 1	Mus musculus	28-31
17900258-6	2007	Azoxymethane (AOM) was given at a dose of 10 mg/kg body weight once a week for 6 weeks to 7-week-old Sf1(+/-) and Sf1(+/+) mice.	Azoxymethane	0-12	splicing factor 1	Mus musculus	101-104
17900258-6	2007	Azoxymethane (AOM) was given at a dose of 10 mg/kg body weight once a week for 6 weeks to 7-week-old Sf1(+/-) and Sf1(+/+) mice.	Azoxymethane	0-12	splicing factor 1	Mus musculus	114-117
17900258-6	2007	Azoxymethane (AOM) was given at a dose of 10 mg/kg body weight once a week for 6 weeks to 7-week-old Sf1(+/-) and Sf1(+/+) mice.	Azoxymethane	14-17	splicing factor 1	Mus musculus	101-104
17200374-10	2007	Importantly, dietary pterostilbene also suppressed azoxymethane-induced colonic cell proliferation and iNOS expression.	Azoxymethane	51-63	nitric oxide synthase 2	Rattus norvegicus	103-107
17634405-6	2007	Here we show that endogenously increased tissue levels of n-3 PUFA in the fat-1 transgenic mouse model lower incidence and growth rate of colon tumors induced by inflammation (dextrane sodium sulfate) plus treatment with carcinogen (azoxymethane).	Azoxymethane	233-245	pumilio RNA binding family member 3	Homo sapiens	62-66
17634405-6	2007	Here we show that endogenously increased tissue levels of n-3 PUFA in the fat-1 transgenic mouse model lower incidence and growth rate of colon tumors induced by inflammation (dextrane sodium sulfate) plus treatment with carcinogen (azoxymethane).	Azoxymethane	233-245	FAT atypical cadherin 1	Mus musculus	74-79
17658518-2	2007	In the current study, we elucidate the mechanism of EIBS by assessing iNOS/nitric oxide axis in the histologically normal colonic mucosa of rats treated with the colon-specific carcinogen, azoxymethane.	Azoxymethane	189-201	nitric oxide synthase 2	Rattus norvegicus	70-74
17616656-2	2007	Here, we report that Tir8-deficient mice exhibited a dramatic intestinal inflammation in response to dextran sulfate sodium salt (DSS) administration in terms of weight loss, intestinal bleeding, and mortality and showed increased susceptibility to carcinogenesis in response to azoxymethane and DSS.	Azoxymethane	279-291	single immunoglobulin and toll-interleukin 1 receptor (TIR) domain	Mus musculus	21-25
17194898-0	2007	Long-term feeding of various fat diets modulates azoxymethane-induced colon carcinogenesis through Wnt/beta-catenin signaling in rats.	Azoxymethane	49-61	Wnt family member 2	Rattus norvegicus	99-102
17194898-0	2007	Long-term feeding of various fat diets modulates azoxymethane-induced colon carcinogenesis through Wnt/beta-catenin signaling in rats.	Azoxymethane	49-61	catenin beta 1	Rattus norvegicus	103-115
17398123-3	2007	SIGIRR-deficient (Sigirr(-/-)) colonic epithelial cells displayed commensal bacteria-dependent homeostatic defects, as shown by constitutive upregulation of inflammatory genes, increased inflammatory responses to dextran sulfate sodium (DSS) challenge, and increased Azoxymethane (AOM)+DSS-induced colitis-associated tumorigenesis.	Azoxymethane	267-279	single immunoglobulin and toll-interleukin 1 receptor (TIR) domain	Mus musculus	0-6
17398123-3	2007	SIGIRR-deficient (Sigirr(-/-)) colonic epithelial cells displayed commensal bacteria-dependent homeostatic defects, as shown by constitutive upregulation of inflammatory genes, increased inflammatory responses to dextran sulfate sodium (DSS) challenge, and increased Azoxymethane (AOM)+DSS-induced colitis-associated tumorigenesis.	Azoxymethane	267-279	single immunoglobulin and toll-interleukin 1 receptor (TIR) domain	Mus musculus	18-24
17398123-3	2007	SIGIRR-deficient (Sigirr(-/-)) colonic epithelial cells displayed commensal bacteria-dependent homeostatic defects, as shown by constitutive upregulation of inflammatory genes, increased inflammatory responses to dextran sulfate sodium (DSS) challenge, and increased Azoxymethane (AOM)+DSS-induced colitis-associated tumorigenesis.	Azoxymethane	281-284	single immunoglobulin and toll-interleukin 1 receptor (TIR) domain	Mus musculus	0-6
17398123-3	2007	SIGIRR-deficient (Sigirr(-/-)) colonic epithelial cells displayed commensal bacteria-dependent homeostatic defects, as shown by constitutive upregulation of inflammatory genes, increased inflammatory responses to dextran sulfate sodium (DSS) challenge, and increased Azoxymethane (AOM)+DSS-induced colitis-associated tumorigenesis.	Azoxymethane	281-284	single immunoglobulin and toll-interleukin 1 receptor (TIR) domain	Mus musculus	18-24
17234795-0	2007	Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis.	Azoxymethane	95-107	epidermal growth factor receptor	Mus musculus	0-32
17234795-4	2007	In the current study, we used a specific EGFR antagonist, gefitinib, to investigate this role of the receptor in azoxymethane colonic premalignancy.	Azoxymethane	113-125	epidermal growth factor receptor	Mus musculus	41-45
17234795-10	2007	Azoxymethane significantly induced pro-transforming growth factor-alpha (6.4+/-1.3-fold) and increased phospho-(active) EGFR (5.9+/-1.1-fold), phospho-(active) ErbB2 (2.3+/-0.2-fold), and phospho-(active) extracellular signal-regulated kinase (3.3+/-0.4-fold) in premalignant colonocytes.	Azoxymethane	0-12	transforming growth factor alpha	Mus musculus	35-71
17234795-10	2007	Azoxymethane significantly induced pro-transforming growth factor-alpha (6.4+/-1.3-fold) and increased phospho-(active) EGFR (5.9+/-1.1-fold), phospho-(active) ErbB2 (2.3+/-0.2-fold), and phospho-(active) extracellular signal-regulated kinase (3.3+/-0.4-fold) in premalignant colonocytes.	Azoxymethane	0-12	epidermal growth factor receptor	Mus musculus	120-124
17234795-10	2007	Azoxymethane significantly induced pro-transforming growth factor-alpha (6.4+/-1.3-fold) and increased phospho-(active) EGFR (5.9+/-1.1-fold), phospho-(active) ErbB2 (2.3+/-0.2-fold), and phospho-(active) extracellular signal-regulated kinase (3.3+/-0.4-fold) in premalignant colonocytes.	Azoxymethane	0-12	erb-b2 receptor tyrosine kinase 2	Mus musculus	160-165
16619040-7	2006	However, when mice are treated with azoxymethane to induce colonic tumors, we find that Ceacam1-/- mice developed a significantly greater number of tumors than their littermate controls.	Azoxymethane	36-48	carcinoembryonic antigen-related cell adhesion molecule 1	Mus musculus	88-95
17190766-0	2007	Effect of azoxymethane and curcumin on transcriptional levels of cyclooxygenase-1 and -2 during initiation of colon carcinogenesis.	Azoxymethane	10-22	prostaglandin-endoperoxide synthase 1	Rattus norvegicus	65-88
17038629-0	2006	Azoxymethane protects intestinal stem cells and reduces crypt epithelial mitosis through a COX-1-dependent mechanism.	Azoxymethane	0-12	cytochrome c oxidase I, mitochondrial	Mus musculus	91-96
16949053-1	2006	The p53 tumor suppressor protein is sequence-normal in azoxymethane (AOM)-induced mouse colon tumors, making them a good model for human colon cancers that retain a wild type p53 gene.	Azoxymethane	55-67	transformation related protein 53, pseudogene	Mus musculus	4-7
16949053-1	2006	The p53 tumor suppressor protein is sequence-normal in azoxymethane (AOM)-induced mouse colon tumors, making them a good model for human colon cancers that retain a wild type p53 gene.	Azoxymethane	69-72	transformation related protein 53, pseudogene	Mus musculus	4-7
16984374-0	2006	Suppression of azoxymethane-induced colon cancer development in rats by a cyclooxygenase-1 selective inhibitor, mofezolac.	Azoxymethane	15-27	prostaglandin-endoperoxide synthase 1	Rattus norvegicus	74-90
16984374-1	2006	We demonstrated recently that mofezolac, a cyclooxygenase-1 (COX-1) selective inhibitor, suppresses the development of azoxymethane (AOM)-induced colonic aberrant crypt foci in F344 rats and intestinal polyps in APC1309 mice.	Azoxymethane	119-131	prostaglandin-endoperoxide synthase 1	Rattus norvegicus	61-66
16984374-1	2006	We demonstrated recently that mofezolac, a cyclooxygenase-1 (COX-1) selective inhibitor, suppresses the development of azoxymethane (AOM)-induced colonic aberrant crypt foci in F344 rats and intestinal polyps in APC1309 mice.	Azoxymethane	133-136	prostaglandin-endoperoxide synthase 1	Rattus norvegicus	61-66
16880406-4	2006	Furthermore, 15-PGDH gene knockout abrogates the normal resistance of C57BL/6J mice to colon tumor induction by the carcinogen azoxymethane (AOM), conferring susceptibility to AOM-induced adenomas and carcinomas in situ.	Azoxymethane	127-139	hydroxyprostaglandin dehydrogenase 15 (NAD)	Mus musculus	13-20
16940160-3	2006	In prior studies in the azoxymethane model of colon cancer, we showed that PKC-zeta was down-regulated in rat colonic tumors.	Azoxymethane	24-36	protein kinase C zeta	Homo sapiens	75-83
16880406-4	2006	Furthermore, 15-PGDH gene knockout abrogates the normal resistance of C57BL/6J mice to colon tumor induction by the carcinogen azoxymethane (AOM), conferring susceptibility to AOM-induced adenomas and carcinomas in situ.	Azoxymethane	141-144	hydroxyprostaglandin dehydrogenase 15 (NAD)	Mus musculus	13-20
16880406-4	2006	Furthermore, 15-PGDH gene knockout abrogates the normal resistance of C57BL/6J mice to colon tumor induction by the carcinogen azoxymethane (AOM), conferring susceptibility to AOM-induced adenomas and carcinomas in situ.	Azoxymethane	176-179	hydroxyprostaglandin dehydrogenase 15 (NAD)	Mus musculus	13-20
16928827-2	2006	In this study, we assessed the ability of PEG to target cyclin D1-beta-catenin-mediated hyperproliferation in the azoxymethane-treated rat model and the human colorectal cancer cell line, HT-29.	Azoxymethane	114-126	cyclin D1	Rattus norvegicus	56-65
16928827-2	2006	In this study, we assessed the ability of PEG to target cyclin D1-beta-catenin-mediated hyperproliferation in the azoxymethane-treated rat model and the human colorectal cancer cell line, HT-29.	Azoxymethane	114-126	catenin beta 1	Rattus norvegicus	66-78
16928827-8	2006	PEG did not alter total beta-catenin expression but rather its nuclear localization, leading us to assess E-cadherin expression (a major determinant of beta-catenin subcellular localization), which was increased by 73% and 71% in the azoxymethane-rat and HT-29 cells, respectively.	Azoxymethane	234-246	cadherin 1	Rattus norvegicus	106-116
16618765-3	2006	This hypothesis was examined by treating wild-type (Pparb+/+) and Pparb-/- with azoxymethane, coupled with a highly specific PPARbeta ligand, GW0742.	Azoxymethane	80-92	peroxisome proliferator activator receptor delta	Mus musculus	66-71
16886601-2	2006	The purpose of this study was to investigate the association between the mRNA expression level of the Mgmt gene and mutation of the beta-catenin gene in rat colon tumors induced by azoxymethane (AOM) plus dextran sulfate sodium (DSS).	Azoxymethane	181-193	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	102-106
16886601-2	2006	The purpose of this study was to investigate the association between the mRNA expression level of the Mgmt gene and mutation of the beta-catenin gene in rat colon tumors induced by azoxymethane (AOM) plus dextran sulfate sodium (DSS).	Azoxymethane	181-193	catenin beta 1	Rattus norvegicus	132-144
16886601-2	2006	The purpose of this study was to investigate the association between the mRNA expression level of the Mgmt gene and mutation of the beta-catenin gene in rat colon tumors induced by azoxymethane (AOM) plus dextran sulfate sodium (DSS).	Azoxymethane	195-198	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	102-106
16886601-2	2006	The purpose of this study was to investigate the association between the mRNA expression level of the Mgmt gene and mutation of the beta-catenin gene in rat colon tumors induced by azoxymethane (AOM) plus dextran sulfate sodium (DSS).	Azoxymethane	195-198	catenin beta 1	Rattus norvegicus	132-144
16331625-7	2006	When IFN-gamma(-/-) mice were treated with AOM and TNBS, significantly higher number of tumors were seen (8.4 +/- 1.7) than in WT (3.3 +/- 2.9) or IL-4(-/-) (3.1 +/- 3.4) mice, which received identical treatments.	Azoxymethane	43-46	interferon gamma	Mus musculus	5-14
16331625-7	2006	When IFN-gamma(-/-) mice were treated with AOM and TNBS, significantly higher number of tumors were seen (8.4 +/- 1.7) than in WT (3.3 +/- 2.9) or IL-4(-/-) (3.1 +/- 3.4) mice, which received identical treatments.	Azoxymethane	43-46	interleukin 4	Mus musculus	147-151
16309164-1	2005	BACKGROUND: In Apc(Min/+) (Min; multiple intestinal neoplasia) mice two separate populations of aberrant crypt foci (ACF) develop in the colon after azoxymethane (AOM) exposure.	Azoxymethane	149-161	APC, WNT signaling pathway regulator	Mus musculus	15-25
16297463-9	2006	The numbers of aberrant crypt foci in the mid-colon, distal colon and rectum following treatment with azoxymethane were also significantly increased by infusion with amidated or glycine-extended gastrin-releasing peptide.	Azoxymethane	102-114	gastrin releasing peptide	Rattus norvegicus	195-220
16619513-1	2006	The activation of ketoprofen, which inhibits the outgrowth of azoxymethane-induced aberrant crypt foci in the rat colon, on the inhibition of arylamine N-acetyltransferase (NAT) activity (N-acetylation of substrates), gene expression (mRNA NAT) and 2-aminofluorene (AF)-DNA adduct formation was studied in a human colon tumor (adenocarcinoma) cell line (colo 205).	Azoxymethane	62-74	bromodomain containing 2	Homo sapiens	152-171
16619513-1	2006	The activation of ketoprofen, which inhibits the outgrowth of azoxymethane-induced aberrant crypt foci in the rat colon, on the inhibition of arylamine N-acetyltransferase (NAT) activity (N-acetylation of substrates), gene expression (mRNA NAT) and 2-aminofluorene (AF)-DNA adduct formation was studied in a human colon tumor (adenocarcinoma) cell line (colo 205).	Azoxymethane	62-74	N-acetyltransferase 1	Rattus norvegicus	173-176
16619513-1	2006	The activation of ketoprofen, which inhibits the outgrowth of azoxymethane-induced aberrant crypt foci in the rat colon, on the inhibition of arylamine N-acetyltransferase (NAT) activity (N-acetylation of substrates), gene expression (mRNA NAT) and 2-aminofluorene (AF)-DNA adduct formation was studied in a human colon tumor (adenocarcinoma) cell line (colo 205).	Azoxymethane	62-74	N-acetyltransferase 1	Rattus norvegicus	240-243
16122953-1	2006	The expression of inducible nitric oxide synthase (iNOS) is markedly elevated in rat colon cancers induced by azoxymethane (AOM).	Azoxymethane	110-122	nitric oxide synthase 2	Rattus norvegicus	18-49
16122953-1	2006	The expression of inducible nitric oxide synthase (iNOS) is markedly elevated in rat colon cancers induced by azoxymethane (AOM).	Azoxymethane	110-122	nitric oxide synthase 2	Rattus norvegicus	51-55
16113056-9	2006	No significant differences were found among the groups in hepatic cytochrome P450 2E1 (CYP2E1) activity, the first enzyme involved in activation of azoxymethane.	Azoxymethane	148-160	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	87-93
16319132-3	2006	Therefore, we examined the expression of SK1 and COX-2 in rat colon tumors induced by azoxymethane (AOM) and the relationship of these two proteins in normal and malignant intestinal epithelial cells.	Azoxymethane	86-98	sphingosine kinase 1	Rattus norvegicus	41-44
16319132-3	2006	Therefore, we examined the expression of SK1 and COX-2 in rat colon tumors induced by azoxymethane (AOM) and the relationship of these two proteins in normal and malignant intestinal epithelial cells.	Azoxymethane	100-103	sphingosine kinase 1	Rattus norvegicus	41-44
16094650-6	2006	In an in vitro carcinogenesis model, IEC6 cells, which had confirmed CYP2E1 expression and activity, were continuously treated with AOM and/or LA for 40 weeks.	Azoxymethane	132-135	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	69-75
17293962-8	2006	CONCLUSION: The azoxymethane increase expression SOD1, while inositol hexaphosphate decreases in a significant way the expression of SOD1 promoted by the administration of the carcinogen azoxymethane.	Azoxymethane	16-28	superoxide dismutase 1, soluble	Mus musculus	49-53
17293962-8	2006	CONCLUSION: The azoxymethane increase expression SOD1, while inositol hexaphosphate decreases in a significant way the expression of SOD1 promoted by the administration of the carcinogen azoxymethane.	Azoxymethane	187-199	superoxide dismutase 1, soluble	Mus musculus	49-53
17293962-8	2006	CONCLUSION: The azoxymethane increase expression SOD1, while inositol hexaphosphate decreases in a significant way the expression of SOD1 promoted by the administration of the carcinogen azoxymethane.	Azoxymethane	187-199	superoxide dismutase 1, soluble	Mus musculus	133-137
17293967-6	2006	RESULTS: mean values of TGF-beta2 expression were 9.0 +/- 3.9% for group 4 (control), 12.7 +/- 4.0% for group 3 (IP6), 19.3 +/- 6.2% for group 2 (AOM), and 13.1 +/- 5.3% for group 1 (IP6+AOM).	Azoxymethane	146-149	transforming growth factor, beta 2	Rattus norvegicus	24-33
16309164-1	2005	BACKGROUND: In Apc(Min/+) (Min; multiple intestinal neoplasia) mice two separate populations of aberrant crypt foci (ACF) develop in the colon after azoxymethane (AOM) exposure.	Azoxymethane	163-166	APC, WNT signaling pathway regulator	Mus musculus	15-25
15961079-2	2005	We report herein that prior to occurrence of neoplastic lesions in the azoxymethane-rat model of colon carcinogenesis; the tumor suppressor gene C-terminal Src kinase (Csk) was down-regulated with a concomitant increase in Src activity.	Azoxymethane	71-83	C-terminal Src kinase	Rattus norvegicus	145-166
15849741-0	2005	Sulindac corrects defective apoptosis and suppresses azoxymethane-induced colonic oncogenesis in p53 knockout mice.	Azoxymethane	53-65	transformation related protein 53, pseudogene	Mus musculus	97-100
15961079-2	2005	We report herein that prior to occurrence of neoplastic lesions in the azoxymethane-rat model of colon carcinogenesis; the tumor suppressor gene C-terminal Src kinase (Csk) was down-regulated with a concomitant increase in Src activity.	Azoxymethane	71-83	C-terminal Src kinase	Rattus norvegicus	168-171
15961079-2	2005	We report herein that prior to occurrence of neoplastic lesions in the azoxymethane-rat model of colon carcinogenesis; the tumor suppressor gene C-terminal Src kinase (Csk) was down-regulated with a concomitant increase in Src activity.	Azoxymethane	71-83	SRC proto-oncogene, non-receptor tyrosine kinase	Rattus norvegicus	156-159
16034162-0	2005	Inhibition of azoxymethane-induced aberrant crypt foci in rat by diphenylmethyl selenocyanate through downregulation of COX-2 and modulation of glutathione-S-transferase and lipid peroxidation.	Azoxymethane	14-26	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	120-125
16034162-0	2005	Inhibition of azoxymethane-induced aberrant crypt foci in rat by diphenylmethyl selenocyanate through downregulation of COX-2 and modulation of glutathione-S-transferase and lipid peroxidation.	Azoxymethane	14-26	hematopoietic prostaglandin D synthase	Rattus norvegicus	144-169
15904466-0	2005	Suppression of azoxymethane-induced colon cancer development in rats by a prostaglandin E receptor EP1-selective antagonist.	Azoxymethane	15-27	prostaglandin E receptor 1	Rattus norvegicus	99-102
15864814-1	2005	BACKGROUND: The authors recently reported that gastrin gene knockout (GAS-KO) mice had an increased risk for colon carcinogenesis in response to azoxymethane (AOM) compared with their wild type (WT) littermates.	Azoxymethane	145-157	gastrin	Mus musculus	47-54
15864814-1	2005	BACKGROUND: The authors recently reported that gastrin gene knockout (GAS-KO) mice had an increased risk for colon carcinogenesis in response to azoxymethane (AOM) compared with their wild type (WT) littermates.	Azoxymethane	159-162	gastrin	Mus musculus	47-54
15700305-0	2005	Absence of acute apoptotic response to genotoxic carcinogens in p53-deficient mice is associated with increased susceptibility to azoxymethane-induced colon tumours.	Azoxymethane	130-142	transformation related protein 53, pseudogene	Mus musculus	64-67
15723712-7	2005	Our findings indicate that lysophosphatidic acid significantly increased the incidence of peritoneal and/or pleural metastases from intestinal adenocarcinomas induced in rats by azoxymethane through RhoA activation.	Azoxymethane	178-190	ras homolog family member A	Rattus norvegicus	199-203
15805260-6	2005	In the following study, we evaluated the influence of genetic deletion of a key intracellular phospholipase, cytoplasmic PLA(2) (cPLA(2)), on azoxymethane-induced colon tumorigenesis.	Azoxymethane	142-154	phospholipase A2, group IB, pancreas	Mus musculus	121-127
15805260-6	2005	In the following study, we evaluated the influence of genetic deletion of a key intracellular phospholipase, cytoplasmic PLA(2) (cPLA(2)), on azoxymethane-induced colon tumorigenesis.	Azoxymethane	142-154	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	129-136
15576447-1	2005	The cytochrome P450 (P450) CYP2E1 enzyme metabolizes and activates a wide array of toxicological substrates, including alcohols, the widely used analgesic acetaminophen, acetone, benzene, halothane, and carcinogens such as azoxymethane and dimethylhydrazine.	Azoxymethane	223-235	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	27-33
15486344-1	2005	Transgenic mice (hGAS) that overexpress human progastrin are more susceptible than wild-type mice (FVB/N) to the induction of colonic aberrant crypt foci (ACF) and adenomas by the chemical carcinogen azoxymethane.	Azoxymethane	200-212	gastrin	Homo sapiens	17-21
15192017-0	2004	Lactoferrin enhances Fas expression and apoptosis in the colon mucosa of azoxymethane-treated rats.	Azoxymethane	73-85	lactotransferrin	Rattus norvegicus	0-11
15297369-0	2004	Azoxymethane-induced pre-adipocyte factor 1 (Pref-1) functions as a differentiation inhibitor in colonic epithelial cells.	Azoxymethane	0-12	delta like non-canonical Notch ligand 1	Mus musculus	21-43
15297369-0	2004	Azoxymethane-induced pre-adipocyte factor 1 (Pref-1) functions as a differentiation inhibitor in colonic epithelial cells.	Azoxymethane	0-12	delta like non-canonical Notch ligand 1	Mus musculus	45-51
15522837-2	2004	The aim of this study was to investigate whether long-term dietary corn oil promotes colon cancer by inhibiting the tumor suppressor gene p53-mediated mitochondria-dependent apoptosis in azoxymethane (AOM)-treated rats.	Azoxymethane	187-199	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	138-141
15522837-2	2004	The aim of this study was to investigate whether long-term dietary corn oil promotes colon cancer by inhibiting the tumor suppressor gene p53-mediated mitochondria-dependent apoptosis in azoxymethane (AOM)-treated rats.	Azoxymethane	201-204	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	138-141
15684064-4	2005	Likewise, Lrh-1+/- mice are protected against the formation of aberrant crypt foci in the colon of mice exposed to the carcinogen azoxymethane.	Azoxymethane	130-142	nuclear receptor subfamily 5, group A, member 2	Mus musculus	10-15
15617833-3	2005	However, in the azoxymethane-treated rat, where beta-catenin is frequently rendered GSK-3beta-insensitive, nabumetone failed to alter beta-catenin levels but did decrease beta-catenin nuclear localization and transcriptional activity as gauged by cyclin D1.	Azoxymethane	16-28	catenin beta 1	Rattus norvegicus	48-60
15578539-0	2004	Leptin reduces the development of the initial precancerous lesions induced by azoxymethane in the rat colonic mucosa.	Azoxymethane	78-90	leptin	Rattus norvegicus	0-6
15322124-3	2004	Here we demonstrate that nullizygous PKCbeta (PKCbetaKO) mice are highly resistant to azoxymethane (AOM)-induced preneoplastic lesions, aberrant crypt foci.	Azoxymethane	86-98	protein kinase C, beta	Mus musculus	37-44
15377995-3	2004	We investigated susceptibility of p21-deficient mice to the colon carcinogen azoxymethane (AOM).	Azoxymethane	77-89	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	34-37
15192017-1	2004	Bovine lactoferrin, a multifunctional glycoprotein, has been shown to strongly inhibit development of azoxymethane (AOM)-induced rat colon tumors.	Azoxymethane	102-114	lactotransferrin	Rattus norvegicus	7-18
15543947-2	2004	Intestinal epithelial cells have been found to modulate the relative levels of the p65-p50 and p50-p50 NF-kappaB complexes in a number of instances, and here we show that this ratio was altered in response to dietary fiber (wheat bran) and carcinogen exposure (azoxymethane).	Azoxymethane	261-273	RELA proto-oncogene, NF-kB subunit	Homo sapiens	83-86
15465771-0	2004	Beef meat and blood sausage promote the formation of azoxymethane-induced mucin-depleted foci and aberrant crypt foci in rat colons.	Azoxymethane	53-65	solute carrier family 13 member 2	Rattus norvegicus	74-79
15543947-2	2004	Intestinal epithelial cells have been found to modulate the relative levels of the p65-p50 and p50-p50 NF-kappaB complexes in a number of instances, and here we show that this ratio was altered in response to dietary fiber (wheat bran) and carcinogen exposure (azoxymethane).	Azoxymethane	261-273	nuclear factor kappa B subunit 1	Homo sapiens	95-98
15543947-2	2004	Intestinal epithelial cells have been found to modulate the relative levels of the p65-p50 and p50-p50 NF-kappaB complexes in a number of instances, and here we show that this ratio was altered in response to dietary fiber (wheat bran) and carcinogen exposure (azoxymethane).	Azoxymethane	261-273	nuclear factor kappa B subunit 1	Homo sapiens	95-98
12370429-4	2002	Heterozygous loss of PPARgamma causes an increase in beta-catenin levels and a greater incidence of colon cancer when animals are treated with azoxymethane.	Azoxymethane	143-155	peroxisome proliferator activated receptor gamma	Mus musculus	21-30
15517863-0	2004	Loss of heterozygosity and nonsense mutation in Apc in azoxymethane-induced colonic tumours in min mice.	Azoxymethane	55-67	APC, WNT signaling pathway regulator	Mus musculus	48-51
15170673-0	2004	Dietary seed oil rich in conjugated linolenic acid from bitter melon inhibits azoxymethane-induced rat colon carcinogenesis through elevation of colonic PPARgamma expression and alteration of lipid composition.	Azoxymethane	78-90	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	153-162
15373703-0	2004	Inhibition of azoxymethane-induced colon carcinogenesis in rats due to JTE-522, a selective cyclooxygenase-2 inhibitor.	Azoxymethane	14-26	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	92-108
12927365-1	2003	We examined the p53 response following acute exposure of mice to the colon-specific carcinogen azoxymethane (AOM).	Azoxymethane	95-107	transformation related protein 53, pseudogene	Mus musculus	16-19
12824873-9	2003	Therefore, the results indicate that susceptibility to AOM-induced tumorigenesis in the colon and also in the liver is enhanced in Parp-1(-/-) mice, and Parp-1 could have a substantial role in colon and liver tumorigenesis.	Azoxymethane	55-58	poly (ADP-ribose) polymerase family, member 1	Mus musculus	131-137
12750256-0	2003	Identification of mucin-depleted foci in the unsectioned colon of azoxymethane-treated rats: correlation with carcinogenesis.	Azoxymethane	66-78	solute carrier family 13 member 2	Rattus norvegicus	18-23
12750256-5	2003	We defined these lesions as mucin-depleted foci (MDF), and they were visible in all azoxymethane-treated rats and correlated with tumor induction (MDF/colon: 8.2 +/- 0.9 and 3.8 +/- 0.9 in controls and synbiotic-fed rats, respectively, P < 0.01; crypts/MDF: 12.2 +/- 2 and 6.4 +/- 1 in controls and synbiotic-fed rats, respectively, P < 0.05, means +/- SE, n = 7).	Azoxymethane	84-96	solute carrier family 13 member 2	Rattus norvegicus	28-33
15312680-0	2004	Lactoferrin modifies apoptosis-related gene expression in the colon of the azoxymethane-treated rat.	Azoxymethane	75-87	lactotransferrin	Rattus norvegicus	0-11
15312680-1	2004	Lactoferrin, an iron-binding glycoprotein, exhibits suppressive effects on development of azoxymethane (AOM)-induced tumors in the rat colon, but the mechanisms are largely unknown.	Azoxymethane	90-102	lactotransferrin	Rattus norvegicus	0-11
15312680-1	2004	Lactoferrin, an iron-binding glycoprotein, exhibits suppressive effects on development of azoxymethane (AOM)-induced tumors in the rat colon, but the mechanisms are largely unknown.	Azoxymethane	104-107	lactotransferrin	Rattus norvegicus	0-11
14762787-0	2004	Leptin reduces the development of the initial precancerous lesions induced by azoxymethane in the rat colonic mucosa.	Azoxymethane	78-90	leptin	Rattus norvegicus	0-6
14762787-3	2004	METHODS: Leptin (1 mg/kg/d) or vehicle was administered systemically by miniosmotic pump in Fischer 344 rats either for 7 days (BrdU-labeling indices study) or 23 days (azoxymethane-induced colonic lesions study).	Azoxymethane	169-181	leptin	Rattus norvegicus	9-15
14762787-6	2004	Unexpectedly, in azoxymethane-treated rats, leptin significantly inhibited aberrant crypt foci formation in the middle and distal colon compared with controls (P = 0.006).	Azoxymethane	17-29	leptin	Rattus norvegicus	44-50
12943528-4	2004	An increased expression of both eNOS and VEGF in colonic tissue from azoxymethane-treated rats compared with that from control rats was found.	Azoxymethane	69-81	nitric oxide synthase 3	Rattus norvegicus	32-36
12943528-4	2004	An increased expression of both eNOS and VEGF in colonic tissue from azoxymethane-treated rats compared with that from control rats was found.	Azoxymethane	69-81	vascular endothelial growth factor A	Rattus norvegicus	41-45
12943528-7	2004	Expression of the VEGF receptor Flk-1, but not Flt-1, was increased in colonic tissue of azoxymethane-treated rats compared with control rats.	Azoxymethane	89-101	vascular endothelial growth factor A	Rattus norvegicus	18-22
12943528-7	2004	Expression of the VEGF receptor Flk-1, but not Flt-1, was increased in colonic tissue of azoxymethane-treated rats compared with control rats.	Azoxymethane	89-101	kinase insert domain receptor	Rattus norvegicus	32-37
12943528-9	2004	Aspirin treatment reduced Flk-1 expression in both control and azoxymethane-treated rats.	Azoxymethane	63-75	kinase insert domain receptor	Rattus norvegicus	26-31
12943528-10	2004	Caspase-3 activity, which has been considered as an apoptotic index, was almost undetectable in azoxymethane-treated rats.	Azoxymethane	96-108	caspase 3	Rattus norvegicus	0-9
12943528-12	2004	Overexpression of eNOS, VEGF and its receptor Flk-1 occurred early after azoxymethane administration in rat colonic tissue, even before morphological changes associated with tumour generation were observed, and aspirin prevented the overexpression of both eNOS and VEGF receptor Flk-1.	Azoxymethane	73-85	nitric oxide synthase 3	Rattus norvegicus	18-22
12943528-12	2004	Overexpression of eNOS, VEGF and its receptor Flk-1 occurred early after azoxymethane administration in rat colonic tissue, even before morphological changes associated with tumour generation were observed, and aspirin prevented the overexpression of both eNOS and VEGF receptor Flk-1.	Azoxymethane	73-85	vascular endothelial growth factor A	Rattus norvegicus	24-28
12943528-12	2004	Overexpression of eNOS, VEGF and its receptor Flk-1 occurred early after azoxymethane administration in rat colonic tissue, even before morphological changes associated with tumour generation were observed, and aspirin prevented the overexpression of both eNOS and VEGF receptor Flk-1.	Azoxymethane	73-85	kinase insert domain receptor	Rattus norvegicus	46-51
14727811-1	2003	The aim of the study reported here was to investigate whether the azoxymethane (AOM)-induced colon cancer rat model mimics the human situation with regard to microsatellite stability, changes in expression of beta-catenin, and/or changes in the sequence of the proto-oncogene Ki-ras.	Azoxymethane	66-78	KRAS proto-oncogene, GTPase	Homo sapiens	276-282
12970140-8	2003	However, azoxymethane treated Cdx2(+/-) mice developed tumours specifically in the distal colon 12 weeks after azoxymethane treatment whereas no tumours were found in wild-type littermates at this stage.	Azoxymethane	9-21	caudal type homeobox 2	Mus musculus	30-34
12720300-0	2003	Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors.	Azoxymethane	64-76	transforming growth factor, beta 1	Mus musculus	28-60
12579275-1	2003	The present study was designed to investigate the protective effect of a dietary water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi or Mannentake) mycelia (designated as MAK) on the induction and development of azoxymethane (AOM)-induced colon tumors in male F344/Du Crj rats.	Azoxymethane	233-245	male germ cell-associated kinase	Rattus norvegicus	192-195
12584182-2	2003	We evaluated the status of cPLA(2) in azoxymethane (AOM)-induced mouse colon tumors.	Azoxymethane	38-50	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	27-34
12584182-2	2003	We evaluated the status of cPLA(2) in azoxymethane (AOM)-induced mouse colon tumors.	Azoxymethane	52-55	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	27-34
12557142-0	2003	Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice.	Azoxymethane	98-110	peroxisome proliferator activated receptor gamma	Mus musculus	0-48
12070019-0	2002	Factor VIII expression in azoxymethane-induced murine fulminant hepatic failure.	Azoxymethane	26-38	coagulation factor VIII	Mus musculus	0-11
12145805-0	2002	Deletion of functional gastrin gene markedly increases colon carcinogenesis in response to azoxymethane in mice.	Azoxymethane	91-103	gastrin	Mus musculus	23-30
12145805-1	2002	BACKGROUND & AIMS: We recently reported that transgenic mice overexpressing progastrin were at a higher risk for developing colon cancers in response to azoxymethane (AOM), whereas mice overexpressing gastrin-17 were at a reduced risk.	Azoxymethane	157-169	gastrin	Mus musculus	83-90
12145805-1	2002	BACKGROUND & AIMS: We recently reported that transgenic mice overexpressing progastrin were at a higher risk for developing colon cancers in response to azoxymethane (AOM), whereas mice overexpressing gastrin-17 were at a reduced risk.	Azoxymethane	171-174	gastrin	Mus musculus	83-90
12239600-5	2002	We have reported for the first time in rats treated with azoxymethane that NMT activity was higher in colonic epithelial neoplasms than in normal colonic tissue and that an increase in NMT activity appeared at an early stage in colonic carcinogenesis.	Azoxymethane	57-69	N-myristoyltransferase 1	Homo sapiens	75-78
12239600-5	2002	We have reported for the first time in rats treated with azoxymethane that NMT activity was higher in colonic epithelial neoplasms than in normal colonic tissue and that an increase in NMT activity appeared at an early stage in colonic carcinogenesis.	Azoxymethane	57-69	N-myristoyltransferase 1	Homo sapiens	185-188
12070019-4	2002	We compared the expression of factor VIII to other hepatic hemostatic factors in azoxymethane-induced murine FHF.	Azoxymethane	81-93	coagulation factor VIII	Mus musculus	30-41
12070019-6	2002	At the highest dose of azoxymethane (50 microg/g body weight), factor VIII activity in plasma decreased by 98% within 36 hours after treatment, which was associated with an 80% reduction in hepatic factor VIII messenger RNA (mRNA).	Azoxymethane	23-35	coagulation factor VIII	Mus musculus	63-74
12070019-6	2002	At the highest dose of azoxymethane (50 microg/g body weight), factor VIII activity in plasma decreased by 98% within 36 hours after treatment, which was associated with an 80% reduction in hepatic factor VIII messenger RNA (mRNA).	Azoxymethane	23-35	coagulation factor VIII	Mus musculus	198-209
12070019-7	2002	In contrast, factor VIII mRNA levels in spleen, kidney, and lung tissue of azoxymethane-treated mice were unchanged.	Azoxymethane	75-87	coagulation factor VIII	Mus musculus	13-24
11756242-6	2002	Moreover, in the rodent-carcinogen model, azoxymethane (AOM)-treatment induced AKT expression in premalignant rat colonocytes.	Azoxymethane	42-54	AKT serine/threonine kinase 1	Rattus norvegicus	79-82
12117783-0	2002	Hemizygous mice for the angiotensin II type 2 receptor gene have attenuated susceptibility to azoxymethane-induced colon tumorigenesis.	Azoxymethane	94-106	angiotensin II receptor, type 2	Mus musculus	24-54
12017282-0	2002	Effect of vaccination with mutant KRAS peptides on rat colon carcinogenesis induced by azoxymethane.	Azoxymethane	87-99	KRAS proto-oncogene, GTPase	Rattus norvegicus	34-38
11756242-6	2002	Moreover, in the rodent-carcinogen model, azoxymethane (AOM)-treatment induced AKT expression in premalignant rat colonocytes.	Azoxymethane	56-59	AKT serine/threonine kinase 1	Rattus norvegicus	79-82
11782374-1	2002	The inducible isoforms of nitric oxide synthase (iNOS) and cyclooxygenase (COX-2) are overexpressed in colonic tumors of humans, as well as in colon tumors that develop in rats after the administration of the colon-specific carcinogen, azoxymethane (AOM).	Azoxymethane	236-248	nitric oxide synthase 2	Homo sapiens	49-53
11743651-7	2002	Quantitative polymerase chain reaction demonstrated that PLK3 mRNA levels were significantly lower in carcinogen (azoxymethane)-induced rat colon tumors than their uninvolved normal colonic mucosa.	Azoxymethane	114-126	polo-like kinase 3	Rattus norvegicus	57-61
11782374-1	2002	The inducible isoforms of nitric oxide synthase (iNOS) and cyclooxygenase (COX-2) are overexpressed in colonic tumors of humans, as well as in colon tumors that develop in rats after the administration of the colon-specific carcinogen, azoxymethane (AOM).	Azoxymethane	236-248	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	75-80
11782374-1	2002	The inducible isoforms of nitric oxide synthase (iNOS) and cyclooxygenase (COX-2) are overexpressed in colonic tumors of humans, as well as in colon tumors that develop in rats after the administration of the colon-specific carcinogen, azoxymethane (AOM).	Azoxymethane	250-253	nitric oxide synthase 2	Homo sapiens	49-53
11782374-1	2002	The inducible isoforms of nitric oxide synthase (iNOS) and cyclooxygenase (COX-2) are overexpressed in colonic tumors of humans, as well as in colon tumors that develop in rats after the administration of the colon-specific carcinogen, azoxymethane (AOM).	Azoxymethane	250-253	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	75-80
11931531-0	2002	Effects of cyclooxygenase-2 inhibitor NS-398 on APC and c-myc expression in rat colon carcinogenesis induced by azoxymethane.	Azoxymethane	112-124	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	11-27
12086401-2	2002	Our previous studies indicated that nimesulide and celecoxib, selective COX-2 inhibitors, show inhibitory effects of intestinal carcinogenesis in azoxymethane-treated rats and mice and in Min mice models.	Azoxymethane	146-158	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	72-77
11931531-0	2002	Effects of cyclooxygenase-2 inhibitor NS-398 on APC and c-myc expression in rat colon carcinogenesis induced by azoxymethane.	Azoxymethane	112-124	APC regulator of WNT signaling pathway	Rattus norvegicus	48-51
11931531-0	2002	Effects of cyclooxygenase-2 inhibitor NS-398 on APC and c-myc expression in rat colon carcinogenesis induced by azoxymethane.	Azoxymethane	112-124	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	56-61
11931531-2	2002	The aim of this study was to examine the effects of NSAIDs on the expression of the tumor suppressor APC gene and the c-myc oncogene in the colons of rats treated with a colon-specific carcinogen, azoxymethane (AOM).	Azoxymethane	197-209	APC regulator of WNT signaling pathway	Rattus norvegicus	101-104
11931531-4	2002	RESULTS: The group of rats simultaneously administered AOM and NS-398, a cyclooxygenase (COX)-2 inhibitor, showed a significant reduction in the number of preneoplastic lesions of colon cancer compared with that in the group of rats treated with AOM alone.	Azoxymethane	55-58	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	73-95
11931531-4	2002	RESULTS: The group of rats simultaneously administered AOM and NS-398, a cyclooxygenase (COX)-2 inhibitor, showed a significant reduction in the number of preneoplastic lesions of colon cancer compared with that in the group of rats treated with AOM alone.	Azoxymethane	246-249	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	73-95
11731424-1	2001	Methylazoxymethanol (MAM) and its chemical and metabolic precursor, azoxymethane (AOM), both strong colon carcinogens in rodents, can be metabolically activated by CYP2E1 in vitro.	Azoxymethane	68-80	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	164-170
11731424-0	2001	Differential effects of CYP2E1 status on the metabolic activation of the colon carcinogens azoxymethane and methylazoxymethanol.	Azoxymethane	91-103	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	24-30
11605062-1	2001	The modifying effects of a dietary water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi or Mannentake) mycelia (MAK) on the development of azoxymethane (AOM)-induced colonic aberrant crypt foci (ACF) were investigated in male F344 rats.	Azoxymethane	159-171	male germ cell-associated kinase	Rattus norvegicus	132-135
11745407-7	2001	The total number of aberrant crypt foci in intact rats treated with the procarcinogen azoxymethane plus glycine-extended gastrin(17) was increased by 48% compared to the value in controls treated with azoxymethane only (p = 0.01).	Azoxymethane	201-213	gastrin	Rattus norvegicus	121-128
11745407-8	2001	We conclude that short term administration of glycine-extended gastrin(17) to mature rats not only has a proliferative effect upon colonic mucosa, but also increases the number of aberrant crypt foci formed in the colorectal mucosa after treatment with azoxymethane.	Azoxymethane	253-265	gastrin	Rattus norvegicus	63-70
11536370-2	2001	We hypothesize that alterations in the TGF-beta pathway contribute to differential sensitivity of mice to the colon carcinogen azoxymethane (AOM).	Azoxymethane	127-139	transforming growth factor, beta 1	Mus musculus	39-47
11509121-4	2001	Well-differentiated adenocarcinoma appeared 5 months after 5 administrations of azoxymethane (10 mg/kg weight) only in a few TCRd -gene knockout mice and the frequency of the carcinoma-bearing mice was increased at 7 and 9 months after the administration.	Azoxymethane	80-92	T cell receptor delta chain	Mus musculus	125-129
11532879-0	2001	High susceptibility of Scid mice to colon carcinogenesis induced by azoxymethane indicates a possible caretaker role for DNA-dependent protein kinase.	Azoxymethane	68-80	protein kinase, DNA activated, catalytic polypeptide	Mus musculus	23-27
11532879-3	2001	In the present study, the susceptibility of Scid mice to colon carcinogenesis due to administration of azoxymethane (AOM) was investigated.	Azoxymethane	103-115	protein kinase, DNA activated, catalytic polypeptide	Mus musculus	44-48
11536370-2	2001	We hypothesize that alterations in the TGF-beta pathway contribute to differential sensitivity of mice to the colon carcinogen azoxymethane (AOM).	Azoxymethane	141-144	transforming growth factor, beta 1	Mus musculus	39-47
11142416-0	2000	Neonatal inoculation with the protein-bound polysaccharide PSK increases resistance of adult animals to challenge with syngeneic tumor cells and reduces azoxymethane-induced precancerous lesions in the colon.	Azoxymethane	153-165	TAO kinase 2	Mus musculus	59-62
11429049-5	2001	Groups 1 - 3 were administered azoxymethane (AOM) s.c. at a dose of 15 mg / kg body weight, once weekly for 3 weeks to induce beta-catenin-accumulated crypts.	Azoxymethane	31-43	catenin beta 1	Rattus norvegicus	126-138
11429049-5	2001	Groups 1 - 3 were administered azoxymethane (AOM) s.c. at a dose of 15 mg / kg body weight, once weekly for 3 weeks to induce beta-catenin-accumulated crypts.	Azoxymethane	45-48	catenin beta 1	Rattus norvegicus	126-138
11245437-9	2001	Finally, transgenic mice expressing elevated PKC betaII in the colonic epithelium exhibit a trend toward increased colon tumor formation after exposure to azoxymethane.	Azoxymethane	155-167	proline rich transmembrane protein 2	Homo sapiens	45-48
11431334-8	2001	In the present study, we treated Min/+ mice with 5 mg/kg body weight azoxymethane (AOM) at weeks 1 and 2 and demonstrated induction of both types of lesions.	Azoxymethane	69-81	APC, WNT signaling pathway regulator	Mus musculus	33-36
11431334-8	2001	In the present study, we treated Min/+ mice with 5 mg/kg body weight azoxymethane (AOM) at weeks 1 and 2 and demonstrated induction of both types of lesions.	Azoxymethane	83-86	APC, WNT signaling pathway regulator	Mus musculus	33-36
11142416-11	2000	In addition, neonatal injection of PSK significantly reduced the number of aberrant crypts and aberrant crypt foci, the precancerous lesions in the colon of F344 rats that received injections s.c. with azoxymethane after 7 weeks of age, to 47% of that of rats that received an injection with saline at the same age.	Azoxymethane	202-214	TAO kinase 2	Mus musculus	35-38
11142416-16	2000	These findings suggest that neonatal injection of PSK induces resistance in adult mice to challenge by syngeneic tumor cells and reduces the azoxymethane-induced precancerous lesions in the colon of adult rats via the thymus functions.	Azoxymethane	141-153	TAO kinase 2	Mus musculus	50-53
11076880-0	2000	Sulindac and a cyclooxygenase-2 inhibitor, etodolac, increase APC mRNA in the colon of rats treated with azoxymethane.	Azoxymethane	105-117	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	15-31
11004662-0	2000	K-ras point mutation is associated with enhancement by deoxycholic acid of colon carcinogenesis induced by azoxymethane, but not with its attenuation by all-trans-retinoic acid.	Azoxymethane	107-119	KRAS proto-oncogene, GTPase	Rattus norvegicus	0-5
10969813-0	2000	Mutational and nonmutational activation of p21ras in rat colonic azoxymethane-induced tumors: effects on mitogen-activated protein kinase, cyclooxygenase-2, and cyclin D1.	Azoxymethane	65-77	HRas proto-oncogene, GTPase	Rattus norvegicus	43-49
10938397-0	2000	Expression of transforming growth factor beta1 and its type II receptor in mouse colon tumors induced by azoxymethane.	Azoxymethane	105-117	transforming growth factor, beta 1	Mus musculus	14-46
10938397-2	2000	We postulated that TGF-beta1 and TbetaR-II alterations may also be involved in mouse colon tumorigenesis induced by the chemical carcinogen, azoxymethane (AOM).	Azoxymethane	141-153	transforming growth factor, beta 1	Mus musculus	19-28
10938397-2	2000	We postulated that TGF-beta1 and TbetaR-II alterations may also be involved in mouse colon tumorigenesis induced by the chemical carcinogen, azoxymethane (AOM).	Azoxymethane	141-153	transforming growth factor, beta receptor II	Mus musculus	33-42
10969813-1	2000	Azoxymethane (AOM)-induced colonic carcinogenesis involves a number of mutations, including those in the K-ras gene and CTNNB1, that codes for beta-catenin.	Azoxymethane	0-12	KRAS proto-oncogene, GTPase	Rattus norvegicus	105-110
10969813-1	2000	Azoxymethane (AOM)-induced colonic carcinogenesis involves a number of mutations, including those in the K-ras gene and CTNNB1, that codes for beta-catenin.	Azoxymethane	0-12	catenin beta 1	Rattus norvegicus	120-126
10969813-1	2000	Azoxymethane (AOM)-induced colonic carcinogenesis involves a number of mutations, including those in the K-ras gene and CTNNB1, that codes for beta-catenin.	Azoxymethane	0-12	catenin beta 1	Rattus norvegicus	143-155
10969813-1	2000	Azoxymethane (AOM)-induced colonic carcinogenesis involves a number of mutations, including those in the K-ras gene and CTNNB1, that codes for beta-catenin.	Azoxymethane	14-17	KRAS proto-oncogene, GTPase	Rattus norvegicus	105-110
10969813-1	2000	Azoxymethane (AOM)-induced colonic carcinogenesis involves a number of mutations, including those in the K-ras gene and CTNNB1, that codes for beta-catenin.	Azoxymethane	14-17	catenin beta 1	Rattus norvegicus	120-126
10969813-1	2000	Azoxymethane (AOM)-induced colonic carcinogenesis involves a number of mutations, including those in the K-ras gene and CTNNB1, that codes for beta-catenin.	Azoxymethane	14-17	catenin beta 1	Rattus norvegicus	143-155
10874009-0	2000	Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis.	Azoxymethane	92-104	catenin beta 1	Rattus norvegicus	22-34
10874009-0	2000	Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis.	Azoxymethane	92-104	nitric oxide synthase 2	Rattus norvegicus	36-67
10874009-0	2000	Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis.	Azoxymethane	92-104	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	72-88
10874009-2	2000	We have described the frequent mutation and an altered cellular localization of beta-catenin in rat colon adenocarcinomas induced by azoxymethane (AOM), along with up-regulation of inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2.	Azoxymethane	133-145	catenin beta 1	Rattus norvegicus	80-92
10942530-0	2000	Differential expression of p16(INK4a) in azoxymethane-induced mouse colon tumorigenesis.	Azoxymethane	41-53	cyclin dependent kinase inhibitor 2A	Mus musculus	27-30
10939592-7	2000	Yet tumors are similarly sized in animals of either genotype receiving azoxymethane for identical times, a finding attributable to the significantly higher number of apoptotic cells detected in GRP/GRP-R coexpressing cancers.	Azoxymethane	71-83	gastrin releasing peptide	Mus musculus	194-197
10939592-7	2000	Yet tumors are similarly sized in animals of either genotype receiving azoxymethane for identical times, a finding attributable to the significantly higher number of apoptotic cells detected in GRP/GRP-R coexpressing cancers.	Azoxymethane	71-83	gastrin releasing peptide receptor	Mus musculus	198-203
10942530-2	2000	We postulated that alterations in the p16(INK4a) gene may also be involved in mouse colon tumorigenesis induced by the chemical carcinogen azoxymethane (AOM).	Azoxymethane	139-151	cyclin dependent kinase inhibitor 2A	Mus musculus	38-41
10942530-0	2000	Differential expression of p16(INK4a) in azoxymethane-induced mouse colon tumorigenesis.	Azoxymethane	41-53	cyclin dependent kinase inhibitor 2A	Mus musculus	31-36
10942530-2	2000	We postulated that alterations in the p16(INK4a) gene may also be involved in mouse colon tumorigenesis induced by the chemical carcinogen azoxymethane (AOM).	Azoxymethane	139-151	cyclin dependent kinase inhibitor 2A	Mus musculus	42-47
10942530-2	2000	We postulated that alterations in the p16(INK4a) gene may also be involved in mouse colon tumorigenesis induced by the chemical carcinogen azoxymethane (AOM).	Azoxymethane	153-156	cyclin dependent kinase inhibitor 2A	Mus musculus	38-41
10836998-0	2000	Frequent mutations of the beta-catenin gene in mouse colon tumors induced by azoxymethane.	Azoxymethane	77-89	catenin (cadherin associated protein), beta 1	Mus musculus	26-38
10942530-2	2000	We postulated that alterations in the p16(INK4a) gene may also be involved in mouse colon tumorigenesis induced by the chemical carcinogen azoxymethane (AOM).	Azoxymethane	153-156	cyclin dependent kinase inhibitor 2A	Mus musculus	42-47
10942530-8	2000	Whereas control colon epithelium was uniformly negative for p16(INK4a) immunoreactivity, p16(INK4a)-immunoreactive cells were markedly increased in preneoplastic lesions and adenomas isolated from AOM-treated mice.	Azoxymethane	197-200	cyclin dependent kinase inhibitor 2A	Mus musculus	93-98
11216473-2	2000	We found that the COX-2 selective inhibitor, nimesulide, reduces azoxymethane (AOM)-induced aberrant crypt foci (ACF) in rats and colon carcinogenesis in mice, as well as formation of intestinal polyps in Min mice.	Azoxymethane	65-77	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	18-23
10708483-0	2000	Azoxymethane induces KI-ras activation in the tumor resistant AKR/J mouse colon.	Azoxymethane	0-12	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	21-27
10677604-8	2000	The AOM-treated group showed a significantly reduced infarction volume (by 42.5%, p<0.001), a significantly greater number of p53 positive cells (by 12.0%, p<0.	Azoxymethane	4-7	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	129-132
10657948-4	2000	The following study was undertaken to test the hypothesis that sPLA(2) plays an equivalent role in murine susceptibility to the colon carcinogen azoxymethane (AOM).	Azoxymethane	145-157	phospholipase A2, group IIA (platelets, synovial fluid)	Mus musculus	63-70
10657948-4	2000	The following study was undertaken to test the hypothesis that sPLA(2) plays an equivalent role in murine susceptibility to the colon carcinogen azoxymethane (AOM).	Azoxymethane	159-162	phospholipase A2, group IIA (platelets, synovial fluid)	Mus musculus	63-70
10648462-8	2000	CONCLUSIONS: These results indicate that COX-2 is expressed very early in the pathogenesis of colitis-associated tumors, and that the expression pattern is similar to that seen in tumors from azoxymethane-treated and Min/+ mice.	Azoxymethane	192-204	cytochrome c oxidase II, mitochondrial	Mus musculus	41-46
12716300-5	2000	Whey protein may also be beneficial, as shown by both animal and human studies, and experimental data have demonstrated that the major component bovine lactoferrin (bLF), inhibits colon carcinogenesis in the post-initiation stage in male F344 rats treated with azoxymethane (AOM) without any overt toxicity.	Azoxymethane	261-273	lactotransferrin	Bos taurus	152-163
10767634-5	2000	Whey protein may also be beneficial, as shown by both animal and human studies, and experimental data have demonstrated that the major component bovine lactoferrin (bLF), inhibits colon carcinogenesis in the post-initiation stage in male F344 rats treated with azoxymethane (AOM) without any overt toxicity.	Azoxymethane	261-273	lactotransferrin	Bos taurus	152-163
10767634-5	2000	Whey protein may also be beneficial, as shown by both animal and human studies, and experimental data have demonstrated that the major component bovine lactoferrin (bLF), inhibits colon carcinogenesis in the post-initiation stage in male F344 rats treated with azoxymethane (AOM) without any overt toxicity.	Azoxymethane	275-278	lactotransferrin	Bos taurus	152-163
10667579-4	2000	Our previous study has shown that celecoxib, an inhibitor of COX-2, while sparing COX-1, inhibited azoxymethane (AOM)-induced colon tumorigenesis when administered during both initiation and postinitiation stages, ie., celecoxib administered continuously before, during, and after carcinogen treatment.	Azoxymethane	99-111	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	61-66
10667579-4	2000	Our previous study has shown that celecoxib, an inhibitor of COX-2, while sparing COX-1, inhibited azoxymethane (AOM)-induced colon tumorigenesis when administered during both initiation and postinitiation stages, ie., celecoxib administered continuously before, during, and after carcinogen treatment.	Azoxymethane	113-116	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	61-66
10678579-12	2000	Nonselective NSAIDs, for instance aspirin, and selective COX-2 inhibitors such as celecoxib (SC-58635) and NS-398 suppress azoxymethane-induced colon carcinogenesis in rats.	Azoxymethane	123-135	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	57-62
11216473-2	2000	We found that the COX-2 selective inhibitor, nimesulide, reduces azoxymethane (AOM)-induced aberrant crypt foci (ACF) in rats and colon carcinogenesis in mice, as well as formation of intestinal polyps in Min mice.	Azoxymethane	79-82	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	18-23
10590233-0	1999	Inhibition of O(6)-methylguanine-DNA methyltransferase increases azoxymethane-induced colonic tumors in rats.	Azoxymethane	65-77	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	14-54
10680590-0	2000	Suppression of azoxymethane-induced colonic aberrant crypt foci by a nitric oxide synthase inhibitor.	Azoxymethane	15-27	nitric oxide synthase 2	Homo sapiens	69-90
10537280-4	1999	Administration of 250, 500, or 1000 ppm of a novel selective EP1 antagonist, ONO-8711, in the diet to azoxymethane-treated C57BL/6J mice also resulted in a dose-dependent reduction of ACF formation.	Azoxymethane	102-114	prostaglandin E receptor 1 (subtype EP1)	Mus musculus	61-64
10636069-1	1999	BACKGROUND: We wanted to investigate the relationship between the fecal levels of granulocyte marker protein (GMP) and the presence of aberrant crypt foci (ACF) and colorectal cancer in rats given injections of azoxymethane (AOM) and fed either of two different diets, a basal diet plus 20% corn oil or 20% beef suet, respectively.	Azoxymethane	211-223	5'-nucleotidase, cytosolic II	Mus musculus	110-113
10709674-3	1999	As discussed above, all six potential chemopreventive agents, aspirin, 2-CPR, DFMO, 4-HPR, piroxicam, and 9-cis-retinoic acid, decreased the level of AOM-induced ACF.	Azoxymethane	150-153	cytochrome p450 oxidoreductase	Homo sapiens	73-76
10403547-0	1999	Expression of the cyclin D1 gene in rat colorectal aberrant crypt foci and tumors induced by azoxymethane.	Azoxymethane	93-105	cyclin D1	Rattus norvegicus	18-27
10403547-2	1999	We examined overexpression of cyclin D1 in several stages of rat colorectal carcinogenesis induced by azoxymethane (AOM) treatment.	Azoxymethane	102-114	cyclin D1	Rattus norvegicus	30-39
10462473-0	1999	Effects of beta-glucuronidase-deficient and lycopene-producing Escherichia coli strains on formation of azoxymethane-induced aberrant crypt foci in the rat colon.	Azoxymethane	104-116	glucuronidase, beta	Rattus norvegicus	11-29
10462473-1	1999	We tried to inhibit the formation of azoxymethane-induced aberrant crypt foci (ACF) in the rat intestine by feeding a culture of a beta-glucuronidase-deficient Escherichia coli strain or a cell suspension of a lycopene-producing E. coli strain.	Azoxymethane	37-49	glucuronidase, beta	Rattus norvegicus	131-149
10462473-6	1999	These results suggest that feeding of the beta-glucuronidase-deficient E. coli is not very effective in preventing colon carcinogenesis, although activity of the fecal beta-glucuronidase is associated with AOM-induced ACF formation, and that lycopene-producing intestinal bacteria can effectively prevent colon carcinogenesis.	Azoxymethane	206-209	glucuronidase, beta	Rattus norvegicus	168-186
10330400-3	1999	Transgenic PKC betaII mice exhibit hyperproliferation of the colonic epithelium and an increased susceptibility to azoxymethane-induced aberrant crypt foci, preneoplastic lesions in the colon.	Azoxymethane	115-127	protein kinase C, beta	Mus musculus	11-21
10069452-0	1999	Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors.	Azoxymethane	103-115	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	25-41
10069452-0	1999	Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors.	Azoxymethane	103-115	transforming growth factor, beta 1	Rattus norvegicus	46-55
10069452-2	1999	We evaluated the expression of COX-2 in replication error-positive (RER) colon cancers, colon cancers metastatic to liver and azoxymethane (AOM)-induced rat colonic tumors.	Azoxymethane	140-143	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	31-36
10709674-3	1999	As discussed above, all six potential chemopreventive agents, aspirin, 2-CPR, DFMO, 4-HPR, piroxicam, and 9-cis-retinoic acid, decreased the level of AOM-induced ACF.	Azoxymethane	150-153	ACF	Homo sapiens	162-165
9855006-0	1998	Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice.	Azoxymethane	81-93	prostaglandin-endoperoxide synthase 2	Mus musculus	60-76
9855006-1	1998	The effects of nimesulide, a selective inhibitor of cyclooxygenase-2 (COX-2) on azoxymethane (AOM)-induced colon carcinogenesis were investigated in mice.	Azoxymethane	80-92	prostaglandin-endoperoxide synthase 2	Mus musculus	70-75
9649126-0	1998	Mutations of the Apc gene in experimental colorectal carcinogenesis induced by azoxymethane in F344 rats.	Azoxymethane	79-91	APC regulator of WNT signaling pathway	Rattus norvegicus	17-20
9649126-2	1998	We analysed mutations in exon 15 of the rat Apc gene using in vitro synthesized protein assay in 66 ACF and in 28 colon tumours induced by azoxymethane.	Azoxymethane	139-151	APC regulator of WNT signaling pathway	Rattus norvegicus	44-47
9426055-0	1998	Beta-catenin is frequently mutated and demonstrates altered cellular location in azoxymethane-induced rat colon tumors.	Azoxymethane	81-93	catenin beta 1	Rattus norvegicus	0-12
9684124-0	1998	Enhanced ligand-induced activation of EGF-receptor and overall tyrosine kinase and phospholipase C in colonocytes isolated from azoxymethane-treated rats.	Azoxymethane	128-140	epidermal growth factor like 1	Rattus norvegicus	38-41
9600336-5	1998	In the azoxymethane (AOM) treated rats, overexpression and nuclear localization of beta-catenin was observed in all adenomas.	Azoxymethane	7-19	catenin beta 1	Rattus norvegicus	83-95
9781370-0	1998	Inhibition of azoxymethane initiated colon tumor and aberrant crypt foci development by bovine lactoferrin administration in F344 rats.	Azoxymethane	14-26	lactotransferrin	Bos taurus	95-106
9426055-3	1998	In the present study, we examined the expression of beta-catenin in rat colon tumors induced by azoxymethane in comparison with adjacent normal colon mucosa by immunostaining and immunoblotting.	Azoxymethane	96-108	catenin beta 1	Rattus norvegicus	52-64
9426055-7	1998	Such frequent mutations of the beta-catenin gene in azoxymethane-induced rat colon tumors suggest that consequent alterations in the stability and localization of the protein may play an important role in this colon carcinogenesis model.	Azoxymethane	52-64	catenin beta 1	Rattus norvegicus	31-43
9311948-4	1997	Azoxymethane suppressed cytosolic PKC lambda protein levels compared with the saline controls at both time points, and this suppression was partially blocked by fish oil feeding at 15 wk and pectin at 37 wk.	Azoxymethane	0-12	protein kinase C, gamma	Rattus norvegicus	34-37
9439679-0	1997	Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats.	Azoxymethane	72-84	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	41-57
9421213-15	1998	The mechanisms underlying these findings rest on the fact that azoxymethane is metabolized mainly by cytochrome P450 2E1, and this enzyme system is not affected by tea.	Azoxymethane	63-75	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	101-120
9570361-0	1997	Inhibition of initiation and early stage development of aberrant crypt foci and enhanced natural killer activity in male rats administered bovine lactoferrin concomitantly with azoxymethane.	Azoxymethane	177-189	lactotransferrin	Bos taurus	146-157
9570361-1	1997	The influence of concomitant administration of bovine lactoferrin (bLF) on induction of aberrant crypt foci (ACF) by azoxymethane was investigated in male F344 rats.	Azoxymethane	117-129	lactotransferrin	Bos taurus	54-65
9311948-5	1997	Also, at 15 wk, azoxymethane-injected rats fed corn oil had higher levels of membrane PKC lambda relative to the other treatment groups.	Azoxymethane	16-28	protein kinase C, gamma	Rattus norvegicus	86-89
9210960-0	1997	Assessment of mutations in Ki-ras and p53 in colon cancers from azoxymethane- and dimethylhydrazine-treated rats.	Azoxymethane	64-76	KRAS proto-oncogene, GTPase	Rattus norvegicus	27-33
9263527-0	1997	Inhibition of azoxymethane-initiated colon tumor by bovine lactoferrin administration in F344 rats.	Azoxymethane	14-26	lactotransferrin	Bos taurus	59-70
9180925-0	1997	Expression of bcl-2, bax, and bcl-XL proteins in azoxymethane-induced rat colonic adenocarcinomas.	Azoxymethane	49-61	BCL2, apoptosis regulator	Rattus norvegicus	14-19
9180925-0	1997	Expression of bcl-2, bax, and bcl-XL proteins in azoxymethane-induced rat colonic adenocarcinomas.	Azoxymethane	49-61	Bcl2-like 1	Rattus norvegicus	30-36
9180925-1	1997	Using western blotting and immunochemical analysis, we investigated alterations in the expression of the apoptosis-related proteins bcl-2, bax, and bcl-X in colonic adenocarcinomas induced by subcutaneous injection of azoxymethane (AOM) (15 mg/kg body weight weekly for 2 wk) into male Sprague-Dawley rats.	Azoxymethane	218-230	BCL2, apoptosis regulator	Rattus norvegicus	132-137
9180925-1	1997	Using western blotting and immunochemical analysis, we investigated alterations in the expression of the apoptosis-related proteins bcl-2, bax, and bcl-X in colonic adenocarcinomas induced by subcutaneous injection of azoxymethane (AOM) (15 mg/kg body weight weekly for 2 wk) into male Sprague-Dawley rats.	Azoxymethane	218-230	Bcl2-like 1	Rattus norvegicus	148-153
8566864-0	1996	Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats.	Azoxymethane	97-109	prostaglandin-endoperoxide synthase 2	Homo sapiens	21-37
9290120-0	1997	Modification of azoxymethane intestinal carcinogenesis in rats by feeding sucrose boluses, pasta, and glucose.	Azoxymethane	16-28	solute carrier family 45, member 1	Rattus norvegicus	91-96
8625306-17	1996	Animals treated with saline or AOM and fed HFCO showed increased levels of DAG kinase and membrane PKC activities in the colonic mucosa when compared to LFCO and HFFO groups.	Azoxymethane	31-34	protein kinase C, gamma	Rattus norvegicus	99-102
8625444-0	1996	Azoxymethane enhances ligand-induced activation of EGF receptor tyrosine kinase in the colonic mucosa of rats.	Azoxymethane	0-12	epidermal growth factor receptor	Rattus norvegicus	51-63
8625444-2	1996	To assess the functional role of TGF-alpha in colonic carcinogenesis the present investigation examines the changes in TGF-alpha-and EGF-induced activation of intrinsic tyrosine kinase (Tyr-k) activity of EGFR in the colonic mucosa of rats after administration of the colonic carcinogen azoxymethane (AOM; 20 mg/kg body wt).	Azoxymethane	287-299	transforming growth factor alpha	Rattus norvegicus	119-128
8625444-2	1996	To assess the functional role of TGF-alpha in colonic carcinogenesis the present investigation examines the changes in TGF-alpha-and EGF-induced activation of intrinsic tyrosine kinase (Tyr-k) activity of EGFR in the colonic mucosa of rats after administration of the colonic carcinogen azoxymethane (AOM; 20 mg/kg body wt).	Azoxymethane	287-299	epidermal growth factor receptor	Rattus norvegicus	205-209
8625444-2	1996	To assess the functional role of TGF-alpha in colonic carcinogenesis the present investigation examines the changes in TGF-alpha-and EGF-induced activation of intrinsic tyrosine kinase (Tyr-k) activity of EGFR in the colonic mucosa of rats after administration of the colonic carcinogen azoxymethane (AOM; 20 mg/kg body wt).	Azoxymethane	301-304	transforming growth factor alpha	Rattus norvegicus	119-128
8625444-2	1996	To assess the functional role of TGF-alpha in colonic carcinogenesis the present investigation examines the changes in TGF-alpha-and EGF-induced activation of intrinsic tyrosine kinase (Tyr-k) activity of EGFR in the colonic mucosa of rats after administration of the colonic carcinogen azoxymethane (AOM; 20 mg/kg body wt).	Azoxymethane	301-304	epidermal growth factor receptor	Rattus norvegicus	205-209
8681445-2	1996	Animals were given three weekly subcutaneous injections of AOM (15 mg/kg body weight) to induce ACE.	Azoxymethane	59-62	angiotensin I converting enzyme	Rattus norvegicus	96-99
8766520-1	1996	Alterations of apoptosis and cell proliferation in the colonic epithelium of rats after exposure to azoxymethane (AOM) were estimated by means of the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) method, measurement of 5-bromo-2"-deoxyuridine (BrdU) incorporation, immunohistochemical staining for proliferating cell nuclear antigen (PCNA), and counting of mitotic cells.	Azoxymethane	100-112	proliferating cell nuclear antigen	Rattus norvegicus	337-371
8766520-1	1996	Alterations of apoptosis and cell proliferation in the colonic epithelium of rats after exposure to azoxymethane (AOM) were estimated by means of the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) method, measurement of 5-bromo-2"-deoxyuridine (BrdU) incorporation, immunohistochemical staining for proliferating cell nuclear antigen (PCNA), and counting of mitotic cells.	Azoxymethane	100-112	proliferating cell nuclear antigen	Rattus norvegicus	373-377
8766520-1	1996	Alterations of apoptosis and cell proliferation in the colonic epithelium of rats after exposure to azoxymethane (AOM) were estimated by means of the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) method, measurement of 5-bromo-2"-deoxyuridine (BrdU) incorporation, immunohistochemical staining for proliferating cell nuclear antigen (PCNA), and counting of mitotic cells.	Azoxymethane	114-117	proliferating cell nuclear antigen	Rattus norvegicus	337-371
8766520-1	1996	Alterations of apoptosis and cell proliferation in the colonic epithelium of rats after exposure to azoxymethane (AOM) were estimated by means of the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) method, measurement of 5-bromo-2"-deoxyuridine (BrdU) incorporation, immunohistochemical staining for proliferating cell nuclear antigen (PCNA), and counting of mitotic cells.	Azoxymethane	114-117	proliferating cell nuclear antigen	Rattus norvegicus	373-377
8613017-10	1996	CONCLUSIONS: COX-2 but not COX-1 gene expression is markedly elevated in most colonic tumors examined in azoxymethane-treated rodents.	Azoxymethane	105-117	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	13-18
8566864-5	1996	It was found that cyclooxygenase-1 and cyclooxygenase-2 mRNA were increased in azoxymethane induced colonic tumours, compared with specimens taken adjacent to the tumours or from the macroscopically normal intestine distant from the tumours.	Azoxymethane	79-91	prostaglandin-endoperoxide synthase 1	Homo sapiens	18-34
8566864-5	1996	It was found that cyclooxygenase-1 and cyclooxygenase-2 mRNA were increased in azoxymethane induced colonic tumours, compared with specimens taken adjacent to the tumours or from the macroscopically normal intestine distant from the tumours.	Azoxymethane	79-91	prostaglandin-endoperoxide synthase 2	Homo sapiens	39-55
8566864-6	1996	Cyclooxygenase-1 and cyclooxygenase-2 mRNA were increased in specimens from the macroscopically normal intestine of azoxymethane treated animals, compared with colonic specimens from saline treated rats.	Azoxymethane	116-128	prostaglandin-endoperoxide synthase 1	Rattus norvegicus	0-16
8566864-6	1996	Cyclooxygenase-1 and cyclooxygenase-2 mRNA were increased in specimens from the macroscopically normal intestine of azoxymethane treated animals, compared with colonic specimens from saline treated rats.	Azoxymethane	116-128	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	21-37
7585585-11	1995	Furthermore, the ability of ursodeoxycholic acid to block AOM-induced increases in particulate PKC-alpha, -beta II, and -zeta, and/or inhibit down-regulation of PKC-zeta, may contribute to the chemopreventive effects of this bile acid.	Azoxymethane	58-61	protein kinase C, alpha	Rattus norvegicus	95-125
8601574-0	1996	Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2.	Azoxymethane	15-27	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	109-125
7621432-1	1995	The effects of combined administration of vasoactive intestinal peptide (VIP) and the ornithine decarboxylase (ODC) inhibitor, 1,3-diaminopropane (DAP), on development of colon tumors induced by azoxymethane (AOM), on ODC activity of the colon wall, and on the labelling index of colon epithelial cells were investigated in inbred Wistar rats.	Azoxymethane	195-207	vasoactive intestinal peptide	Rattus norvegicus	42-71
8526349-1	1995	Inhibition of expression of ras-p21 and p53 by sulindac during azoxymethane-induced colon carcinogenesis.	Azoxymethane	63-75	tumor protein p53	Homo sapiens	40-43
7656228-5	1995	First, PLA2, activity in colon tumors produced using azoxymethane (AOM) in Fischer-344 rats was examined.	Azoxymethane	53-65	phospholipase A2	Zea mays	7-11
7621432-1	1995	The effects of combined administration of vasoactive intestinal peptide (VIP) and the ornithine decarboxylase (ODC) inhibitor, 1,3-diaminopropane (DAP), on development of colon tumors induced by azoxymethane (AOM), on ODC activity of the colon wall, and on the labelling index of colon epithelial cells were investigated in inbred Wistar rats.	Azoxymethane	195-207	ornithine decarboxylase 1	Rattus norvegicus	86-109
7727039-5	1995	The approximately 11% frequency of mutation in IQ-induced ACF is within the range of previous ACF studies of azoxymethane, which reported a 7-37% incidence of Ki-ras mutation.	Azoxymethane	109-121	KRAS proto-oncogene, GTPase	Rattus norvegicus	159-165
7789532-5	1995	The present studies demonstrate that dietary piroxicam selectively preserved the expression of protein kinase C-zeta in azoxymethane-induced tumors; suggesting that this is at least one mechanism involved in this agent"s chemopreventive actions in this organ.	Azoxymethane	120-132	protein kinase C, zeta	Rattus norvegicus	95-116
7705952-7	1995	Gastrin levels in rats with AOM-induced tumors were significantly higher than in controls.	Azoxymethane	28-31	gastrin	Rattus norvegicus	0-7
7789532-0	1995	Selective preservation of protein kinase C-zeta in the chemoprevention of azoxymethane-induced colonic tumors by piroxicam.	Azoxymethane	74-86	protein kinase C, zeta	Rattus norvegicus	26-47
8056450-0	1994	Ornithine decarboxylase inhibitor attenuates bombesin enhancement of intestinal carcinogenesis and metastasis induced by azoxymethane.	Azoxymethane	121-133	ornithine decarboxylase 1	Rattus norvegicus	0-23
7697797-0	1995	Transgenic expression of human MGMT protects against azoxymethane-induced aberrant crypt foci and G to A mutations in the K-ras oncogene of mouse colon.	Azoxymethane	53-65	O-6-methylguanine-DNA methyltransferase	Homo sapiens	31-35
7697797-0	1995	Transgenic expression of human MGMT protects against azoxymethane-induced aberrant crypt foci and G to A mutations in the K-ras oncogene of mouse colon.	Azoxymethane	53-65	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	122-127
7697797-2	1995	In this study we evaluated the ability of transgenic overexpression of MGMT in the colon to protect mice from the development of azoxymethane(AOM)-induced aberrant crypt foci (ACF) and mutations in K-ras.	Azoxymethane	129-141	O-6-methylguanine-DNA methyltransferase	Mus musculus	71-75
21607428-0	1994	Inhibition by calmodulin antagonist trifluoperazine of experimental carcinogenesis in rat colon induced by azoxymethane.	Azoxymethane	107-119	calmodulin 1	Rattus norvegicus	14-24
8033306-1	1994	In our previous study, we demonstrated that azoxymethane (AOM) treatment significantly enhanced the expression of ras p21, the protein product of ras genes, and that the dietary administration of chemopreventive agents such as D,L-alpha-difluoromethylornithine (DFMO), a irreversible inhibitor of ornithine decarboxylase, and piroxicam, a non-steroidal anti-inflammatory drug (NSAID), exerted a significant inhibitory effect on AOM-induced ras p21 expression.	Azoxymethane	44-56	KRAS proto-oncogene, GTPase	Rattus norvegicus	118-121
8033306-1	1994	In our previous study, we demonstrated that azoxymethane (AOM) treatment significantly enhanced the expression of ras p21, the protein product of ras genes, and that the dietary administration of chemopreventive agents such as D,L-alpha-difluoromethylornithine (DFMO), a irreversible inhibitor of ornithine decarboxylase, and piroxicam, a non-steroidal anti-inflammatory drug (NSAID), exerted a significant inhibitory effect on AOM-induced ras p21 expression.	Azoxymethane	44-56	ornithine decarboxylase 1	Rattus norvegicus	297-320
8033306-1	1994	In our previous study, we demonstrated that azoxymethane (AOM) treatment significantly enhanced the expression of ras p21, the protein product of ras genes, and that the dietary administration of chemopreventive agents such as D,L-alpha-difluoromethylornithine (DFMO), a irreversible inhibitor of ornithine decarboxylase, and piroxicam, a non-steroidal anti-inflammatory drug (NSAID), exerted a significant inhibitory effect on AOM-induced ras p21 expression.	Azoxymethane	44-56	KRAS proto-oncogene, GTPase	Rattus norvegicus	444-447
8033306-1	1994	In our previous study, we demonstrated that azoxymethane (AOM) treatment significantly enhanced the expression of ras p21, the protein product of ras genes, and that the dietary administration of chemopreventive agents such as D,L-alpha-difluoromethylornithine (DFMO), a irreversible inhibitor of ornithine decarboxylase, and piroxicam, a non-steroidal anti-inflammatory drug (NSAID), exerted a significant inhibitory effect on AOM-induced ras p21 expression.	Azoxymethane	58-61	KRAS proto-oncogene, GTPase	Rattus norvegicus	118-121
8033306-1	1994	In our previous study, we demonstrated that azoxymethane (AOM) treatment significantly enhanced the expression of ras p21, the protein product of ras genes, and that the dietary administration of chemopreventive agents such as D,L-alpha-difluoromethylornithine (DFMO), a irreversible inhibitor of ornithine decarboxylase, and piroxicam, a non-steroidal anti-inflammatory drug (NSAID), exerted a significant inhibitory effect on AOM-induced ras p21 expression.	Azoxymethane	58-61	ornithine decarboxylase 1	Rattus norvegicus	297-320
8033306-1	1994	In our previous study, we demonstrated that azoxymethane (AOM) treatment significantly enhanced the expression of ras p21, the protein product of ras genes, and that the dietary administration of chemopreventive agents such as D,L-alpha-difluoromethylornithine (DFMO), a irreversible inhibitor of ornithine decarboxylase, and piroxicam, a non-steroidal anti-inflammatory drug (NSAID), exerted a significant inhibitory effect on AOM-induced ras p21 expression.	Azoxymethane	58-61	KRAS proto-oncogene, GTPase	Rattus norvegicus	444-447
8149495-0	1994	Sequential analysis of K-ras mutations in aberrant crypt foci and colonic tumors induced by azoxymethane in Fischer-344 rats on high-risk diet.	Azoxymethane	92-104	KRAS proto-oncogene, GTPase	Rattus norvegicus	23-28
1988118-0	1991	Enhancement by methionine enkephalin of colon carcinogenesis induced by azoxymethane.	Azoxymethane	72-84	proenkephalin	Rattus norvegicus	26-36
8149347-0	1994	Monoamine oxidase B inhibitor enhances experimental carcinogenesis in rat colon induced by azoxymethane.	Azoxymethane	91-103	monoamine oxidase B	Rattus norvegicus	0-19
7598792-0	1994	Histochemical studies of progressive p53 mutations during colonic carcinogenesis in Sprague-Dawley rats induced by N-methyl-N-nitro-nitrosoguanidine or azoxymethane.	Azoxymethane	152-164	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	37-40
8242846-0	1993	Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon.	Azoxymethane	34-46	ornithine decarboxylase 1	Rattus norvegicus	55-78
8242846-8	1993	Dietary curcumin significantly decreased the levels of AOM-induced ODC activity in the liver and colon (P < 0.0001) and TPK activity in the liver and colon (P < 0.01-0.0001) and the formation of 5(S)-, 8(S)-, 12(S)- and 15(S)-hydroxyeicosatetraenoic acids (HETEs) in the liver and colon (P < 0.0001).	Azoxymethane	55-58	ornithine decarboxylase 1	Rattus norvegicus	67-70
8339252-15	1993	Although other mechanisms are not excluded, inhibition of AOM-induced colon carcinogenesis by anethole trithione and diallyl disulfide may be associated, in part, with increased activities of phase II enzymes such as GST, NAD(P)H-dependent quinone reductase, and UDP-glucuronosyl transferase in the liver and colon.	Azoxymethane	58-61	hematopoietic prostaglandin D synthase	Rattus norvegicus	217-220
8386981-0	1993	Alpha 1-antitrypsin as a biomarker in azoxymethane induced intestinal tumors in F344 rats.	Azoxymethane	38-50	serpin family A member 1	Homo sapiens	0-19
8422651-0	1993	Effect of restricted caloric intake on the development of the azoxymethane-induced glutathione S-transferase placental form positive hepatocellular foci in male F344 rats.	Azoxymethane	62-74	hematopoietic prostaglandin D synthase	Rattus norvegicus	83-108
8422651-1	1993	The modifying effect of 30% caloric restriction on the occurrence of azoxymethane (AOM)-induced glutathione S-transferase placental form (GST-P) positive hepatocellular foci was investigated in male F344 rats.	Azoxymethane	69-81	glutathione S-transferase pi 1	Rattus norvegicus	96-143
8422651-1	1993	The modifying effect of 30% caloric restriction on the occurrence of azoxymethane (AOM)-induced glutathione S-transferase placental form (GST-P) positive hepatocellular foci was investigated in male F344 rats.	Azoxymethane	83-86	glutathione S-transferase pi 1	Rattus norvegicus	96-143
8319499-2	1993	The expression of the mutant p53 gene product in aberrant crypt foci and in adenocarcinomas induced by azoxymethane was investigated immunohistochemically, using the rat model system.	Azoxymethane	103-115	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	29-32
1997099-9	1991	Azoxymethane increased in CCPR, but this was suppressed by the high dose of EGF.	Azoxymethane	0-12	epidermal growth factor like 1	Rattus norvegicus	76-79
1997099-10	1991	These results suggest that (1) luminal EGF and azoxymethane independently increase the colonic CCPR and their combined effect is not synergistic but antagonistic; (2) EGF may have a role in normal epithelial growth, but does not potentiate colonic carcinogenesis in this model.	Azoxymethane	47-59	epidermal growth factor like 1	Rattus norvegicus	167-170
8403199-0	1993	K-ras mutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane-induced colon carcinogenesis.	Azoxymethane	76-88	KRAS proto-oncogene, GTPase	Rattus norvegicus	0-5
8403199-10	1993	These data suggest that K-ras mutations play a role during the stages of carcinogenesis in azoxymethane-induced rat colon cancer.	Azoxymethane	91-103	KRAS proto-oncogene, GTPase	Rattus norvegicus	24-29
20233899-4	2010	Contrary to our hypothesis, deletion of STAT2 inhibited azoxymethane/dextran sodium sulfate-induced colorectal carcinogenesis as measured by prolonged survival, lower adenoma incidence, smaller polyps, and less chronic inflammation.	Azoxymethane	56-68	signal transducer and activator of transcription 2	Homo sapiens	40-45
2206944-0	1990	Enhancement by neurotensin of experimental carcinogenesis induced in rat colon by azoxymethane.	Azoxymethane	82-94	neurotensin	Rattus norvegicus	15-26
20233899-7	2010	Deletion of STAT2 decreased azoxymethane/dextran sodium sulfate-induced expression and release of proinflammatory mediators, such as interleukin-6 and CCL2, and decreased interleukin-6 release from skin carcinoma cells, which then decreased STAT3 activation.	Azoxymethane	28-40	signal transducer and activator of transcription 3	Homo sapiens	241-246
20233899-7	2010	Deletion of STAT2 decreased azoxymethane/dextran sodium sulfate-induced expression and release of proinflammatory mediators, such as interleukin-6 and CCL2, and decreased interleukin-6 release from skin carcinoma cells, which then decreased STAT3 activation.	Azoxymethane	28-40	signal transducer and activator of transcription 2	Homo sapiens	12-17
20233899-7	2010	Deletion of STAT2 decreased azoxymethane/dextran sodium sulfate-induced expression and release of proinflammatory mediators, such as interleukin-6 and CCL2, and decreased interleukin-6 release from skin carcinoma cells, which then decreased STAT3 activation.	Azoxymethane	28-40	interleukin 6	Homo sapiens	133-146
20233899-7	2010	Deletion of STAT2 decreased azoxymethane/dextran sodium sulfate-induced expression and release of proinflammatory mediators, such as interleukin-6 and CCL2, and decreased interleukin-6 release from skin carcinoma cells, which then decreased STAT3 activation.	Azoxymethane	28-40	C-C motif chemokine ligand 2	Homo sapiens	151-155
20233899-7	2010	Deletion of STAT2 decreased azoxymethane/dextran sodium sulfate-induced expression and release of proinflammatory mediators, such as interleukin-6 and CCL2, and decreased interleukin-6 release from skin carcinoma cells, which then decreased STAT3 activation.	Azoxymethane	28-40	interleukin 6	Homo sapiens	171-184
9855016-0	1998	Altered expression of cyclin D1 and cyclin-dependent kinase 4 in azoxymethane-induced mouse colon tumorigenesis.	Azoxymethane	65-77	cyclin D1	Mus musculus	22-31
9855016-0	1998	Altered expression of cyclin D1 and cyclin-dependent kinase 4 in azoxymethane-induced mouse colon tumorigenesis.	Azoxymethane	65-77	cyclin-dependent kinase 4	Mus musculus	36-61
9855016-2	1998	We hypothesize that altered expression of cyclin D1 and Cdk4 may also be involved in mouse colon tumorigenesis induced by the chemical carcinogen, azoxymethane (AOM).	Azoxymethane	147-159	cyclin D1	Mus musculus	42-51
9855016-2	1998	We hypothesize that altered expression of cyclin D1 and Cdk4 may also be involved in mouse colon tumorigenesis induced by the chemical carcinogen, azoxymethane (AOM).	Azoxymethane	147-159	cyclin-dependent kinase 4	Mus musculus	56-60
9855016-2	1998	We hypothesize that altered expression of cyclin D1 and Cdk4 may also be involved in mouse colon tumorigenesis induced by the chemical carcinogen, azoxymethane (AOM).	Azoxymethane	161-164	cyclin D1	Mus musculus	42-51
9855016-2	1998	We hypothesize that altered expression of cyclin D1 and Cdk4 may also be involved in mouse colon tumorigenesis induced by the chemical carcinogen, azoxymethane (AOM).	Azoxymethane	161-164	cyclin-dependent kinase 4	Mus musculus	56-60
34914638-9	2022	Finally, the SOAT1 inhibitor (Avasimibe) showed the significant levels of therapeutic effects on both AOM/DSS-induced and ApcMin/+ spontaneous intestine cancer.	Azoxymethane	102-105	sterol O-acyltransferase 1	Homo sapiens	13-18
34628032-8	2022	Moreover, colitis-associated colorectal cancer development was higher in GPR65 KO mice than WT mice when treated with AOM/DSS.	Azoxymethane	118-121	G-protein coupled receptor 65	Mus musculus	73-78
33535870-9	2021	Mechanistically, tanshinone IIA downregulated the NF-kappaB signalling pathway in the colonic tumours of AOM/DSS-treated mice.	Azoxymethane	105-108	ATPase, class II, type 9A	Mus musculus	28-31
33535870-9	2021	Mechanistically, tanshinone IIA downregulated the NF-kappaB signalling pathway in the colonic tumours of AOM/DSS-treated mice.	Azoxymethane	105-108	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	50-59
34702807-0	2021	The overexpression of Tipe2 in CRC cells suppresses survival while endogenous Tipe2 accelerates AOM/DSS induced-tumor initiation.	Azoxymethane	96-99	tumor necrosis factor, alpha-induced protein 8-like 2	Mus musculus	78-83
34876395-0	2021	Correlation Between THSD7A Expression and Tumor Characteristics of Azoxymethane-Induced Colon Cancer Model in Rats.	Azoxymethane	67-79	thrombospondin type 1 domain containing 7A	Rattus norvegicus	20-26
34876395-2	2021	Thus, we investigated the correlation between THSD7A expression and pathologic determinants of azoxymethane (AOM)-induced CRC in a rat model.	Azoxymethane	109-112	thrombospondin type 1 domain containing 7A	Rattus norvegicus	46-52
34876395-11	2021	CONCLUSION: Negative staining for THSD7A seems to be linked to invasive pathologic determinants in AOM-induced CRC in rats.	Azoxymethane	99-102	thrombospondin type 1 domain containing 7A	Rattus norvegicus	34-40
34947813-6	2021	Interestingly, the knockout of CXCL13 inhibits benzo(a)pyrene-induced lung cancer and azoxymethane/dextran sodium sulfate-induced colorectal cancer in mice.	Azoxymethane	86-98	chemokine (C-X-C motif) ligand 13	Mus musculus	31-37
34625710-3	2021	Here, we show that CCL11 is involved in the pathogenesis of DSS-induced colitis and in colon tumorigenesis in the azoxymethane (AOM)-DSS model of colitis-associated carcinogenesis (CAC).	Azoxymethane	114-126	chemokine (C-C motif) ligand 11	Mus musculus	19-24
34625710-3	2021	Here, we show that CCL11 is involved in the pathogenesis of DSS-induced colitis and in colon tumorigenesis in the azoxymethane (AOM)-DSS model of colitis-associated carcinogenesis (CAC).	Azoxymethane	128-131	chemokine (C-C motif) ligand 11	Mus musculus	19-24
34625710-7	2021	Studies in bone marrow chimera mice revealed that hematopoietic- and epithelial-cell-derived CCL11 were both important for tumorigenesis in the AOM-DSS model.	Azoxymethane	144-147	chemokine (C-C motif) ligand 11	Mus musculus	93-98
34702807-10	2021	These data suggest strongly that the overexpressed Tipe2 suppresses tumor cells proliferation and survival, but endogenous Tipe2 promotes the initiation of tumorigenesis when exposure to dangerous environment such as AOM/DSS-related inflammation.	Azoxymethane	217-220	tumor necrosis factor, alpha-induced protein 8-like 2	Mus musculus	123-128
34307147-2	2021	We previously reported that Nrf2 deficiency enhances the anti-tumorigenic effect of 17beta-estradiol (E2) in an azoxymethane (AOM)/dextran sodium sulfate (DSS) model of colitis-associated cancer (CAC).	Azoxymethane	112-124	nuclear factor, erythroid derived 2, like 2	Mus musculus	28-32
34744741-4	2021	The results showed that 50 mg/kg SPS-1, an active fraction isolated from SPS, could significantly inhibit CRC induced by AOM/DSS and changed the polarization of macrophages to the M1 phenotype.	Azoxymethane	121-124	selenophosphate synthetase 1	Mus musculus	33-38
34622729-8	2021	CONCLUSIONS: The inhibitory effects of piceatannol on AOM/DSS-induced colon tumor growth appear to be associated with reductions in colon MCP-1 and PD-1 levels through the downregulated expression of COX-2 in the tumor microenvironment.	Azoxymethane	54-57	mast cell protease 1	Mus musculus	138-143
34622729-8	2021	CONCLUSIONS: The inhibitory effects of piceatannol on AOM/DSS-induced colon tumor growth appear to be associated with reductions in colon MCP-1 and PD-1 levels through the downregulated expression of COX-2 in the tumor microenvironment.	Azoxymethane	54-57	programmed cell death 1	Mus musculus	148-152
34622729-8	2021	CONCLUSIONS: The inhibitory effects of piceatannol on AOM/DSS-induced colon tumor growth appear to be associated with reductions in colon MCP-1 and PD-1 levels through the downregulated expression of COX-2 in the tumor microenvironment.	Azoxymethane	54-57	cytochrome c oxidase II, mitochondrial	Mus musculus	200-205
34638991-2	2021	Our previous study showed that the deficiency of the 15 kDa selenoprotein (Selenof) significantly reduced the formation of aberrant crypt foci (ACF) in a mouse model of azoxymethane (AOM)-induced colon carcinogenesis.	Azoxymethane	169-181	selenoprotein F	Mus musculus	53-73
34638991-2	2021	Our previous study showed that the deficiency of the 15 kDa selenoprotein (Selenof) significantly reduced the formation of aberrant crypt foci (ACF) in a mouse model of azoxymethane (AOM)-induced colon carcinogenesis.	Azoxymethane	169-181	selenoprotein F	Mus musculus	75-82
34273909-7	2021	Tumor-associated proteins, including p65 and Ki-67, were downregulated by the IRAK1/4 inhibitor in AOM/DSS-treated mice.	Azoxymethane	99-102	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	37-40
34273909-7	2021	Tumor-associated proteins, including p65 and Ki-67, were downregulated by the IRAK1/4 inhibitor in AOM/DSS-treated mice.	Azoxymethane	99-102	antigen identified by monoclonal antibody Ki 67	Mus musculus	45-50
34273909-7	2021	Tumor-associated proteins, including p65 and Ki-67, were downregulated by the IRAK1/4 inhibitor in AOM/DSS-treated mice.	Azoxymethane	99-102	interleukin-1 receptor-associated kinase 1	Mus musculus	78-85
34352441-5	2021	The rat CRC model was induced by AOM/DSS, in which we verified activity in the Wnt/beta-catenin pathway by examining GSK3beta phosphorylation.	Azoxymethane	33-36	catenin beta 1	Rattus norvegicus	83-95
34526999-14	2021	In the prophylactic setting, after immunization with CDC25B or COX2 peptides mice treated with AOM developed significantly fewer tumors as compared to controls (p<0.0002) with 50% of mice remaining tumor free in each antigen group.	Azoxymethane	95-98	cell division cycle 25B	Mus musculus	53-59
34160895-10	2021	Of note, TFAM knockout increased the susceptibility of mice to azoxymethane/DSS-induced CAC and TFAM overexpression protected mice from intestinal inflammation and colitis-associated tumorigenesis.	Azoxymethane	63-75	transcription factor A, mitochondrial	Mus musculus	9-13
34307147-2	2021	We previously reported that Nrf2 deficiency enhances the anti-tumorigenic effect of 17beta-estradiol (E2) in an azoxymethane (AOM)/dextran sodium sulfate (DSS) model of colitis-associated cancer (CAC).	Azoxymethane	126-129	nuclear factor, erythroid derived 2, like 2	Mus musculus	28-32
34307147-6	2021	Based on Western blotting results, PD-L1 expression was reduced in Nrf2 knockout (KO) female and E2-treated male mice when compared with their wild-type counterparts, following AOM/DSS treatment; this supports the association of PD-L1 expression with tumor progression.	Azoxymethane	177-180	CD274 antigen	Mus musculus	35-40
34307147-6	2021	Based on Western blotting results, PD-L1 expression was reduced in Nrf2 knockout (KO) female and E2-treated male mice when compared with their wild-type counterparts, following AOM/DSS treatment; this supports the association of PD-L1 expression with tumor progression.	Azoxymethane	177-180	nuclear factor, erythroid derived 2, like 2	Mus musculus	67-71
34307147-6	2021	Based on Western blotting results, PD-L1 expression was reduced in Nrf2 knockout (KO) female and E2-treated male mice when compared with their wild-type counterparts, following AOM/DSS treatment; this supports the association of PD-L1 expression with tumor progression.	Azoxymethane	177-180	CD274 antigen	Mus musculus	229-234
34118646-8	2021	KEY FINDINGS: Topiramate improved the body weight gain, decreased serum CEA, augmented the antioxidant defenses in the colonic tissues with significant amelioration of the inflammatory changes, decline in tissue VEGF and p-AKT/mTOR/MAP kinase signaling and increased Nrf2/HO-1 content in a dose-dependent manner when compared to rats treated with azoxymethane alone.	Azoxymethane	347-359	NFE2 like bZIP transcription factor 2	Rattus norvegicus	267-271
34118646-8	2021	KEY FINDINGS: Topiramate improved the body weight gain, decreased serum CEA, augmented the antioxidant defenses in the colonic tissues with significant amelioration of the inflammatory changes, decline in tissue VEGF and p-AKT/mTOR/MAP kinase signaling and increased Nrf2/HO-1 content in a dose-dependent manner when compared to rats treated with azoxymethane alone.	Azoxymethane	347-359	heme oxygenase 1	Rattus norvegicus	272-276
34099522-4	2021	To understand the role of DNA repair, especially homologous recombination (HR), in chemical carcinogen-induced CRC growth, we unraveled the role of RAD51AP1 (RAD51-Associated Protein 1), a protein involved in HR, in genotoxic carcinogen (Azoxymethane, AOM)-induced CRC.	Azoxymethane	238-250	RAD51 associated protein 1	Mus musculus	148-156
34099522-4	2021	To understand the role of DNA repair, especially homologous recombination (HR), in chemical carcinogen-induced CRC growth, we unraveled the role of RAD51AP1 (RAD51-Associated Protein 1), a protein involved in HR, in genotoxic carcinogen (Azoxymethane, AOM)-induced CRC.	Azoxymethane	238-250	RAD51 associated protein 1	Mus musculus	158-184
34099522-4	2021	To understand the role of DNA repair, especially homologous recombination (HR), in chemical carcinogen-induced CRC growth, we unraveled the role of RAD51AP1 (RAD51-Associated Protein 1), a protein involved in HR, in genotoxic carcinogen (Azoxymethane, AOM)-induced CRC.	Azoxymethane	252-255	RAD51 associated protein 1	Mus musculus	148-156
34099522-4	2021	To understand the role of DNA repair, especially homologous recombination (HR), in chemical carcinogen-induced CRC growth, we unraveled the role of RAD51AP1 (RAD51-Associated Protein 1), a protein involved in HR, in genotoxic carcinogen (Azoxymethane, AOM)-induced CRC.	Azoxymethane	252-255	RAD51 associated protein 1	Mus musculus	158-184
34099522-5	2021	Although AOM treatment alone significantly increased RAD51AP1 expression, the combination of AOM and Dextran Sulfate Sodium (DSS) treatment dramatically increased by several folds.	Azoxymethane	9-12	RAD51 associated protein 1	Mus musculus	53-61
34154626-7	2021	Functionally, IMP3 promote the malignant biological process of CRC cells via MEKK1/MEK1/ERK signaling pathway both in vitro and in vivo, Moreover, IMP3-/- mice show decreased the expression of MEKK1 as well as colorectal tumors compared with wild-type mice after treatment with azoxymethane/dextran sodium sulfate.	Azoxymethane	278-290	IMP3, U3 small nucleolar ribonucleoprotein	Mus musculus	14-18
34154626-7	2021	Functionally, IMP3 promote the malignant biological process of CRC cells via MEKK1/MEK1/ERK signaling pathway both in vitro and in vivo, Moreover, IMP3-/- mice show decreased the expression of MEKK1 as well as colorectal tumors compared with wild-type mice after treatment with azoxymethane/dextran sodium sulfate.	Azoxymethane	278-290	mitogen-activated protein kinase kinase 1	Mus musculus	77-82
34154626-7	2021	Functionally, IMP3 promote the malignant biological process of CRC cells via MEKK1/MEK1/ERK signaling pathway both in vitro and in vivo, Moreover, IMP3-/- mice show decreased the expression of MEKK1 as well as colorectal tumors compared with wild-type mice after treatment with azoxymethane/dextran sodium sulfate.	Azoxymethane	278-290	mitogen-activated protein kinase kinase 1	Mus musculus	83-87
34154626-7	2021	Functionally, IMP3 promote the malignant biological process of CRC cells via MEKK1/MEK1/ERK signaling pathway both in vitro and in vivo, Moreover, IMP3-/- mice show decreased the expression of MEKK1 as well as colorectal tumors compared with wild-type mice after treatment with azoxymethane/dextran sodium sulfate.	Azoxymethane	278-290	mitogen-activated protein kinase 1	Mus musculus	88-91
34154626-7	2021	Functionally, IMP3 promote the malignant biological process of CRC cells via MEKK1/MEK1/ERK signaling pathway both in vitro and in vivo, Moreover, IMP3-/- mice show decreased the expression of MEKK1 as well as colorectal tumors compared with wild-type mice after treatment with azoxymethane/dextran sodium sulfate.	Azoxymethane	278-290	IMP3, U3 small nucleolar ribonucleoprotein	Mus musculus	147-151
34154626-7	2021	Functionally, IMP3 promote the malignant biological process of CRC cells via MEKK1/MEK1/ERK signaling pathway both in vitro and in vivo, Moreover, IMP3-/- mice show decreased the expression of MEKK1 as well as colorectal tumors compared with wild-type mice after treatment with azoxymethane/dextran sodium sulfate.	Azoxymethane	278-290	mitogen-activated protein kinase kinase 1	Mus musculus	193-198
34109174-3	2021	Here, based on the BRD7 knockout (BRD7-/-) and BRD7 flox/flox (BRD7+/+) mouse models constructed in our previous work, we established an azoxymethane/dextran sodium sulfate (AOM/DSS)-induced mouse model.	Azoxymethane	137-149	bromodomain containing 7	Mus musculus	19-23
34109174-3	2021	Here, based on the BRD7 knockout (BRD7-/-) and BRD7 flox/flox (BRD7+/+) mouse models constructed in our previous work, we established an azoxymethane/dextran sodium sulfate (AOM/DSS)-induced mouse model.	Azoxymethane	137-149	bromodomain containing 7	Mus musculus	34-38
34109174-3	2021	Here, based on the BRD7 knockout (BRD7-/-) and BRD7 flox/flox (BRD7+/+) mouse models constructed in our previous work, we established an azoxymethane/dextran sodium sulfate (AOM/DSS)-induced mouse model.	Azoxymethane	137-149	bromodomain containing 7	Mus musculus	47-51
34109174-3	2021	Here, based on the BRD7 knockout (BRD7-/-) and BRD7 flox/flox (BRD7+/+) mouse models constructed in our previous work, we established an azoxymethane/dextran sodium sulfate (AOM/DSS)-induced mouse model.	Azoxymethane	137-149	bromodomain containing 7	Mus musculus	63-67
34109174-3	2021	Here, based on the BRD7 knockout (BRD7-/-) and BRD7 flox/flox (BRD7+/+) mouse models constructed in our previous work, we established an azoxymethane/dextran sodium sulfate (AOM/DSS)-induced mouse model.	Azoxymethane	174-177	bromodomain containing 7	Mus musculus	19-23
34109174-3	2021	Here, based on the BRD7 knockout (BRD7-/-) and BRD7 flox/flox (BRD7+/+) mouse models constructed in our previous work, we established an azoxymethane/dextran sodium sulfate (AOM/DSS)-induced mouse model.	Azoxymethane	174-177	bromodomain containing 7	Mus musculus	34-38
34109174-3	2021	Here, based on the BRD7 knockout (BRD7-/-) and BRD7 flox/flox (BRD7+/+) mouse models constructed in our previous work, we established an azoxymethane/dextran sodium sulfate (AOM/DSS)-induced mouse model.	Azoxymethane	174-177	bromodomain containing 7	Mus musculus	47-51
34109174-3	2021	Here, based on the BRD7 knockout (BRD7-/-) and BRD7 flox/flox (BRD7+/+) mouse models constructed in our previous work, we established an azoxymethane/dextran sodium sulfate (AOM/DSS)-induced mouse model.	Azoxymethane	174-177	bromodomain containing 7	Mus musculus	63-67
34109174-4	2021	BRD7+/+ mice were found to be highly susceptible to AOM/DSS-induced colitis-associated CRC, and BRD7 significantly promoted cell proliferation and cell cycle G1/S transition but showed no significant effect on cell apoptosis.	Azoxymethane	52-55	bromodomain containing 7	Mus musculus	0-4
34070183-8	2021	These results suggest that at one month after the end of the DSS or AOM inductions, a smouldering inflammation is present in both induced conditions, since the pro-inflammatory cytokines still exceed, in proportion, the local homeostatic regulation of which TGF-beta1 is a part (inflammatory threshold).	Azoxymethane	68-71	transforming growth factor, beta 1	Rattus norvegicus	258-267
35631174-6	2022	FTH1 expression increased in the mice"s colons in the IC + AOM/DSS group compared with that observed in the ID and IOL + AOM/DSS groups.	Azoxymethane	59-62	ferritin heavy polypeptide 1	Mus musculus	0-4
34087454-8	2021	Additionally, comparing to WT mice, IDO-/- mice treated with AOM/DSS exhibited fewer and smaller tumor burdens in colon, with less Treg and more CD8+ T cells infiltration, while Kyn administration abolished this regulation.	Azoxymethane	61-64	indoleamine 2,3-dioxygenase 1	Mus musculus	36-39
35378414-9	2022	The administration of 10 mg/kg tetra- and pentahydroxyflavanones to AOM/DSS-treated mice also resulted in decreases of 59.5 and 42.5% in IL-10 levels and 58.1 and 93.9% in PD-1 levels, respectively, in the colon.	Azoxymethane	68-71	interleukin 10	Mus musculus	137-142
35378414-9	2022	The administration of 10 mg/kg tetra- and pentahydroxyflavanones to AOM/DSS-treated mice also resulted in decreases of 59.5 and 42.5% in IL-10 levels and 58.1 and 93.9% in PD-1 levels, respectively, in the colon.	Azoxymethane	68-71	programmed cell death 1	Mus musculus	172-176
35378414-10	2022	CONCLUSION: The inhibitory effects of tetra- and pentahydroxyflavanones on the growth of colon tumors in AOM/DSS-treated mice appear to be associated with decreases in the colon levels of IL-10 and PD-1 through the down-regulated expression of COX-2 and CD8+ T-cell exhaustion by TOX/TOX2 in the tumor microenvironment.	Azoxymethane	105-108	interleukin 10	Mus musculus	188-193
35378414-10	2022	CONCLUSION: The inhibitory effects of tetra- and pentahydroxyflavanones on the growth of colon tumors in AOM/DSS-treated mice appear to be associated with decreases in the colon levels of IL-10 and PD-1 through the down-regulated expression of COX-2 and CD8+ T-cell exhaustion by TOX/TOX2 in the tumor microenvironment.	Azoxymethane	105-108	programmed cell death 1	Mus musculus	198-202
35503250-8	2022	Finally, uncoupling MTG16:E protein interactions partially phenocopied the enhanced tumorigenicity of Mtg16-/- colon in the azoxymethane(AOM)/DSS-induced model of CAC, indicating that MTG16 protects from tumorigenesis through additional mechanisms.	Azoxymethane	124-136	CBFA2/RUNX1 partner transcriptional co-repressor 3	Homo sapiens	20-25
35503250-8	2022	Finally, uncoupling MTG16:E protein interactions partially phenocopied the enhanced tumorigenicity of Mtg16-/- colon in the azoxymethane(AOM)/DSS-induced model of CAC, indicating that MTG16 protects from tumorigenesis through additional mechanisms.	Azoxymethane	124-136	CBFA2/RUNX1 partner transcriptional co-repressor 3	Homo sapiens	102-107
35503250-8	2022	Finally, uncoupling MTG16:E protein interactions partially phenocopied the enhanced tumorigenicity of Mtg16-/- colon in the azoxymethane(AOM)/DSS-induced model of CAC, indicating that MTG16 protects from tumorigenesis through additional mechanisms.	Azoxymethane	137-140	CBFA2/RUNX1 partner transcriptional co-repressor 3	Homo sapiens	20-25
35503250-8	2022	Finally, uncoupling MTG16:E protein interactions partially phenocopied the enhanced tumorigenicity of Mtg16-/- colon in the azoxymethane(AOM)/DSS-induced model of CAC, indicating that MTG16 protects from tumorigenesis through additional mechanisms.	Azoxymethane	137-140	CBFA2/RUNX1 partner transcriptional co-repressor 3	Homo sapiens	102-107
35563010-2	2022	Methods: CA-CRC was induced in P2X7R+/+ and P2X7R-/- mice with azoxymethane (AOM) combined with dextran sodium sulfate (DSS).	Azoxymethane	63-75	cation channel, sperm associated 3	Mus musculus	9-15
35563010-2	2022	Methods: CA-CRC was induced in P2X7R+/+ and P2X7R-/- mice with azoxymethane (AOM) combined with dextran sodium sulfate (DSS).	Azoxymethane	63-75	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	31-36
35563010-2	2022	Methods: CA-CRC was induced in P2X7R+/+ and P2X7R-/- mice with azoxymethane (AOM) combined with dextran sodium sulfate (DSS).	Azoxymethane	77-80	cation channel, sperm associated 3	Mus musculus	9-15
35563010-2	2022	Methods: CA-CRC was induced in P2X7R+/+ and P2X7R-/- mice with azoxymethane (AOM) combined with dextran sodium sulfate (DSS).	Azoxymethane	77-80	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	31-36
35399505-6	2022	Further, we demonstrated that Vim-/- mice did not develop colitis-associated cancer model upon DSS treatment spontaneously but increased tumor numbers and size in the distal colon in the azoxymethane/DSS model comparing with WT mice.	Azoxymethane	187-199	vimentin	Mus musculus	30-33
35365782-5	2022	In Villin-ACKR3 transgenic mice with a high expression level of CKR3 in their intestinal epithelial cells, administration of AOM/DSS induced more severe colorectal tumorigenesis than their WT littermates.	Azoxymethane	125-128	atypical chemokine receptor 3	Mus musculus	10-15
35365782-5	2022	In Villin-ACKR3 transgenic mice with a high expression level of CKR3 in their intestinal epithelial cells, administration of AOM/DSS induced more severe colorectal tumorigenesis than their WT littermates.	Azoxymethane	125-128	chemokine (C-C motif) receptor 3	Mus musculus	64-68
35101901-3	2022	Consistent with these findings, TIPE2 deficiency significantly inhibited the development of CRC in mice treated with azoxymethane/dextran sodium sulfate and in Apcmin/+ mice.	Azoxymethane	117-129	tumor necrosis factor, alpha-induced protein 8-like 2	Mus musculus	32-37
35359953-4	2022	Genetic deletion of IL25 inhibited tumor formation and growth and prolonged survival in AOM/DSS-treated mice.	Azoxymethane	88-91	interleukin 25	Mus musculus	20-24
35232776-9	2022	In azoxymethane-induced CRC model, Sqle tg mice showed increased tumourigenesis compared with wild-type mice (p<0.01).	Azoxymethane	3-15	squalene epoxidase	Mus musculus	35-39
35163788-0	2022	T-Cell-Specific CerS4 Depletion Prolonged Inflammation and Enhanced Tumor Burden in the AOM/DSS-Induced CAC Model.	Azoxymethane	88-91	ceramide synthase 4	Mus musculus	16-21
35205671-5	2022	Here, we found that IRF9 had an oncogenic effect in CRC; loss of IRF9 reduced tumorigenesis in both azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced and spontaneous CRC models.	Azoxymethane	100-112	interferon regulatory factor 9	Homo sapiens	20-24
35205671-5	2022	Here, we found that IRF9 had an oncogenic effect in CRC; loss of IRF9 reduced tumorigenesis in both azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced and spontaneous CRC models.	Azoxymethane	100-112	interferon regulatory factor 9	Homo sapiens	65-69
35205671-5	2022	Here, we found that IRF9 had an oncogenic effect in CRC; loss of IRF9 reduced tumorigenesis in both azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced and spontaneous CRC models.	Azoxymethane	114-117	interferon regulatory factor 9	Homo sapiens	20-24
35205671-5	2022	Here, we found that IRF9 had an oncogenic effect in CRC; loss of IRF9 reduced tumorigenesis in both azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced and spontaneous CRC models.	Azoxymethane	114-117	interferon regulatory factor 9	Homo sapiens	65-69
35163788-10	2022	The higher tumor incidence in CerS4 LCK/Cre mice and the toxic effect of AOM/DSS in CerS4 KO mice exhibited the importance of CerS4 in other tissues and revealed the complexity of general targeting CerS4.	Azoxymethane	73-76	ceramide synthase 4	Mus musculus	84-89
35163788-10	2022	The higher tumor incidence in CerS4 LCK/Cre mice and the toxic effect of AOM/DSS in CerS4 KO mice exhibited the importance of CerS4 in other tissues and revealed the complexity of general targeting CerS4.	Azoxymethane	73-76	ceramide synthase 4	Mus musculus	126-131
35163788-10	2022	The higher tumor incidence in CerS4 LCK/Cre mice and the toxic effect of AOM/DSS in CerS4 KO mice exhibited the importance of CerS4 in other tissues and revealed the complexity of general targeting CerS4.	Azoxymethane	73-76	ceramide synthase 4	Mus musculus	198-203
35148799-10	2022	RESULTS: In preclinical settings, loss of EMILIN-2 associated with an increased number of tumor lesions upon AOM/DSS treatment.	Azoxymethane	109-112	elastin microfibril interfacer 2	Homo sapiens	42-50
35163788-3	2022	CerS4 KO mice were highly sensitive to the toxic effect of AOM/DSS, leading to a high mortality rate.	Azoxymethane	59-62	ceramide synthase 4	Mus musculus	0-5
35014688-7	2022	The obese Wistar rats exposed to azoxymethane to induce colon cancer exhibited a more severe colon tumor outcome, which was associated with significantly increased MACC1 levels compared with their non-obese littermates.	Azoxymethane	33-45	MET transcriptional regulator MACC1	Rattus norvegicus	164-169
3621182-0	1987	Enhancement by vasoactive intestinal peptide of experimental carcinogenesis induced by azoxymethane in rat colon.	Azoxymethane	87-99	vasoactive intestinal peptide	Rattus norvegicus	15-44
2790802-0	1989	Attenuation of azoxymethane-induced colonic mucosal ornithine decarboxylase and tyrosine kinase activity by calcium in rats.	Azoxymethane	15-27	ornithine decarboxylase 1	Rattus norvegicus	52-75
2493096-1	1989	During azoxymethane (AOM)-induced colonic carcinogenesis in rats, biphasic induction of ornithine decarboxylase (ODC) activity occurs in the colonic mucosa.	Azoxymethane	7-19	ornithine decarboxylase 1	Rattus norvegicus	88-111
2493096-1	1989	During azoxymethane (AOM)-induced colonic carcinogenesis in rats, biphasic induction of ornithine decarboxylase (ODC) activity occurs in the colonic mucosa.	Azoxymethane	7-19	ornithine decarboxylase 1	Rattus norvegicus	113-116
2493096-1	1989	During azoxymethane (AOM)-induced colonic carcinogenesis in rats, biphasic induction of ornithine decarboxylase (ODC) activity occurs in the colonic mucosa.	Azoxymethane	21-24	ornithine decarboxylase 1	Rattus norvegicus	88-111
2493096-1	1989	During azoxymethane (AOM)-induced colonic carcinogenesis in rats, biphasic induction of ornithine decarboxylase (ODC) activity occurs in the colonic mucosa.	Azoxymethane	21-24	ornithine decarboxylase 1	Rattus norvegicus	113-116
2752519-1	1989	In previous studies, we have shown that inositol hexaphosphate (InsP6), a constituent of cereal diet, inhibited azoxymethane-induced experimental large intestinal cancer (LIC) in Fischer 344 rats.	Azoxymethane	112-124	inositol hexaphosphate kinase 1	Mus musculus	64-69
2501972-0	1989	Early alterations of rat intestinal diamine oxidase activity by azoxymethane, an intestinal carcinogen.	Azoxymethane	64-76	amine oxidase, copper containing 1	Rattus norvegicus	36-51
2501972-3	1989	In vitro, azoxymethane was a very weak inhibitor of rat intestinal diamine oxidase activity.	Azoxymethane	10-22	amine oxidase, copper containing 1	Rattus norvegicus	67-82
2501972-4	1989	In vivo, after subcutaneous injection of a single dose of azoxymethane, diamine oxidase activity was increased in the duodenum but was mainly inhibited in the colon.	Azoxymethane	58-70	amine oxidase, copper containing 1	Rattus norvegicus	72-87
2501972-5	1989	Intestinal diamine oxidase activity may then be influenced by regulatory processes induced by azoxymethane rather than by a direct effect.	Azoxymethane	94-106	amine oxidase, copper containing 1	Rattus norvegicus	11-26
3621182-1	1987	The effects of vasoactive intestinal peptide (VIP) on the incidence and histology of colonic tumors induced by azoxymethane (AOM) were investigated in Wistar rats.	Azoxymethane	111-123	vasoactive intestinal peptide	Rattus norvegicus	46-49
3731101-0	1986	Kinetic changes in mucosal ornithine decarboxylase activity during azoxymethane-induced colonic carcinogenesis in the rat.	Azoxymethane	67-79	ornithine decarboxylase 1	Rattus norvegicus	27-50
2881630-0	1987	Effect of a long-acting analogue of somatostatin, SMS 201-995, on the development of intestinal tumours in azoxymethane-treated rats.	Azoxymethane	107-119	somatostatin	Rattus norvegicus	36-48
3568008-1	1987	Because the role of proteolytic enzymes in carcinogenesis is not yet well understood, we studied two arylamidases cleaving Boc-(Ala)2-p-nitroanilide and Bz-Lys-p-nitroanilide in the sera of rats during azoxymethane (AOM)-induced development of bowel carcinomas.	Azoxymethane	202-214	BOC cell adhesion associated, oncogene regulated	Rattus norvegicus	123-126
3568008-1	1987	Because the role of proteolytic enzymes in carcinogenesis is not yet well understood, we studied two arylamidases cleaving Boc-(Ala)2-p-nitroanilide and Bz-Lys-p-nitroanilide in the sera of rats during azoxymethane (AOM)-induced development of bowel carcinomas.	Azoxymethane	216-219	BOC cell adhesion associated, oncogene regulated	Rattus norvegicus	123-126
33564842-3	2021	When treated with azoxymethane and dextran sodium sulphate (AOM/DSS) as a model of IBD, Gsto1  -/- mice were highly sensitive to colitis and showed a significant increase in the size and number of colon tumours compared with wildtype mice (WT).	Azoxymethane	18-30	glutathione S-transferase omega 1	Mus musculus	88-93
3862909-0	1985	Effect of different levels of dietary trans fat or corn oil on azoxymethane-induced colon carcinogenesis in F344 rats.	Azoxymethane	63-75	FAT atypical cadherin 1	Rattus norvegicus	44-47
3862909-1	1985	The effect of various levels of dietary corn oil or trans fat on azoxymethane (AOM; CAS: 25843-45-2)-induced carcinogenesis was investigated in female F344 rats fed the AIN-76 semipurified diets.	Azoxymethane	65-77	FAT atypical cadherin 1	Rattus norvegicus	58-61
34006646-5	2021	Mice lacking Gal-1 (Lgals1 -/- ) developed a lower number of tumors and showed a decreased frequency of a particular population of CD8+CD122+PD-1+ Tregs in the azoxymethane-dextran sodium sulfate model of colitis-associated CRC.	Azoxymethane	160-172	lectin, galactose binding, soluble 1	Mus musculus	20-26
34006646-5	2021	Mice lacking Gal-1 (Lgals1 -/- ) developed a lower number of tumors and showed a decreased frequency of a particular population of CD8+CD122+PD-1+ Tregs in the azoxymethane-dextran sodium sulfate model of colitis-associated CRC.	Azoxymethane	160-172	CD8a molecule	Homo sapiens	131-134
33901495-9	2021	Although MondoA-deficient Tregs were less immune suppressive and selectively promoted Th1 responses in a subcutaneous MC38 tumor model, Treg-specific MondoA knockout mice were more susceptible to AOM-DSS-induced colorectal cancer.	Azoxymethane	196-199	MLX interacting protein	Homo sapiens	150-156
33861936-1	2021	The anticancer effects of Shinan (Shinan-South Korea) sea salts on azoxymethane (AOM)/dextran sodium sulfate (DSS) with high fat diet (HFD)-induced colon cancer and obesity in C57BL/6N mice were studied.	Azoxymethane	67-79	sepia	Mus musculus	54-57
33842405-0	2021	Nuclear Factor Erythroid 2-related Factor 2 Knockout Suppresses the Development of Aggressive Colorectal Cancer Formation Induced by Azoxymethane/Dextran Sulfate Sodium-Treatment in Female Mice.	Azoxymethane	133-145	nuclear factor, erythroid derived 2, like 2	Mus musculus	0-43
32860065-3	2021	METHODS: We analyzed TRIM21 expression in tumor tissues from patients with colorectal cancer (CRC) and ulcerative colitis (UC)-associated cancer by immunohistochemistry and real-time polymerase chain reaction and established a CAC model in TRIM21-/- and wild type mice by azoxymethane (AOM) and dextran sodium sulfate (DSS).	Azoxymethane	272-284	tripartite motif containing 21	Homo sapiens	21-27
7053860-0	1982	Effect of beta-glucuronidase inhibitor on azoxymethane-induced colonic carcinogenesis in rats.	Azoxymethane	42-54	glucuronidase, beta	Rattus norvegicus	10-28
621376-0	1978	The cytochemical demonstration of beta-glucuronidase in colon neoplasms of rats exposed to azoxymethane.	Azoxymethane	91-103	glucuronidase, beta	Rattus norvegicus	34-52
33564842-3	2021	When treated with azoxymethane and dextran sodium sulphate (AOM/DSS) as a model of IBD, Gsto1  -/- mice were highly sensitive to colitis and showed a significant increase in the size and number of colon tumours compared with wildtype mice (WT).	Azoxymethane	60-63	glutathione S-transferase omega 1	Mus musculus	88-93
33564842-4	2021	Gsto1  -/- mice treated with AOM/DSS had significantly lower serum IL-1beta and IL-18 levels as well as significantly decreased IFN-gamma, decreased pSTAT1 and increased pSTAT3 levels in the distal colon compared to similarly treated WT mice.	Azoxymethane	29-32	glutathione S-transferase omega 1	Mus musculus	0-5
33564842-4	2021	Gsto1  -/- mice treated with AOM/DSS had significantly lower serum IL-1beta and IL-18 levels as well as significantly decreased IFN-gamma, decreased pSTAT1 and increased pSTAT3 levels in the distal colon compared to similarly treated WT mice.	Azoxymethane	29-32	interleukin 1 alpha	Mus musculus	67-75
33564842-4	2021	Gsto1  -/- mice treated with AOM/DSS had significantly lower serum IL-1beta and IL-18 levels as well as significantly decreased IFN-gamma, decreased pSTAT1 and increased pSTAT3 levels in the distal colon compared to similarly treated WT mice.	Azoxymethane	29-32	interleukin 18	Mus musculus	80-85
33564842-4	2021	Gsto1  -/- mice treated with AOM/DSS had significantly lower serum IL-1beta and IL-18 levels as well as significantly decreased IFN-gamma, decreased pSTAT1 and increased pSTAT3 levels in the distal colon compared to similarly treated WT mice.	Azoxymethane	29-32	interferon gamma	Mus musculus	128-137
33564842-5	2021	Histologically, AOM/DSS treated Gsto1  -/- mice showed increased active chronic inflammation with macrophage infiltration, epithelial dysplasia and invasive adenocarcinoma compared with AOM/DSS treated WT mice.	Azoxymethane	16-19	glutathione S-transferase omega 1	Mus musculus	32-37
33535045-5	2021	Myofibroblast MyD88-deficient mice are resistant to azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced tumorigenesis, as evidenced by the decrease in the number and sizes of tumors.	Azoxymethane	52-64	myeloid differentiation primary response gene 88	Mus musculus	14-19
33535045-5	2021	Myofibroblast MyD88-deficient mice are resistant to azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced tumorigenesis, as evidenced by the decrease in the number and sizes of tumors.	Azoxymethane	66-69	myeloid differentiation primary response gene 88	Mus musculus	14-19
33367479-6	2021	Lastly, the suppression of ARRB2 expression was enough to attenuate the progression of CRC induced by azoxymethane/dextran sodium sulfate.	Azoxymethane	102-114	arrestin beta 2	Homo sapiens	27-32
33537297-6	2020	First, AOM treatment significantly up-regulated the expression of BDNF, tropomycin receptor kinase B (TrkB), and phosphorylated AKT (p-AKT) in the hippocampus, enhanced adult hippocampal neurogenesis, and improved the spatial learning/memory and cognitive functions in the post-MCAO ischemic rats in vivo.	Azoxymethane	7-10	brain-derived neurotrophic factor	Rattus norvegicus	66-70
33537297-6	2020	First, AOM treatment significantly up-regulated the expression of BDNF, tropomycin receptor kinase B (TrkB), and phosphorylated AKT (p-AKT) in the hippocampus, enhanced adult hippocampal neurogenesis, and improved the spatial learning/memory and cognitive functions in the post-MCAO ischemic rats in vivo.	Azoxymethane	7-10	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	72-100
33537297-6	2020	First, AOM treatment significantly up-regulated the expression of BDNF, tropomycin receptor kinase B (TrkB), and phosphorylated AKT (p-AKT) in the hippocampus, enhanced adult hippocampal neurogenesis, and improved the spatial learning/memory and cognitive functions in the post-MCAO ischemic rats in vivo.	Azoxymethane	7-10	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	102-106
33537297-6	2020	First, AOM treatment significantly up-regulated the expression of BDNF, tropomycin receptor kinase B (TrkB), and phosphorylated AKT (p-AKT) in the hippocampus, enhanced adult hippocampal neurogenesis, and improved the spatial learning/memory and cognitive functions in the post-MCAO ischemic rats in vivo.	Azoxymethane	7-10	AKT serine/threonine kinase 1	Rattus norvegicus	128-131
33537297-6	2020	First, AOM treatment significantly up-regulated the expression of BDNF, tropomycin receptor kinase B (TrkB), and phosphorylated AKT (p-AKT) in the hippocampus, enhanced adult hippocampal neurogenesis, and improved the spatial learning/memory and cognitive functions in the post-MCAO ischemic rats in vivo.	Azoxymethane	7-10	AKT serine/threonine kinase 1	Rattus norvegicus	135-138
32468854-5	2021	C57BL6 wild-type (WT) mice and a strain defective in the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) were used, in which tumors were induced by azoxymethane (AOM) followed by dextran sodium sulfate (DSS).	Azoxymethane	164-176	O-6-methylguanine-DNA methyltransferase	Mus musculus	115-119
33314701-5	2021	OMA1 knockout suppresses colorectal cancer development in AOM/DSS and xenograft mice models of colorectal cancer.	Azoxymethane	58-61	OMA1 zinc metallopeptidase	Mus musculus	0-4
33643790-7	2021	Furthermore, inhibition of CXCL12 from senescent tumor cells enhances T cell infiltration and results in reducing the number and size of tumors in azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced CRC.	Azoxymethane	147-159	C-X-C motif chemokine ligand 12	Homo sapiens	27-33
33643790-7	2021	Furthermore, inhibition of CXCL12 from senescent tumor cells enhances T cell infiltration and results in reducing the number and size of tumors in azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced CRC.	Azoxymethane	161-164	C-X-C motif chemokine ligand 12	Homo sapiens	27-33
32805281-5	2020	CCAT2 transgene and control mice were given azoxymethane and dextran sulphate sodium (DSS) to induce colon tumors.	Azoxymethane	44-56	colon cancer associated transcript 2	Homo sapiens	0-5
31617778-7	2021	Immunohistochemically, CEA, COX-2, and Ki-67 immune-expressions decreased, and the immune-expression of caspase-3 increased in AOM + JB treated rats.	Azoxymethane	127-130	carcinoembryonic antigen gene family 4	Rattus norvegicus	23-26
31617778-7	2021	Immunohistochemically, CEA, COX-2, and Ki-67 immune-expressions decreased, and the immune-expression of caspase-3 increased in AOM + JB treated rats.	Azoxymethane	127-130	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	28-33
31617778-7	2021	Immunohistochemically, CEA, COX-2, and Ki-67 immune-expressions decreased, and the immune-expression of caspase-3 increased in AOM + JB treated rats.	Azoxymethane	127-130	caspase 3	Rattus norvegicus	104-113
33068552-0	2020	17beta-Estradiol strongly inhibits azoxymethane/dextran sulfate sodium-induced colorectal cancer development in Nrf2 knockout male mice.	Azoxymethane	35-47	nuclear factor, erythroid derived 2, like 2	Mus musculus	112-116
33110234-9	2021	We further demonstrated that Gal2-KO mice developed significantly larger tumors than WT mice using Azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced colorectal cancer model.	Azoxymethane	99-111	lectin, galactose-binding, soluble 2	Mus musculus	29-33
33110234-9	2021	We further demonstrated that Gal2-KO mice developed significantly larger tumors than WT mice using Azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced colorectal cancer model.	Azoxymethane	113-116	lectin, galactose-binding, soluble 2	Mus musculus	29-33
32749453-3	2020	Here, we demonstrate that constitutive AKT activation in intestinal epithelial cells markedly enhances tumor invasion and metastasis in Trp53DeltaIEC mice (Trp53DeltaIECAktE17K) upon challenge with the carcinogen azoxymethane.	Azoxymethane	213-225	thymoma viral proto-oncogene 1	Mus musculus	39-42
32810576-7	2020	Moreover, TLR3-/-TLR7-/- mice developed colitis-associated colon cancer following AOM/DSS treatment.	Azoxymethane	82-85	toll-like receptor 3	Mus musculus	10-14
32810576-7	2020	Moreover, TLR3-/-TLR7-/- mice developed colitis-associated colon cancer following AOM/DSS treatment.	Azoxymethane	82-85	toll-like receptor 7	Mus musculus	17-21
32581195-8	2020	AOM/DSS-treated Pierce1 TG mice were comparable with respect to colon lengths, the number of polyps, and tumor sizes to those of the control mice.	Azoxymethane	0-3	piercer of microtubule wall 1	Mus musculus	16-23
32882406-8	2020	In addition, our results showed that RNF186-/- mice exhibited significantly increased tumour burden compared to the wild type (WT) mice following treatment with azoxymethane/dextran sulfate sodium (AOM/DSS).	Azoxymethane	161-173	ring finger protein 186	Mus musculus	37-43
32882406-8	2020	In addition, our results showed that RNF186-/- mice exhibited significantly increased tumour burden compared to the wild type (WT) mice following treatment with azoxymethane/dextran sulfate sodium (AOM/DSS).	Azoxymethane	198-201	ring finger protein 186	Mus musculus	37-43
32758571-7	2020	Therefore, the inhibition of AOM/DSS-induced colon carcinogenesis and colon tumor growth by 2,3-, 3,4-, and 4,4"-dihydroxystilbenes appears to be due to the suppression of M2 TAM differentiation and activation and PD-1 expression (immunosuppression) via reductions in COX-2 expression levels in the colon tumor microenvironment.	Azoxymethane	29-32	programmed cell death 1	Mus musculus	214-218
32758571-7	2020	Therefore, the inhibition of AOM/DSS-induced colon carcinogenesis and colon tumor growth by 2,3-, 3,4-, and 4,4"-dihydroxystilbenes appears to be due to the suppression of M2 TAM differentiation and activation and PD-1 expression (immunosuppression) via reductions in COX-2 expression levels in the colon tumor microenvironment.	Azoxymethane	29-32	cytochrome c oxidase II, mitochondrial	Mus musculus	268-273
32591441-8	2020	In further experiments, we found that the levels of IL-10 were elevated in the serum of Azoxymethane (AOM)/Dextran Sodium Sulfate (DSS)-treated AURKAflox/+;VillinCre+ mice.	Azoxymethane	88-100	interleukin 10	Mus musculus	52-57
32653643-0	2020	Blocking NFATc3 ameliorates azoxymethane/dextran sulfate sodium induced colitis-associated colorectal cancer in mice via the inhibition of inflammatory responses and epithelial-mesenchymal transition.	Azoxymethane	28-40	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 3	Mus musculus	9-15
32591441-8	2020	In further experiments, we found that the levels of IL-10 were elevated in the serum of Azoxymethane (AOM)/Dextran Sodium Sulfate (DSS)-treated AURKAflox/+;VillinCre+ mice.	Azoxymethane	102-105	interleukin 10	Mus musculus	52-57
32526927-4	2020	Resveratrol treatment in the azoxymethane (AOM) and dextran sodium sulphate (DSS) CRC murine model caused an increase in anti-inflammatory CD4 + FOXP3 + (Tregs) and CD4 + IL10 + cells, a decrease in proinflammatory Th1 and Th17 cells, and attenuated CRC development.	Azoxymethane	43-46	CD4 antigen	Mus musculus	139-142
32640217-3	2020	In a dextran sodium sulfate and azoxymethane (DSS/AOM) mouse model, deficiency and pharmacological inhibition of extracellular GzmA both attenuate gut inflammation and prevent CRC development, including the initial steps of cell transformation and epithelial-to-mesenchymal transition.	Azoxymethane	32-44	granzyme A	Mus musculus	127-131
32640217-3	2020	In a dextran sodium sulfate and azoxymethane (DSS/AOM) mouse model, deficiency and pharmacological inhibition of extracellular GzmA both attenuate gut inflammation and prevent CRC development, including the initial steps of cell transformation and epithelial-to-mesenchymal transition.	Azoxymethane	50-53	granzyme A	Mus musculus	127-131
32640217-5	2020	Accordingly, colon tissues from DSS/AOM-treated, GzmA-deficient animals present reduced levels of pSTAT3.	Azoxymethane	36-39	granzyme A	Mus musculus	49-53
32851100-7	2020	IHC staining in both human sample and AOM/DSS induced mouse CRC model revealed significant downregulation of MPC1.	Azoxymethane	38-41	mitochondrial pyruvate carrier 1	Mus musculus	109-113
32630271-11	2020	In summary, we show that CerS5-ko mice were more susceptible to dextran sodium sulfate-induced colitis and azoxymethane/dextran sodium sulfate-induced colitis-associated colon cancer.	Azoxymethane	107-119	ceramide synthase 5	Mus musculus	25-30
32554929-5	2020	IRF1 functions in both the myeloid and epithelial compartments to confer protection against AOM/DSS-induced colorectal tumorigenesis.	Azoxymethane	92-95	interferon regulatory factor 1	Mus musculus	0-4
32526927-4	2020	Resveratrol treatment in the azoxymethane (AOM) and dextran sodium sulphate (DSS) CRC murine model caused an increase in anti-inflammatory CD4 + FOXP3 + (Tregs) and CD4 + IL10 + cells, a decrease in proinflammatory Th1 and Th17 cells, and attenuated CRC development.	Azoxymethane	43-46	forkhead box P3	Mus musculus	145-150
32526927-4	2020	Resveratrol treatment in the azoxymethane (AOM) and dextran sodium sulphate (DSS) CRC murine model caused an increase in anti-inflammatory CD4 + FOXP3 + (Tregs) and CD4 + IL10 + cells, a decrease in proinflammatory Th1 and Th17 cells, and attenuated CRC development.	Azoxymethane	43-46	CD4 antigen	Mus musculus	165-168
32526927-4	2020	Resveratrol treatment in the azoxymethane (AOM) and dextran sodium sulphate (DSS) CRC murine model caused an increase in anti-inflammatory CD4 + FOXP3 + (Tregs) and CD4 + IL10 + cells, a decrease in proinflammatory Th1 and Th17 cells, and attenuated CRC development.	Azoxymethane	43-46	interleukin 10	Mus musculus	171-175
32210144-0	2020	Alpha-Glucosidase Inhibitor Voglibose Suppresses Azoxymethane-Induced Colonic Preneoplastic Lesions in Diabetic and Obese Mice.	Azoxymethane	49-61	sucrase isomaltase (alpha-glucosidase)	Mus musculus	0-17
32294981-6	2020	In an azoxymethane/dextran sulfate sodium-induced, colitis-associated, CRC model, EPHB3 expression increased along with tumor development.	Azoxymethane	6-18	EPH receptor B3	Homo sapiens	82-87
32276475-4	2020	Here, we analyzed whether H4R is involved in the pathogenesis of AOM/DSS-induced CRC in mice.	Azoxymethane	65-68	histamine receptor H4	Mus musculus	26-29
31891805-6	2020	Data shown in this report indicates that in leptin knockdown obese mice, AOM/DSS induced polyps are smaller and lesser in numbers as compared to AOM/DSS induced polyps in diet induced obese mice.	Azoxymethane	73-76	leptin	Mus musculus	44-50
32266177-5	2020	The expression of COX-2 and inducible nitric oxide synthase (iNOS) was upregulated in the colon tissues of mice treated with AOM and DSS, and this was inhibited by celecoxib administration.	Azoxymethane	125-128	cytochrome c oxidase II, mitochondrial	Mus musculus	18-23
32266177-5	2020	The expression of COX-2 and inducible nitric oxide synthase (iNOS) was upregulated in the colon tissues of mice treated with AOM and DSS, and this was inhibited by celecoxib administration.	Azoxymethane	125-128	nitric oxide synthase 2, inducible	Mus musculus	28-59
32266177-5	2020	The expression of COX-2 and inducible nitric oxide synthase (iNOS) was upregulated in the colon tissues of mice treated with AOM and DSS, and this was inhibited by celecoxib administration.	Azoxymethane	125-128	nitric oxide synthase 2, inducible	Mus musculus	61-65
32131398-4	2020	Treatment of azoxymethane/dextran sulfate sodium (AOM/DSS) into Nudt7 knockout (Nudt7-/-) mice significantly induced lipid accumulation and the expression levels of CRC-related genes whereas xenografting of Nudt7-overexpressed LS-174T cells into mice significantly reduced lipid accumulation and the expression levels of CRC-related genes.	Azoxymethane	50-53	nudix (nucleoside diphosphate linked moiety X)-type motif 7	Mus musculus	64-69
32131398-4	2020	Treatment of azoxymethane/dextran sulfate sodium (AOM/DSS) into Nudt7 knockout (Nudt7-/-) mice significantly induced lipid accumulation and the expression levels of CRC-related genes whereas xenografting of Nudt7-overexpressed LS-174T cells into mice significantly reduced lipid accumulation and the expression levels of CRC-related genes.	Azoxymethane	50-53	nudix (nucleoside diphosphate linked moiety X)-type motif 7	Mus musculus	80-85
32131398-4	2020	Treatment of azoxymethane/dextran sulfate sodium (AOM/DSS) into Nudt7 knockout (Nudt7-/-) mice significantly induced lipid accumulation and the expression levels of CRC-related genes whereas xenografting of Nudt7-overexpressed LS-174T cells into mice significantly reduced lipid accumulation and the expression levels of CRC-related genes.	Azoxymethane	13-25	nudix (nucleoside diphosphate linked moiety X)-type motif 7	Mus musculus	64-69
32131398-4	2020	Treatment of azoxymethane/dextran sulfate sodium (AOM/DSS) into Nudt7 knockout (Nudt7-/-) mice significantly induced lipid accumulation and the expression levels of CRC-related genes whereas xenografting of Nudt7-overexpressed LS-174T cells into mice significantly reduced lipid accumulation and the expression levels of CRC-related genes.	Azoxymethane	13-25	nudix (nucleoside diphosphate linked moiety X)-type motif 7	Mus musculus	80-85
32131398-4	2020	Treatment of azoxymethane/dextran sulfate sodium (AOM/DSS) into Nudt7 knockout (Nudt7-/-) mice significantly induced lipid accumulation and the expression levels of CRC-related genes whereas xenografting of Nudt7-overexpressed LS-174T cells into mice significantly reduced lipid accumulation and the expression levels of CRC-related genes.	Azoxymethane	50-53	nudix (nucleoside diphosphate linked moiety X)-type motif 7	Mus musculus	80-85
32131398-4	2020	Treatment of azoxymethane/dextran sulfate sodium (AOM/DSS) into Nudt7 knockout (Nudt7-/-) mice significantly induced lipid accumulation and the expression levels of CRC-related genes whereas xenografting of Nudt7-overexpressed LS-174T cells into mice significantly reduced lipid accumulation and the expression levels of CRC-related genes.	Azoxymethane	13-25	nudix (nucleoside diphosphate linked moiety X)-type motif 7	Mus musculus	80-85
32075312-9	2020	The cancer specificity and burden correlation of plasma KARS1 level were validated using azoxymethane (AOM)/dextran sodium sulfate (DSS) model, and paired pre- and post-surgery CRC patient plasma.	Azoxymethane	89-101	lysyl-tRNA synthetase 1	Homo sapiens	56-61
31988379-4	2020	Reconstitution of ApcMin/+ or azoxymethane- and dextran sulfate sodium-treated mice with an isolate of F. rodentium (F. PB1) or its metabolic products reduced tumour growth.	Azoxymethane	30-42	submaxillary gland androgen regulated protein 3A	Homo sapiens	120-123
32041873-7	2020	Finally, when the gut is acutely stressed by azoxymethane/dextran sulfate (AOM/DSS) exposure, both Xist-deleted and wild-type mice develop gastrointestinal tumors.	Azoxymethane	45-57	inactive X specific transcripts	Mus musculus	99-103
32075312-9	2020	The cancer specificity and burden correlation of plasma KARS1 level were validated using azoxymethane (AOM)/dextran sodium sulfate (DSS) model, and paired pre- and post-surgery CRC patient plasma.	Azoxymethane	103-106	lysyl-tRNA synthetase 1	Homo sapiens	56-61
32075312-10	2020	In the AOM/DSS model, the plasma level of KARS1 showed high correlation with number of polyps, but not for inflammation.	Azoxymethane	7-10	lysyl-tRNA synthetase 1	Homo sapiens	42-47
32024285-0	2020	High-Fat Diet Propelled AOM/DSS-Induced Colitis-Associated Colon Cancer Alleviated by Administration of Aster glehni via STAT3 Signaling Pathway.	Azoxymethane	24-27	signal transducer and activator of transcription 3	Mus musculus	121-126
32050698-0	2020	Chemopreventive Effect of the Germinated Oat and its Phenolic-AVA Extract in Azoxymethane/Dextran Sulfate Sodium (AOM/DSS) Model of Colon Carcinogenesis in Mice.	Azoxymethane	114-117	ornithine aminotransferase	Mus musculus	41-44
32050698-4	2020	Therefore, our objective was to evaluate the chemopreventive effect of the sprouted oat (SO) and its phenolic-AVA extract (AVA) in azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced CRC mouse model.	Azoxymethane	131-143	ornithine aminotransferase	Mus musculus	84-87
32050698-4	2020	Therefore, our objective was to evaluate the chemopreventive effect of the sprouted oat (SO) and its phenolic-AVA extract (AVA) in azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced CRC mouse model.	Azoxymethane	145-148	ornithine aminotransferase	Mus musculus	84-87
31734229-7	2020	AOM-treated mice had increased TSP-1 and TGFbeta1 mRNA and protein expression in the liver.	Azoxymethane	0-3	thrombospondin 1	Mus musculus	31-36
31734229-7	2020	AOM-treated mice had increased TSP-1 and TGFbeta1 mRNA and protein expression in the liver.	Azoxymethane	0-3	transforming growth factor, beta 1	Mus musculus	41-49
31734229-8	2020	TSP-1-/- mice administered AOM had reduced liver injury as assessed by histology and serum transaminase levels compared with C57Bl/6 AOM-treated mice.	Azoxymethane	27-30	thrombospondin 1	Mus musculus	0-5
31734229-10	2020	TSP-1-/- AOM-treated mice had a reduced rate of neurologic decline, less cerebral edema, and a decrease in microglia activation in comparison with C57Bl/6 mice treated with AOM.	Azoxymethane	9-12	thrombospondin 1	Mus musculus	0-5
31734229-11	2020	Taken together, TSP-1 is an activator of TGFbeta1 signaling during AOM-induced acute liver failure and contributes to both liver pathology and HE progression.	Azoxymethane	67-70	thrombospondin 1	Mus musculus	16-21
31734229-11	2020	Taken together, TSP-1 is an activator of TGFbeta1 signaling during AOM-induced acute liver failure and contributes to both liver pathology and HE progression.	Azoxymethane	67-70	transforming growth factor, beta 1	Mus musculus	41-49
31714664-7	2020	Further, the mRNA expressions of iNOS and COX-2 were also downregulated in XHA treated rats compared to AOM-induced rats.	Azoxymethane	104-107	nitric oxide synthase 2	Rattus norvegicus	33-37
31662330-9	2020	Map9 deletion accelerated colorectal cancer formation both in ApcMin /+ mice and azoxymethane-treated mice, and reduced survival in ApcMin /+ mice.	Azoxymethane	81-93	microtubule-associated protein 9	Mus musculus	0-4
31714664-7	2020	Further, the mRNA expressions of iNOS and COX-2 were also downregulated in XHA treated rats compared to AOM-induced rats.	Azoxymethane	104-107	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	42-47
31874252-9	2020	Treatment with AOM/DSS significantly increased prostaglandin (PG)E2 and 8-iso-PGF2alpha levels along with cyclooxygenase-2 (COX-2), tumor necrosis factor (TNF)-alpha, nuclear factor kappa B (NFkB) and inducible nitric oxide synthase (iNOS) gene expression, in colon specimens.	Azoxymethane	15-18	prostaglandin-endoperoxide synthase 2	Mus musculus	106-122
31874252-9	2020	Treatment with AOM/DSS significantly increased prostaglandin (PG)E2 and 8-iso-PGF2alpha levels along with cyclooxygenase-2 (COX-2), tumor necrosis factor (TNF)-alpha, nuclear factor kappa B (NFkB) and inducible nitric oxide synthase (iNOS) gene expression, in colon specimens.	Azoxymethane	15-18	prostaglandin-endoperoxide synthase 2	Mus musculus	124-129
31874252-9	2020	Treatment with AOM/DSS significantly increased prostaglandin (PG)E2 and 8-iso-PGF2alpha levels along with cyclooxygenase-2 (COX-2), tumor necrosis factor (TNF)-alpha, nuclear factor kappa B (NFkB) and inducible nitric oxide synthase (iNOS) gene expression, in colon specimens.	Azoxymethane	15-18	tumor necrosis factor	Mus musculus	132-165
31874252-9	2020	Treatment with AOM/DSS significantly increased prostaglandin (PG)E2 and 8-iso-PGF2alpha levels along with cyclooxygenase-2 (COX-2), tumor necrosis factor (TNF)-alpha, nuclear factor kappa B (NFkB) and inducible nitric oxide synthase (iNOS) gene expression, in colon specimens.	Azoxymethane	15-18	nitric oxide synthase 2, inducible	Mus musculus	201-232
31874252-9	2020	Treatment with AOM/DSS significantly increased prostaglandin (PG)E2 and 8-iso-PGF2alpha levels along with cyclooxygenase-2 (COX-2), tumor necrosis factor (TNF)-alpha, nuclear factor kappa B (NFkB) and inducible nitric oxide synthase (iNOS) gene expression, in colon specimens.	Azoxymethane	15-18	nitric oxide synthase 2, inducible	Mus musculus	234-238
31894839-8	2020	In vivo, azoxymethane/dextran sulfate sodium (AOM/DSS)-treated CRC mice, when administered EPS1-1, exhibited activation of the AMPK pathway, inhibition of mTORC1, and accumulation of p53 in tumor tissues.	Azoxymethane	9-21	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	127-131
31894839-8	2020	In vivo, azoxymethane/dextran sulfate sodium (AOM/DSS)-treated CRC mice, when administered EPS1-1, exhibited activation of the AMPK pathway, inhibition of mTORC1, and accumulation of p53 in tumor tissues.	Azoxymethane	9-21	CREB regulated transcription coactivator 1	Mus musculus	155-161
31894839-8	2020	In vivo, azoxymethane/dextran sulfate sodium (AOM/DSS)-treated CRC mice, when administered EPS1-1, exhibited activation of the AMPK pathway, inhibition of mTORC1, and accumulation of p53 in tumor tissues.	Azoxymethane	9-21	transformation related protein 53, pseudogene	Mus musculus	183-186
31836665-8	2020	Colon tumors from either CR-infected ApcP Min/+ or azoxymethane/dextran sodium sulfate (AOM/DSS)-treated mice had high LRP5/6 or FZD10 levels, and chronic Notch blockade through the gamma-secretase inhibitor dibenzazepine down-regulated LRP5/6 and FZD10 expression.	Azoxymethane	88-91	frizzled class receptor 10	Mus musculus	129-134
31836665-8	2020	Colon tumors from either CR-infected ApcP Min/+ or azoxymethane/dextran sodium sulfate (AOM/DSS)-treated mice had high LRP5/6 or FZD10 levels, and chronic Notch blockade through the gamma-secretase inhibitor dibenzazepine down-regulated LRP5/6 and FZD10 expression.	Azoxymethane	51-63	low density lipoprotein receptor-related protein 5	Mus musculus	119-125
31903123-10	2020	After AOM/DSS administration, the colorectums of CARD3-/- mice had fewer tumors than those of control mice.	Azoxymethane	6-9	receptor (TNFRSF)-interacting serine-threonine kinase 2	Mus musculus	49-54
31836665-8	2020	Colon tumors from either CR-infected ApcP Min/+ or azoxymethane/dextran sodium sulfate (AOM/DSS)-treated mice had high LRP5/6 or FZD10 levels, and chronic Notch blockade through the gamma-secretase inhibitor dibenzazepine down-regulated LRP5/6 and FZD10 expression.	Azoxymethane	51-63	frizzled class receptor 10	Mus musculus	129-134
31855601-4	2020	Compound H13 has a favorable PK profile and high tissue distribution specificity in the colon, as well as good efficacy in the AOM-DSS mouse model for colitis-associated colonic tumorigenesis.	Azoxymethane	127-130	histocompatibility 13	Mus musculus	9-12
31968249-6	2020	Notably, compared with their wild-type littermates, MAVS knockout mice display decreased resistance to azoxymethane (AOM) or AOM/dextran sulfate sodium salt (DSS)-induced colon cancer.	Azoxymethane	103-115	mitochondrial antiviral signaling protein	Mus musculus	52-56
31968249-6	2020	Notably, compared with their wild-type littermates, MAVS knockout mice display decreased resistance to azoxymethane (AOM) or AOM/dextran sulfate sodium salt (DSS)-induced colon cancer.	Azoxymethane	117-120	mitochondrial antiviral signaling protein	Mus musculus	52-56
31968249-6	2020	Notably, compared with their wild-type littermates, MAVS knockout mice display decreased resistance to azoxymethane (AOM) or AOM/dextran sulfate sodium salt (DSS)-induced colon cancer.	Azoxymethane	125-128	mitochondrial antiviral signaling protein	Mus musculus	52-56
31968254-2	2020	Here, we demonstrate that periostin deficiency significantly inhibits the occurrence of colorectal cancer in azoxymethane/dextran sulfate sodium-treated mice and in ApcMin/+ mice.	Azoxymethane	109-121	periostin, osteoblast specific factor	Mus musculus	26-35
31836532-5	2020	The formation of colon tumours induced by AOM/DSS treatment was significantly attenuated in TRPV4-deficient mice (TRPV4KO).	Azoxymethane	42-45	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	92-97
31836532-7	2020	AOM/DSS treatment upregulated the expression of CD105, vascular endothelial growth factor receptor 2, and TRPV4 in wildtype, but the upregulation of CD105 was significantly attenuated in TRPV4KO.	Azoxymethane	0-3	endoglin	Mus musculus	48-53
31836532-7	2020	AOM/DSS treatment upregulated the expression of CD105, vascular endothelial growth factor receptor 2, and TRPV4 in wildtype, but the upregulation of CD105 was significantly attenuated in TRPV4KO.	Azoxymethane	0-3	kinase insert domain protein receptor	Mus musculus	55-100
31836532-7	2020	AOM/DSS treatment upregulated the expression of CD105, vascular endothelial growth factor receptor 2, and TRPV4 in wildtype, but the upregulation of CD105 was significantly attenuated in TRPV4KO.	Azoxymethane	0-3	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	106-111
31836532-7	2020	AOM/DSS treatment upregulated the expression of CD105, vascular endothelial growth factor receptor 2, and TRPV4 in wildtype, but the upregulation of CD105 was significantly attenuated in TRPV4KO.	Azoxymethane	0-3	endoglin	Mus musculus	149-154
31818852-5	2020	E1, E2 and E3 are associated with AOM exposure, walnut consumption and TWD diet, respectively.	Azoxymethane	34-37	ATPase, H+ transporting, lysosomal V1 subunit E1	Mus musculus	4-13
31125123-2	2020	We report that VPS33B was downregulated in dextran sulfate sodium/azoxymethane (DSS/AOM) -induced CRC mice models and nicotine-treated CRC cells via the PI3K/AKT/c-Jun pathway.	Azoxymethane	66-78	vacuolar protein sorting 33B	Mus musculus	15-21
31125123-2	2020	We report that VPS33B was downregulated in dextran sulfate sodium/azoxymethane (DSS/AOM) -induced CRC mice models and nicotine-treated CRC cells via the PI3K/AKT/c-Jun pathway.	Azoxymethane	84-87	vacuolar protein sorting 33B	Mus musculus	15-21
31173626-4	2019	METHODS: Angiopoietin-2 wild-type, heterozygote, and knockout mice received a single injection of the procarcinogen azoxymethane and had an IBD-promoting chemical irritant (dextran sodium sulfate) added to their drinking water over a 7-week period.	Azoxymethane	116-128	angiopoietin 2	Mus musculus	9-23
31628914-9	2019	KEY FINDINGS: In the AOM/DSS model of colitis-associated tumorigenesis, Nrf2-/- mice showed a phenotype similar to WT mice, but with significantly more tumors and a much higher percentage of adenocarcinomas.	Azoxymethane	21-24	nuclear factor, erythroid derived 2, like 2	Mus musculus	72-76
30859181-6	2019	Most significantly, azoxymethane-treated mice with conditional Apc expression, but absent the Cre recombinase gene, demonstrated nearly 50% tumor incidence with 2 or more large colon tumors per mouse of human-like histology, but no small intestine tumors - unlike the azoxymethane-resistant C57BL/6J-background Min mouse model.	Azoxymethane	20-32	APC, WNT signaling pathway regulator	Mus musculus	63-66
30859181-6	2019	Most significantly, azoxymethane-treated mice with conditional Apc expression, but absent the Cre recombinase gene, demonstrated nearly 50% tumor incidence with 2 or more large colon tumors per mouse of human-like histology, but no small intestine tumors - unlike the azoxymethane-resistant C57BL/6J-background Min mouse model.	Azoxymethane	268-280	APC, WNT signaling pathway regulator	Mus musculus	63-66
31862898-9	2019	Accordingly, RAI16-/- mice displayed significantly increased tumor burden compared with WT mice assessed in CAC model induced by AOM/DSS.	Azoxymethane	129-132	FHF complex subunit HOOK interacting protein 2B	Mus musculus	13-18
30844440-4	2019	In an azoxymethane/dextran sulfate sodium model of colitis-associated tumorigenesis, Mkp-1-/- mice exhibited a phenotype similar to Nrf2-/- mice with significantly more tumors than WT mice.	Azoxymethane	6-18	dual specificity phosphatase 1	Mus musculus	85-90
31195598-7	2019	First, expression of the TNIIIA2-containing TNC peptides/fragments was detected in dysplastic lesions of an azoxymethane/dextran sodium sulfate (AOM/DSS) mouse model.	Azoxymethane	108-120	tenascin C	Mus musculus	44-47
31195598-7	2019	First, expression of the TNIIIA2-containing TNC peptides/fragments was detected in dysplastic lesions of an azoxymethane/dextran sodium sulfate (AOM/DSS) mouse model.	Azoxymethane	145-148	tenascin C	Mus musculus	44-47
31432570-11	2019	IRX5 was significantly increased in azoxymethane/dextran sodium sulfate intestinal tissue of mice and IRX5-overexpressing may also enhance chemokines CXCL1 and CXCL8.	Azoxymethane	36-48	Iroquois homeobox 5	Mus musculus	0-4
31681563-0	2019	Increased Incidence of Colon Tumors in AOM-Treated Apc 1638N/+ Mice Reveals Higher Frequency of Tumor Associated Neutrophils in Colon Than Small Intestine.	Azoxymethane	39-42	APC, WNT signaling pathway regulator	Mus musculus	51-54
31681563-4	2019	Therefore, the Apc 1638N/+ line was treated repeatedly with azoxymethane (AOM) and 90% colon tumor incidence and 4 to 5 colon tumors per mouse were achieved.	Azoxymethane	60-72	APC, WNT signaling pathway regulator	Mus musculus	15-18
31681563-4	2019	Therefore, the Apc 1638N/+ line was treated repeatedly with azoxymethane (AOM) and 90% colon tumor incidence and 4 to 5 colon tumors per mouse were achieved.	Azoxymethane	74-77	APC, WNT signaling pathway regulator	Mus musculus	15-18
31681563-9	2019	Thus, Apc 1638N/+ mice treated with AOM are a suitable and straightforward model to study the influence of immune cells and chemokines on colon carcinogenesis.	Azoxymethane	36-39	APC, WNT signaling pathway regulator	Mus musculus	6-9
30375302-3	2019	In this study, microRNA-array differential analysis revealed strongly enhanced expression of miR-24-1-5p in the colon tissue of azoxymethane/dextran sulphate sodium-induced mice that were fed with black raspberry anthocyanins for 9 weeks.	Azoxymethane	128-140	microRNA 24-1	Mus musculus	93-101
31154022-15	2019	Fenofibrate protected human PPARA transgenic mice from azoxymethane and DSS-induced colon cancer.	Azoxymethane	55-67	peroxisome proliferator activated receptor alpha	Mus musculus	28-33
31480481-3	2019	However, the effect of a combined treatment of microencapsulated BF and LYC on IGF-1/IGF-1R/IGFBPs (Insulin-like growth factor-binding proteins) expression in an azoxymethane (AOM)-dextran sulfate sodium (DSS)-induced CRC model have not been demonstrated.	Azoxymethane	162-174	insulin-like growth factor 1	Mus musculus	79-84
31480481-3	2019	However, the effect of a combined treatment of microencapsulated BF and LYC on IGF-1/IGF-1R/IGFBPs (Insulin-like growth factor-binding proteins) expression in an azoxymethane (AOM)-dextran sulfate sodium (DSS)-induced CRC model have not been demonstrated.	Azoxymethane	162-174	insulin-like growth factor I receptor	Mus musculus	85-91
31480481-3	2019	However, the effect of a combined treatment of microencapsulated BF and LYC on IGF-1/IGF-1R/IGFBPs (Insulin-like growth factor-binding proteins) expression in an azoxymethane (AOM)-dextran sulfate sodium (DSS)-induced CRC model have not been demonstrated.	Azoxymethane	162-174	insulin-like growth factor binding protein 3	Mus musculus	92-98
31480481-3	2019	However, the effect of a combined treatment of microencapsulated BF and LYC on IGF-1/IGF-1R/IGFBPs (Insulin-like growth factor-binding proteins) expression in an azoxymethane (AOM)-dextran sulfate sodium (DSS)-induced CRC model have not been demonstrated.	Azoxymethane	176-179	insulin-like growth factor 1	Mus musculus	79-84
31480481-3	2019	However, the effect of a combined treatment of microencapsulated BF and LYC on IGF-1/IGF-1R/IGFBPs (Insulin-like growth factor-binding proteins) expression in an azoxymethane (AOM)-dextran sulfate sodium (DSS)-induced CRC model have not been demonstrated.	Azoxymethane	176-179	insulin-like growth factor I receptor	Mus musculus	85-91
31480481-3	2019	However, the effect of a combined treatment of microencapsulated BF and LYC on IGF-1/IGF-1R/IGFBPs (Insulin-like growth factor-binding proteins) expression in an azoxymethane (AOM)-dextran sulfate sodium (DSS)-induced CRC model have not been demonstrated.	Azoxymethane	176-179	insulin-like growth factor binding protein 3	Mus musculus	92-98
31239268-4	2019	Similarly, colon-specific knockout of Trim67 significantly accelerated azoxymethane-induced colorectal cancer in mice.	Azoxymethane	71-83	tripartite motif-containing 67	Mus musculus	38-44
30973663-9	2019	Moreover, when the colorectum of azoxymethane-treated rats was observed using a thin fluorescent endoscope with AF-EGFR-Ab, all 10 small colorectal adenomas (&lt;=3 mm) were detected with a clear fluorescence signal.	Azoxymethane	33-45	epidermal growth factor receptor	Mus musculus	115-119
30676667-6	2019	ESE-1 knockout in mice increased azoxymethane (AOM)-induced and dextran sulfate sodium (DSS)-promoted formation of aberrant crypt foci (ACF).	Azoxymethane	33-45	E74-like factor 3	Mus musculus	0-5
30676667-6	2019	ESE-1 knockout in mice increased azoxymethane (AOM)-induced and dextran sulfate sodium (DSS)-promoted formation of aberrant crypt foci (ACF).	Azoxymethane	47-50	E74-like factor 3	Mus musculus	0-5
30611867-3	2019	Heterozygous knockout IGF-1R attenuated azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis and colitis associated cancer (CAC) in Igf1r+/- mice.	Azoxymethane	40-52	insulin-like growth factor I receptor	Mus musculus	22-28
30944312-5	2019	We discovered that Ct55 deficiency alleviated inflammatory responses, decreased cell proliferation and colitis-associated tumorigenesis in an azoxymethane/dextran sulfate sodium (AOM/DSS) mouse model.	Azoxymethane	142-154	cancer/testis antigen 55	Mus musculus	19-23
30913881-7	2019	In addition, MA significantly suppressed the tumorigenesis and regulated the AMPK-mTOR pathway in azoxymethane/dextran sulfate sodium mice and xenograft tumor mice.	Azoxymethane	98-110	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	77-81
30913881-7	2019	In addition, MA significantly suppressed the tumorigenesis and regulated the AMPK-mTOR pathway in azoxymethane/dextran sulfate sodium mice and xenograft tumor mice.	Azoxymethane	98-110	mechanistic target of rapamycin kinase	Mus musculus	82-86
30611867-3	2019	Heterozygous knockout IGF-1R attenuated azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis and colitis associated cancer (CAC) in Igf1r+/- mice.	Azoxymethane	40-52	insulin-like growth factor I receptor	Mus musculus	143-148
30611867-3	2019	Heterozygous knockout IGF-1R attenuated azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis and colitis associated cancer (CAC) in Igf1r+/- mice.	Azoxymethane	54-57	insulin-like growth factor I receptor	Mus musculus	22-28
30611867-3	2019	Heterozygous knockout IGF-1R attenuated azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis and colitis associated cancer (CAC) in Igf1r+/- mice.	Azoxymethane	54-57	insulin-like growth factor I receptor	Mus musculus	143-148
30538296-4	2019	Here, we show that Casp11-/- mice are highly susceptible to the azoxymethane (AOM)-DSS model of colitis-associated cancer (CAC), compared to their wild type (WT) littermates.	Azoxymethane	64-76	caspase 4, apoptosis-related cysteine peptidase	Mus musculus	19-25
30538296-4	2019	Here, we show that Casp11-/- mice are highly susceptible to the azoxymethane (AOM)-DSS model of colitis-associated cancer (CAC), compared to their wild type (WT) littermates.	Azoxymethane	78-81	caspase 4, apoptosis-related cysteine peptidase	Mus musculus	19-25
31040926-5	2019	AOM/DSS treatment of Apc1638N/+ mice phenocopied CR+AOM treatment as colonic tumors exhibited pronounced changes in Ki-67, EZH2 and Dclk1 accompanied by infiltration of F4/80+ macrophages, CD3+ lymphocytes and CD3/beta-catenin co-localization.	Azoxymethane	0-3	doublecortin like kinase 1	Homo sapiens	132-137
29952003-5	2018	We show here that mice lacking geminin develop a significantly higher number of tumors and bear a larger tumor burden than sham-treated controls in urethane-induced lung and azoxymethane/dextran sodium sulfate-induced colon carcinogenesis.	Azoxymethane	174-186	geminin	Mus musculus	31-38
30204842-9	2019	Exposure to azoxymethane/DSS resulted in extensive epithelial apoptosis in Postn-/- mice compared with that in wild-type mice.	Azoxymethane	12-24	periostin, osteoblast specific factor	Mus musculus	75-80
30365932-16	2019	Mice with knockdown of beta-catenin had a lower tumor burden after administration of azoxymethane and dextran sodium sulfate, regardless of Trib3 overexpression.	Azoxymethane	85-97	catenin (cadherin associated protein), beta 1	Mus musculus	23-35
30099074-13	2018	CONCLUSIONS: In mice, we demonstrated that combined inactivation of Mir34a and Tp53 promotes azoxymethane-induced colorectal carcinogenesis and tumor progression and metastasis by increasing levels of IL6R and PAI1.	Azoxymethane	93-105	microRNA 34a	Mus musculus	68-74
30099074-13	2018	CONCLUSIONS: In mice, we demonstrated that combined inactivation of Mir34a and Tp53 promotes azoxymethane-induced colorectal carcinogenesis and tumor progression and metastasis by increasing levels of IL6R and PAI1.	Azoxymethane	93-105	transformation related protein 53	Mus musculus	79-83
30099074-13	2018	CONCLUSIONS: In mice, we demonstrated that combined inactivation of Mir34a and Tp53 promotes azoxymethane-induced colorectal carcinogenesis and tumor progression and metastasis by increasing levels of IL6R and PAI1.	Azoxymethane	93-105	interleukin 6 receptor, alpha	Mus musculus	201-205
30099074-13	2018	CONCLUSIONS: In mice, we demonstrated that combined inactivation of Mir34a and Tp53 promotes azoxymethane-induced colorectal carcinogenesis and tumor progression and metastasis by increasing levels of IL6R and PAI1.	Azoxymethane	93-105	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	210-214
30268501-8	2018	Another clone of anti-IL-11 antibodies stained stromal cells surrounding tumors of the colon of wild-type, but not Il11-deficient mice following treatment with Azoxymethane plus dextran sulfate sodium.	Azoxymethane	160-172	interleukin 11	Mus musculus	22-27
30295289-4	2018	However, for the experiment that compared inflammation, invasion, and neoplasia in azoxymethane (AOM)-treated interleukin-10-deficient mice mono-associated with NC101 or NC101[Formula: see text] pks the experimental timing of the replication attempt was longer than that of the original study.	Azoxymethane	83-95	interleukin 10	Mus musculus	110-124
30295289-4	2018	However, for the experiment that compared inflammation, invasion, and neoplasia in azoxymethane (AOM)-treated interleukin-10-deficient mice mono-associated with NC101 or NC101[Formula: see text] pks the experimental timing of the replication attempt was longer than that of the original study.	Azoxymethane	97-100	interleukin 10	Mus musculus	110-124
30472235-8	2019	JMJD2D-knockout and wild-type (control) mice were given azoxymethane followed by dextran sodium sulfate to induce colitis-associated CRC; some mice were given the JMJD2D inhibitor 5-chloro-8-hydroxyquinoline (5-c-8HQ) or vehicle to examine the effects of 5-c-8HQ on intestinal tumor formation.	Azoxymethane	56-68	lysine (K)-specific demethylase 4D	Mus musculus	0-6
30457689-6	2019	The NADH fluorescence intensity measured by two-photon excitation fluorescence (TPEF) microscopy was consistently increased in CRC cell lines, azoxymethane/dextran sodium sulfate (AOM/DSS)-induced CRC tissues and tumor tissues from CRC patients.	Azoxymethane	143-155	transmembrane protein with EGF like and two follistatin like domains 2	Homo sapiens	80-84
30365932-15	2019	Mice with overexpression of Trib3 developed more tumors after administration of azoxymethane and dextran sodium sulfate than BALB/c mice.	Azoxymethane	80-92	tribbles pseudokinase 3	Mus musculus	28-33
30202097-3	2019	Here, we present evidence that SLC7A2 plays a role in modulating colon tumorigenesis in the azoxymethane (AOM)-DSS model of colitis-associated carcinogenesis (CAC).	Azoxymethane	92-104	solute carrier family 7 (cationic amino acid transporter, y+ system), member 2	Mus musculus	31-37
30202097-3	2019	Here, we present evidence that SLC7A2 plays a role in modulating colon tumorigenesis in the azoxymethane (AOM)-DSS model of colitis-associated carcinogenesis (CAC).	Azoxymethane	106-109	solute carrier family 7 (cationic amino acid transporter, y+ system), member 2	Mus musculus	31-37
30232408-7	2019	Treatment with klotho inhibited formation of colon polyps induced by the carcinogen azoxymethane, and KL1 treatment slowed growth of orthotopically-implanted colorectal tumors.	Azoxymethane	84-96	klotho	Homo sapiens	15-21
32566755-7	2019	Results: We found that KLF4 expression is lost in tumor sections obtained from CRC patients and in those of mouse colon following azoxymethane and dextran sodium sulfate (AOM/DSS) treatment when compared to their respective normal appearing mucosa.	Azoxymethane	130-142	Kruppel like factor 4	Homo sapiens	23-27
32566755-7	2019	Results: We found that KLF4 expression is lost in tumor sections obtained from CRC patients and in those of mouse colon following azoxymethane and dextran sodium sulfate (AOM/DSS) treatment when compared to their respective normal appearing mucosa.	Azoxymethane	171-174	Kruppel like factor 4	Homo sapiens	23-27
30798535-2	2019	The azoxymethane/interleukin-10 knockout (AOM/Il10-/-) model is a powerful tool for assessing the effects of intestinal microbiota and inflammation on colon tumorigenesis.	Azoxymethane	4-16	interleukin 10	Mus musculus	46-50
30108164-4	2019	Mice with intestinal epithelium-specific deletion of Klf4 (Klf4DeltaIS ) and control mice (Klf4fl/fl ) were used to explore the role of KLF4 in the development of azoxymethane (AOM) and dextran sodium sulfate (DSS)-induced CAC.	Azoxymethane	163-175	Kruppel-like factor 4 (gut)	Mus musculus	136-140
30362310-0	2018	Effects of Grape Juice in Superoxide Dismutase and Catalase in Colorectal Cancer Carcinogenesis Induced by Azoxymethane Background: The intestinal mucosa is commonly exposed to oxidant nutrients and carcinogens, which can lead tothe generation of free radicals.	Azoxymethane	107-119	catalase	Rattus norvegicus	51-59
29688249-7	2018	Furthermore, in a colitis-associated colon cancer model, the PHD2-conditional knockout mice had similar susceptibility to azoxymethane (AOM)-induced colonic tumorigenesis as control mice did.	Azoxymethane	122-134	egl-9 family hypoxia-inducible factor 1	Mus musculus	61-65
30232275-3	2018	Azoxymethane and dextran sodium sulfate-treated (DSS-treated) animals deficient in lipin-1 harbored fewer tumors and carcinomas than WT animals due to decreased cellular proliferation, lower expression of antiapoptotic and protumorigenic factors, and a reduced infiltration of macrophages in colon tumors.	Azoxymethane	0-12	lipin 1	Homo sapiens	83-90
30143645-6	2018	Deficiency of TRIM27 significantly impairs dextran sulfate sodium (DSS)-induced STAT3 activation, inflammatory cytokine expression and colitis as well as azoxymethane (AOM)/DSS-induced colitis-associated cancer in mice.	Azoxymethane	154-166	tripartite motif-containing 27	Mus musculus	14-20
29778535-5	2018	Azoxymethane-treated mice developed FHF and hepatic encephalopathy, associated with higher autotaxin (ATX) activities in serum than controls.	Azoxymethane	0-12	ectonucleotide pyrophosphatase/phosphodiesterase 2	Mus musculus	91-100
29778535-5	2018	Azoxymethane-treated mice developed FHF and hepatic encephalopathy, associated with higher autotaxin (ATX) activities in serum than controls.	Azoxymethane	0-12	ectonucleotide pyrophosphatase/phosphodiesterase 2	Mus musculus	102-105
30107089-13	2018	Finally, we observed enhanced association of CHIP with the UBXN2A-mot-2 complex in tumors in an azoxymethane/dextran sulfate sodium-induced mouse CRC model.	Azoxymethane	96-108	UBX domain protein 2A	Mus musculus	59-71
30061214-0	2018	Cannabinoid Receptor-1 Up-regulation in Azoxymethane (AOM)-treated Mice After Dietary Treatment with Quercetin.	Azoxymethane	40-52	cannabinoid receptor 1 (brain)	Mus musculus	0-22
29730197-8	2018	Moreover, both chemical inhibition and genetic knockout of HSF1 succeeded in increasing MIR137 expression, reducing GLS1 expression, and alleviating colorectal tumorigenesis in azoxymethane (AOM)/dextran sulfate sodium (DSS) mice.	Azoxymethane	177-189	heat shock factor 1	Mus musculus	59-63
29730197-8	2018	Moreover, both chemical inhibition and genetic knockout of HSF1 succeeded in increasing MIR137 expression, reducing GLS1 expression, and alleviating colorectal tumorigenesis in azoxymethane (AOM)/dextran sulfate sodium (DSS) mice.	Azoxymethane	191-194	heat shock factor 1	Mus musculus	59-63
30221056-2	2018	Here, we report that S100A4 expression was increased in azoxymethane (AOM) and dextran sulfate sodium (DSS) induced colorectal cancer (CRC) in mice.	Azoxymethane	56-68	S100 calcium binding protein A4	Mus musculus	21-27
30221056-2	2018	Here, we report that S100A4 expression was increased in azoxymethane (AOM) and dextran sulfate sodium (DSS) induced colorectal cancer (CRC) in mice.	Azoxymethane	70-73	S100 calcium binding protein A4	Mus musculus	21-27
29228136-4	2018	Moreover, CAC model was induced in wild-type and CD177-/- mice by azoxymethane/dextran sodium sulphate.	Azoxymethane	66-78	CD177 antigen	Mus musculus	49-54
29440355-2	2018	In this article, we report that mice deficient in cathelin-related antimicrobial peptide (CRAMP) were defective in the development of colon mucosa and highly sensitive to dextran sulfate sodium (DSS)-elicited colitis, as well as azoxymethane-mediated carcinogenesis.	Azoxymethane	229-241	cathelicidin antimicrobial peptide	Mus musculus	50-88
29440355-2	2018	In this article, we report that mice deficient in cathelin-related antimicrobial peptide (CRAMP) were defective in the development of colon mucosa and highly sensitive to dextran sulfate sodium (DSS)-elicited colitis, as well as azoxymethane-mediated carcinogenesis.	Azoxymethane	229-241	cathelicidin antimicrobial peptide	Mus musculus	90-95
29867954-9	2018	In mouse models of dextran sulfate sodium (DSS)-induced colitis and azoxymethane/DSS induced colon cancer, NoxO1 has a protective role and may influence the population of natural killer cells.	Azoxymethane	68-80	NADPH oxidase organizer 1	Mus musculus	107-112
29748582-5	2018	Remarkably, USP49 expression was regulated by p53 and USP49 in knockout mice, which are more susceptible to azoxymethane/dextran sulfate sodium (AOM/DSS)-induced colon tumors.	Azoxymethane	108-120	ubiquitin specific peptidase 49	Mus musculus	12-17
29748582-5	2018	Remarkably, USP49 expression was regulated by p53 and USP49 in knockout mice, which are more susceptible to azoxymethane/dextran sulfate sodium (AOM/DSS)-induced colon tumors.	Azoxymethane	108-120	transformation related protein 53, pseudogene	Mus musculus	46-49
29748582-5	2018	Remarkably, USP49 expression was regulated by p53 and USP49 in knockout mice, which are more susceptible to azoxymethane/dextran sulfate sodium (AOM/DSS)-induced colon tumors.	Azoxymethane	108-120	ubiquitin specific peptidase 49	Mus musculus	54-59
29197088-6	2018	In our azoxymethane/dextran sodium sulfate (AOM/DSS) model of colitis-associated CRC, MK2 inhibitor treatment eliminated murine tumor development.	Azoxymethane	7-19	MAP kinase-activated protein kinase 2	Mus musculus	86-89
29622769-11	2018	SOCS2 overexpression was detected in a murine model of azoxymethane/dextran sulfate sodium-induced colitis-associated colon cancer compared to mock-treated controls.	Azoxymethane	55-67	suppressor of cytokine signaling 2	Mus musculus	0-5
29228136-9	2018	Consistently, CD177 depletion aggravated azoxymethane/dextran sodium sulphate-induced CAC in mice.	Azoxymethane	41-53	CD177 antigen	Mus musculus	14-19
29326691-6	2017	The protective effect of anti-S100a9 antibody treatment was also observed in azoxymethane (AOM)/DSS-induced colitis-associated cancer (CAC) mouse model.	Azoxymethane	77-89	S100 calcium binding protein A9 (calgranulin B)	Mus musculus	30-36
29233556-6	2018	In addition, colonic ATOH1+ IECs acquired tumor stem cell-like properties in the azoxymethane-DSS tumor model.	Azoxymethane	81-93	atonal bHLH transcription factor 1	Homo sapiens	21-26
29118162-5	2018	Expression of the mutant K-ras allele accelerated azoxymethane (AOM)-induced colon carcinogenesis in C57BL/6 mice, a strain otherwise resistant to this carcinogen.	Azoxymethane	50-62	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	25-30
29118162-5	2018	Expression of the mutant K-ras allele accelerated azoxymethane (AOM)-induced colon carcinogenesis in C57BL/6 mice, a strain otherwise resistant to this carcinogen.	Azoxymethane	64-67	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	25-30
28875496-4	2018	Using azoxymethane (AOM)- and dextran sulfate sodium (DSS)-driven CRC mouse models, we found that GPR55 plays a tumor-promoting role that involves alterations of leukocyte populations, i.e. myeloid-derived suppressor cells and T lymphocytes, within the tumor tissues.	Azoxymethane	6-18	G protein-coupled receptor 55	Mus musculus	98-103
28875496-4	2018	Using azoxymethane (AOM)- and dextran sulfate sodium (DSS)-driven CRC mouse models, we found that GPR55 plays a tumor-promoting role that involves alterations of leukocyte populations, i.e. myeloid-derived suppressor cells and T lymphocytes, within the tumor tissues.	Azoxymethane	20-23	G protein-coupled receptor 55	Mus musculus	98-103
29028945-4	2017	First, we show that SphK1 deficient mice significantly attenuated azoxymethane (AOM)-induced colon carcinogenesis as measured by colon tumor incidence, multiplicity, and volume.	Azoxymethane	66-78	sphingosine kinase 1	Mus musculus	20-25
29028945-4	2017	First, we show that SphK1 deficient mice significantly attenuated azoxymethane (AOM)-induced colon carcinogenesis as measured by colon tumor incidence, multiplicity, and volume.	Azoxymethane	80-83	sphingosine kinase 1	Mus musculus	20-25
29070673-2	2017	Abrogation of IL-17A signaling in mice attenuated tissue repair of dextran sulfate sodium (DSS)-induced damage in colon epithelium and markedly reduced tumor development in an azoxymethane/DSS model of colitis-associated cancer.	Azoxymethane	176-188	interleukin 17A	Mus musculus	14-20
29416724-2	2018	The present data from azoxymethane-initiated, dextran sulfate sodium-promoted colitis associated cancer (CAC) model strongly indicate the potential of rTRAIL in cancer prevention rather than in cancer therapeutics.	Azoxymethane	22-34	TNF superfamily member 10	Rattus norvegicus	151-157
28780076-5	2017	CAC was induced in cre-negative littermate mice (control) and mice with conditional disruption of Bmi1 and/or Mel18 by intraperitoneal injection of azoxymethane (AOM) followed by addition of dextran sulfate sodium (DSS) to drinking water.	Azoxymethane	148-160	polycomb group ring finger 2	Mus musculus	110-115
29070673-6	2017	PLET1 deficiency impaired tissue repair of DSS-induced damage in colon epithelium and reduced tumor formation in an azoxymethane/DSS model of colitis-associated cancer.	Azoxymethane	116-128	placenta expressed transcript 1	Mus musculus	0-5
28089732-4	2017	Intestinally-targeted transgenic expression of ALOX15 in mice inhibited dextran sodium sulfate-induced colitis from promoting azoxymethane- induced colorectal tumorigenesis, demonstrating that ALOX15 can suppress inflammation-driven promotion of carcinogen-induced colorectal tumorigenesis and therefore ALOX15 downregulation during tumorigenesis is likely to enhance the link between colitis and colorectal tumorigenesis.	Azoxymethane	126-138	arachidonate 15-lipoxygenase	Mus musculus	47-53
29017096-4	2017	METHODS: 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or 3,3"-diindolylmethane (DIM) were used to activate aryl hydrocarbon receptor (Ahr) in azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced CAC in mice.	Azoxymethane	140-152	aryl-hydrocarbon receptor	Mus musculus	105-130
29017096-4	2017	METHODS: 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or 3,3"-diindolylmethane (DIM) were used to activate aryl hydrocarbon receptor (Ahr) in azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced CAC in mice.	Azoxymethane	154-157	aryl-hydrocarbon receptor	Mus musculus	105-130
28089732-4	2017	Intestinally-targeted transgenic expression of ALOX15 in mice inhibited dextran sodium sulfate-induced colitis from promoting azoxymethane- induced colorectal tumorigenesis, demonstrating that ALOX15 can suppress inflammation-driven promotion of carcinogen-induced colorectal tumorigenesis and therefore ALOX15 downregulation during tumorigenesis is likely to enhance the link between colitis and colorectal tumorigenesis.	Azoxymethane	126-138	arachidonate 15-lipoxygenase	Mus musculus	193-199
28089732-4	2017	Intestinally-targeted transgenic expression of ALOX15 in mice inhibited dextran sodium sulfate-induced colitis from promoting azoxymethane- induced colorectal tumorigenesis, demonstrating that ALOX15 can suppress inflammation-driven promotion of carcinogen-induced colorectal tumorigenesis and therefore ALOX15 downregulation during tumorigenesis is likely to enhance the link between colitis and colorectal tumorigenesis.	Azoxymethane	126-138	arachidonate 15-lipoxygenase	Mus musculus	193-199
28718722-9	2017	These data suggest that citrus peel possesses an ability to suppress cellular oxidative stress through induction of NRF2, thereby preventing azoxymethane-induced colon carcinogenesis.	Azoxymethane	141-153	NFE2 like bZIP transcription factor 2	Rattus norvegicus	116-120
28380450-9	2017	Loss of GPR56 also inhibited progastrin-dependent colonic crypt fission and colorectal carcinogenesis in the azoxymethane (AOM) mouse model of colorectal cancer.	Azoxymethane	109-121	adhesion G protein-coupled receptor G1	Mus musculus	8-13
28725183-6	2017	The current study aimed to assess the role of bile-acid mediated S1PR2 signaling in neuroinflammation and disease progression during azoxymethane (AOM)-induced HE in mice.	Azoxymethane	133-145	sphingosine-1-phosphate receptor 2	Mus musculus	65-70
28468928-2	2017	In this study, we investigated the cGMP-elevating ability of the phosphodiesterase-5 (PDE5) inhibitor sildenafil to prevent disease in the azoxymethane/dextran sulfate sodium (AOM/DSS) inflammation-driven colorectal cancer model.	Azoxymethane	139-151	phosphodiesterase 5A, cGMP-specific	Mus musculus	65-84
28468928-2	2017	In this study, we investigated the cGMP-elevating ability of the phosphodiesterase-5 (PDE5) inhibitor sildenafil to prevent disease in the azoxymethane/dextran sulfate sodium (AOM/DSS) inflammation-driven colorectal cancer model.	Azoxymethane	139-151	phosphodiesterase 5A, cGMP-specific	Mus musculus	86-90
28468928-2	2017	In this study, we investigated the cGMP-elevating ability of the phosphodiesterase-5 (PDE5) inhibitor sildenafil to prevent disease in the azoxymethane/dextran sulfate sodium (AOM/DSS) inflammation-driven colorectal cancer model.	Azoxymethane	176-179	phosphodiesterase 5A, cGMP-specific	Mus musculus	65-84
28468928-2	2017	In this study, we investigated the cGMP-elevating ability of the phosphodiesterase-5 (PDE5) inhibitor sildenafil to prevent disease in the azoxymethane/dextran sulfate sodium (AOM/DSS) inflammation-driven colorectal cancer model.	Azoxymethane	176-179	phosphodiesterase 5A, cGMP-specific	Mus musculus	86-90
27805617-8	2017	Furthermore, biweekly oral administration of CTBp significantly reduced disease severity and tumorigenesis in the azoxymethane/DSS model of ulcerative colitis and colon cancer.	Azoxymethane	114-126	phosphate cytidylyltransferase 1B, choline	Homo sapiens	45-49
28578586-2	2017	CRC induced by chemical carcinogens, such as heterocyclic aromatic amines and azoxymethane, in mice also involves dysregulation of Wnt signaling but via activating missense mutations in the beta-catenin oncogene despite the fact that genetically modified mice harboring an inactive APC allele efficiently develop CRC.	Azoxymethane	78-90	catenin (cadherin associated protein), beta 1	Mus musculus	190-202
28455963-5	2017	In this study, TrkC was frequently overexpressed in CRC cells, patients" tumor samples and an azoxymethane/dextran sulphate sodium-induced mouse model of colitis-associated CRCs.	Azoxymethane	94-106	neurotrophic receptor tyrosine kinase 3	Homo sapiens	15-19
28380450-9	2017	Loss of GPR56 also inhibited progastrin-dependent colonic crypt fission and colorectal carcinogenesis in the azoxymethane (AOM) mouse model of colorectal cancer.	Azoxymethane	123-126	adhesion G protein-coupled receptor G1	Mus musculus	8-13
28915552-4	2017	Importantly, intestinal epithelial cell (IEC)-specific deletion of Dicer mice got more tumors after azoxymethane and dextran sulfate sodium (DSS) administration.	Azoxymethane	100-112	dicer 1, ribonuclease III	Homo sapiens	67-72
28410235-3	2017	In the current study, we utilized a genetic approach to investigate the effect of CysLT1R in the induced azoxymethane/dextran sulfate sodium (AOM/DSS) model of colitis-associated colon cancer.	Azoxymethane	142-145	cysteinyl leukotriene receptor 1	Mus musculus	82-89
28350804-6	2017	Utilizing a mouse model of colitis-related colon carcinoma induced by the carcinogen azoxymethane (AOM), followed by the inflammatory agent dextran sodium sulfate (DSS), we found that Sdc1 deficiency results in increased susceptibility to colitis-associated tumorigenesis.	Azoxymethane	85-97	syndecan 1	Mus musculus	184-188
28193514-12	2017	Colon tissues from MIR301A-knockout mice had increased epithelial barrier integrity and formed fewer tumors following administration of azoxymethane than control mice.	Azoxymethane	136-148	microRNA 301	Mus musculus	19-26
28031321-7	2017	Moreover, syndecan-2 expression was detected in azoxymethane/DSS-induced colon tumors.	Azoxymethane	48-60	syndecan 2	Mus musculus	10-20
28350804-6	2017	Utilizing a mouse model of colitis-related colon carcinoma induced by the carcinogen azoxymethane (AOM), followed by the inflammatory agent dextran sodium sulfate (DSS), we found that Sdc1 deficiency results in increased susceptibility to colitis-associated tumorigenesis.	Azoxymethane	99-102	syndecan 1	Mus musculus	184-188
28301579-3	2017	Several mouse models of CAC have been proposed, including chemical induction through exposure to dextran sulfate sodium (DSS) with the genotoxic agents azoxymethane (AOM), 1,2-dymethylhydrazine (DHM) or targeted genetic mutations.	Azoxymethane	152-164	recessive cataract	Mus musculus	24-27
28405523-3	2017	Lineage tracing in Hdc-CreERT2;R26-LSL-tdTomato mice revealed that in homeostasis, there is a strong bias by HDC+ myeloid cells toward the CD11b+Ly6Ghi granulocytic lineage, which was accelerated during azoxymethane/dextran sodium sulfate (AOM/DSS)-induced colonic carcinogenesis.	Azoxymethane	203-215	histidine decarboxylase	Mus musculus	109-112
28039905-0	2017	Ultraviolet A eye irradiation ameliorates colon carcinoma induced by azoxymethane and dextran sodium sulfate through beta-endorphin and methionine-enkephalin.	Azoxymethane	69-81	pro-opiomelanocortin-alpha	Mus musculus	117-131
27876571-19	2017	miR21a-/- mice had a later appearance of fecal blood and diarrhea after administration of azoxymethane and dextran sodium sulfate, and had longer survival times compared with control mice.	Azoxymethane	90-102	microRNA 21a	Mus musculus	0-6
27609772-6	2016	It is noteworthy that mice lacking nCDase treated with azoxymethane were protected from tumor formation.	Azoxymethane	55-67	N-acylsphingosine amidohydrolase 2	Mus musculus	35-41
28884622-2	2017	OBJECTIVE: To test whether 3-dimensional (3-D) noninvasive in vivo NIRF imaging can detect effects of epidermal growth factor receptor (EGFR) inhibitor on both polypoid and flat tumor load in azoxymethane (AOM)-induced colon tumors or tumors in ApcMin/+ mice.	Azoxymethane	192-204	epidermal growth factor receptor	Mus musculus	102-134
28884622-2	2017	OBJECTIVE: To test whether 3-dimensional (3-D) noninvasive in vivo NIRF imaging can detect effects of epidermal growth factor receptor (EGFR) inhibitor on both polypoid and flat tumor load in azoxymethane (AOM)-induced colon tumors or tumors in ApcMin/+ mice.	Azoxymethane	192-204	epidermal growth factor receptor	Mus musculus	136-140
27965594-0	2016	Lack of Adrenomedullin Results in Microbiota Changes and Aggravates Azoxymethane and Dextran Sulfate Sodium-Induced Colitis in Mice.	Azoxymethane	68-80	adrenomedullin	Mus musculus	8-22
27869219-7	2016	Finally, Spred2 KO mice developed significantly fewer tumors in response to azoxymethane plus DSS.	Azoxymethane	76-88	sprouty-related EVH1 domain containing 2	Mus musculus	9-15
27869785-7	2016	In the azoxymethane DSS model IL-6RDeltaIEC mice were not protected from inflammation-induced carcinogenesis but showed comparable tumor load to wild-type mice.	Azoxymethane	7-19	interleukin 6 receptor, alpha	Mus musculus	30-48
27562646-3	2016	Consistent with this, Tnik-deficient mice are resistant to azoxymethane-induced colon tumorigenesis, and Tnik(-/-)/Apc(min/+) mutant mice develop significantly fewer intestinal tumours.	Azoxymethane	59-71	TRAF2 and NCK interacting kinase	Mus musculus	22-26
25994220-6	2016	Following azoxymethane and dextran sulfate sodium intervention, miR-21-knockout mice showed reduced expression of proinflammatory and procarcinogenic cytokines (interleukin (IL) 6, IL-23, IL-17A and IL-21) and a decrease in the size and number of tumours compared with the control mouse group.	Azoxymethane	10-22	microRNA 21a	Mus musculus	64-70
26973250-8	2016	In addition, Olfm4 deletion significantly enhanced intestinal-crypt proliferation and inflammation induced by azoxymethane/dextran sodium sulfate.	Azoxymethane	110-122	olfactomedin 4	Mus musculus	13-18
27561705-14	2016	Soluble fractalkine infusion into the brain significantly reduced neurological decline in AOM-treated mice compared to saline-infused AOM-treated mice.	Azoxymethane	90-93	chemokine (C-X3-C motif) ligand 1	Mus musculus	8-19
27033117-0	2016	High-fat diets rich in saturated fat protect against azoxymethane/dextran sulfate sodium-induced colon cancer.	Azoxymethane	53-65	CD36 molecule	Mus musculus	5-8
27561705-15	2016	Infusion of soluble fractalkine into AOM-treated mice reduced liver damage, lessened microglia activation, and suppressed expression of chemokine ligand 2, interleukin-6, and tumor necrosis factor alpha compared to saline-infused mice.	Azoxymethane	37-40	chemokine (C-X3-C motif) ligand 1	Mus musculus	20-31
27561705-15	2016	Infusion of soluble fractalkine into AOM-treated mice reduced liver damage, lessened microglia activation, and suppressed expression of chemokine ligand 2, interleukin-6, and tumor necrosis factor alpha compared to saline-infused mice.	Azoxymethane	37-40	interleukin 6	Mus musculus	156-169
27561705-15	2016	Infusion of soluble fractalkine into AOM-treated mice reduced liver damage, lessened microglia activation, and suppressed expression of chemokine ligand 2, interleukin-6, and tumor necrosis factor alpha compared to saline-infused mice.	Azoxymethane	37-40	tumor necrosis factor	Mus musculus	175-202
27300306-4	2016	EXPERIMENTAL APPROACH: Production of IL-33 from intestinal tissue was studied in a murine cancer model induced by azoxymethane (AOM) and DSS in vivo and in cultures of IEC-6 epithelial cells.	Azoxymethane	114-126	interleukin 33	Mus musculus	37-42
27080303-4	2016	In this study, we found that transgenic mice overexpressing miR-17~92 specifically in epithelial cells of the small and large intestines exhibited decreased tumor size and tumor angiogenesis in azoxymethane and dextran sulfate sodium salt (AOM-DSS)-induced CRC model as compared to their littermates control.	Azoxymethane	194-206	Mir17 host gene (non-protein coding)	Mus musculus	60-69
27033117-0	2016	High-fat diets rich in saturated fat protect against azoxymethane/dextran sulfate sodium-induced colon cancer.	Azoxymethane	53-65	CD36 molecule	Mus musculus	33-36
27178440-8	2016	Olfm4 deletion in mice treated with azoxymethane/dextran sodium sulfate led to robust intestinal inflammation and intestinal crypt hyperplasia.	Azoxymethane	36-48	olfactomedin 4	Mus musculus	0-5
26300003-3	2016	In this study, we provide strong evidences of enhanced CRTC1 protein content and transcriptional activity in mouse models of sporadic (APC(min/+) mice) or colitis-associated colon cancer azoxymethane/dextran sulfate sodium (AOM/DSS-treated mice), and in human colorectal tumors specimens compared with adjacent normal mucosa.	Azoxymethane	187-199	CREB regulated transcription coactivator 1	Mus musculus	55-60
26983689-2	2016	However, Ptk6-null mice were also resistant to azoxymethane-induced colon tumorigenesis.	Azoxymethane	47-59	PTK6 protein tyrosine kinase 6	Mus musculus	9-13
26921636-4	2016	Here we show that the cholesterol promoted colon carcinogenesis in azoxymethane (AOM)-treated mice through activating the NLRP3 inflammasome.	Azoxymethane	67-79	NLR family, pyrin domain containing 3	Mus musculus	122-127
27086921-2	2016	Here, we report that the Mbd4 DNA glycosylase is protective in the azoxymethane/dextran sodium sulfate (AOM/DSS) mouse model of inflammation-driven colon cancer.	Azoxymethane	67-79	methyl-CpG binding domain protein 4	Mus musculus	25-29
27086921-2	2016	Here, we report that the Mbd4 DNA glycosylase is protective in the azoxymethane/dextran sodium sulfate (AOM/DSS) mouse model of inflammation-driven colon cancer.	Azoxymethane	104-107	methyl-CpG binding domain protein 4	Mus musculus	25-29
26921636-4	2016	Here we show that the cholesterol promoted colon carcinogenesis in azoxymethane (AOM)-treated mice through activating the NLRP3 inflammasome.	Azoxymethane	81-84	NLR family, pyrin domain containing 3	Mus musculus	122-127
26758693-0	2016	Imaging colon cancer development in mice: IL-6 deficiency prevents adenoma in azoxymethane-treated Smad3 knockouts.	Azoxymethane	78-90	SMAD family member 3	Mus musculus	99-104
26476372-3	2016	Here, under the hypothesis that Shh inhibitors can prevent CAC, mouse model was generated to develop CAC by azoxymethane (AOM)-initiated, dextran sodium sulfate-promoted carcinogenesis.	Azoxymethane	108-120	sonic hedgehog	Mus musculus	32-35
26476372-3	2016	Here, under the hypothesis that Shh inhibitors can prevent CAC, mouse model was generated to develop CAC by azoxymethane (AOM)-initiated, dextran sodium sulfate-promoted carcinogenesis.	Azoxymethane	122-125	sonic hedgehog	Mus musculus	32-35
26565021-9	2016	Despite worse colitis, p85(DeltaIEC) mice have reduced tumor burden after azoxymethane/dextran sodium sulfate treatment.	Azoxymethane	74-86	extracellular matrix protein 1	Mus musculus	23-26
25772234-5	2016	In line with increased IEC proliferation, DUSP10 KO mice developed more colon tumours with increased severity compared with WT mice in response to administration of DSS and azoxymethane (AOM).	Azoxymethane	173-185	dual specificity phosphatase 10	Mus musculus	42-48
26344057-14	2015	Mice that expressed SIGIRR(N86/102S) developed more inflammation and formed larger tumors after administration of azoxymethane and dextran sulfate sodium than control mice; colon tissues from these mutant mice expressed higher levels of the inflammatory cytokines IL-17A and IL-6 had activation of the transcription factors STAT3 and NFkappaB.	Azoxymethane	114-126	single immunoglobulin and toll-interleukin 1 receptor (TIR) domain	Mus musculus	20-26
27150094-5	2016	This review describes a common CAC model that utilizes the pro-carcinogenic compound azoxymethane (AOM) followed by dextran sulfate sodium (DSS) which induces the inflammatory insult.	Azoxymethane	85-97	recessive cataract	Mus musculus	31-34
27150094-5	2016	This review describes a common CAC model that utilizes the pro-carcinogenic compound azoxymethane (AOM) followed by dextran sulfate sodium (DSS) which induces the inflammatory insult.	Azoxymethane	99-102	recessive cataract	Mus musculus	31-34
26218141-5	2015	Starting at 10 weeks of age, wild-type or Il10 mice received 6 weekly intraperitoneal injections of azoxymethane (AOM) or phosphate-buffered saline (PBS) and were started on either a control or a curcumin-supplemented diet.	Azoxymethane	100-112	interleukin 10	Mus musculus	42-46
26431492-5	2015	Here we demonstrate that CHI3L1 (aka Brp39) knockout (KO) mice treated with azoxymethane (AOM)/dextran sulphate sodium (DSS) developed severe colitis but lesser incidence of CAC as compared to that in wild-type (WT) mice.	Azoxymethane	76-88	chitinase-like 1	Mus musculus	25-31
26431492-5	2015	Here we demonstrate that CHI3L1 (aka Brp39) knockout (KO) mice treated with azoxymethane (AOM)/dextran sulphate sodium (DSS) developed severe colitis but lesser incidence of CAC as compared to that in wild-type (WT) mice.	Azoxymethane	76-88	chitinase-like 1	Mus musculus	37-42
26431492-5	2015	Here we demonstrate that CHI3L1 (aka Brp39) knockout (KO) mice treated with azoxymethane (AOM)/dextran sulphate sodium (DSS) developed severe colitis but lesser incidence of CAC as compared to that in wild-type (WT) mice.	Azoxymethane	90-93	chitinase-like 1	Mus musculus	25-31
26431492-5	2015	Here we demonstrate that CHI3L1 (aka Brp39) knockout (KO) mice treated with azoxymethane (AOM)/dextran sulphate sodium (DSS) developed severe colitis but lesser incidence of CAC as compared to that in wild-type (WT) mice.	Azoxymethane	90-93	chitinase-like 1	Mus musculus	37-42
26398937-8	2015	We also detected diminished expression of membrane-associated alpha-catenin and increased intestinal permeability in gpA33(DeltaN-Bcat) mice in challenge conditions, providing a potential explanation for the observed mild chronic intestinal inflammation and increased susceptibility to azoxymethane and mutant Apc-dependent tumorigenesis.	Azoxymethane	286-298	glycoprotein A33 (transmembrane)	Mus musculus	117-122
26492449-3	2015	The aim of this study was to evaluate the effect of red grape juice on the expression of COX-2 and Ki-67 expression following colon carcinogenesis induced by azoxymethane (AOM).	Azoxymethane	158-170	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	89-94
26492449-3	2015	The aim of this study was to evaluate the effect of red grape juice on the expression of COX-2 and Ki-67 expression following colon carcinogenesis induced by azoxymethane (AOM).	Azoxymethane	172-175	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	89-94
26055138-9	2015	A miR214 chemical inhibitor blocked this circuit and reduced the severity of DSS-induced colitis in mice, as well as the number and size of tumors that formed in mice given azoxymethane and DSS.	Azoxymethane	173-185	microRNA 214	Mus musculus	2-8
26194191-4	2015	Interestingly, stromal deletion of Imp1 (Dermo1Cre;Imp1(LoxP/LoxP), or Imp1(DeltaMes)) in the azoxymethane/dextran sodium sulfate (AOM/DSS) model of colitis-associated cancer resulted in increased tumor numbers of larger size and more advanced histologic grade than controls.	Azoxymethane	94-106	imprintor 1	Mus musculus	35-39
26496833-8	2015	Atg5 (flox/flox)/K19 (CreERT) mice were first treated with azoxymethane/dextran sodium sulfate and then injected with tamoxifen to inhibit autophagy in CK19-positive epithelial cells.	Azoxymethane	59-71	autophagy related 5	Mus musculus	0-4
26440614-7	2015	The CHI3L1 positive colonic epithelial cells were highly proliferative and exhibited malignant transformation and expansion when exposed in vivo to azoxymethane, one of the well-known colonic carcinogens.	Azoxymethane	148-160	chitinase-like 1	Mus musculus	4-10
26439841-6	2015	In the context of colitis-associated tumorigenesis, both systemic EPRAP null mutation and EPRAP-deficiency in the bone marrow enhanced intestinal polyp formation induced by azoxymethane (AOM)/DSS treatment.	Azoxymethane	173-185	fem-1 homolog A	Homo sapiens	66-71
26439841-6	2015	In the context of colitis-associated tumorigenesis, both systemic EPRAP null mutation and EPRAP-deficiency in the bone marrow enhanced intestinal polyp formation induced by azoxymethane (AOM)/DSS treatment.	Azoxymethane	173-185	fem-1 homolog A	Homo sapiens	90-95
26319614-0	2015	Probiotic Pediococcus pentosaceus strain GS4 alleviates azoxymethane-induced toxicity in mice.	Azoxymethane	56-68	speedy/RINGO cell cycle regulator family, member A	Mus musculus	41-44
26374068-3	2015	To address this gap in knowledge we treated M1R-deficient and WT mice with azoxymethane (AOM) for six weeks and assessed liver injury responses 14 weeks after the last dose of AOM.	Azoxymethane	75-87	cholinergic receptor, muscarinic 1, CNS	Mus musculus	44-47
26122663-3	2015	In this study, we show that genetic and pharmacological targeting of PLD1 disrupts spontaneous and colitis-associated intestinal tumorigenesis in Apc(Min/+) and azoxymethane/dextran sodium sulfate mice models.	Azoxymethane	161-173	phospholipase D1	Mus musculus	69-73
26035389-9	2015	Gpa33(-/-) mice also exhibited rapid onset and reduced resolution of DSS-induced colitis, and a striking increase in the number of colitis-associated tumours produced by treatment with the colon-specific mutagen azoxymethane (AOM) followed by two cycles of DSS.	Azoxymethane	212-224	glycoprotein A33 (transmembrane)	Mus musculus	0-5
26109431-3	2015	We investigated cancer susceptibility associated with MUTYH inactivation in a mouse model of inflammation-dependent carcinogenesis induced by azoxymethane (AOM) and dextran sulphate (DSS).	Azoxymethane	142-154	mutY DNA glycosylase	Mus musculus	54-59
26109431-7	2015	The colon of untreated Mutyh-/- mice expressed higher basal levels of pro-inflammatory cytokines GM-CSF and IFNgamma, and treatment with AOM/DSS induced an early decrease in circulating CD4+ and CD8+ T lymphocytes and an increase in myeloid-derived suppressor cells (MDSCs).	Azoxymethane	137-140	mutY DNA glycosylase	Mus musculus	23-28
26196182-11	2015	CONCLUSIONS: These results indicated that GADD34 upregulated pro-inflammatory mediator production leading to a higher tumour burden following azoxymethane (AOM)/DSS treatment.	Azoxymethane	142-154	protein phosphatase 1, regulatory subunit 15A	Mus musculus	42-48
26107252-3	2015	We found that Aim2-deficient mice had greater tumor load than Asc-deficient mice in the azoxymethane/dextran sodium sulfate (AOM/DSS) model of colorectal cancer.	Azoxymethane	88-100	absent in melanoma 2	Mus musculus	14-18
26107252-3	2015	We found that Aim2-deficient mice had greater tumor load than Asc-deficient mice in the azoxymethane/dextran sodium sulfate (AOM/DSS) model of colorectal cancer.	Azoxymethane	125-128	absent in melanoma 2	Mus musculus	14-18
26463023-2	2015	METHODS: Mice with EGFR gene defects in macrophages (Egfr(fl/fl) LysM-Cre) and with EGFR gene expression in macrophages (LysM-Cre) (control group) were treated with azoxymethane (AOM) to establish colorectal tumor models.	Azoxymethane	165-177	epidermal growth factor receptor	Mus musculus	19-23
25804623-8	2015	To clarify its role in colon cancer in vivo, a mouse model exposed to the colon carcinogen azoxymethane and nongenotoxic carcinogen dextran sodium sulfate revealed that Spink3 (mouse homolog of SPINK1) is overexpressed in cancerous tissues.	Azoxymethane	91-103	serine peptidase inhibitor, Kazal type 1	Mus musculus	169-175
25713055-5	2015	We report that intestinally targeted transgenic 15-LOX-1 expression in mice inhibited azoxymethane- and dextran sodium sulfate-induced CAC, IL-6 expression, STAT3 phosphorylation, and IL-6/STAT3 downstream target (Notch3 and MUC1) expression.	Azoxymethane	86-98	arachidonate 15-lipoxygenase	Homo sapiens	48-56
25713055-5	2015	We report that intestinally targeted transgenic 15-LOX-1 expression in mice inhibited azoxymethane- and dextran sodium sulfate-induced CAC, IL-6 expression, STAT3 phosphorylation, and IL-6/STAT3 downstream target (Notch3 and MUC1) expression.	Azoxymethane	86-98	interleukin 6	Mus musculus	184-188
25713055-5	2015	We report that intestinally targeted transgenic 15-LOX-1 expression in mice inhibited azoxymethane- and dextran sodium sulfate-induced CAC, IL-6 expression, STAT3 phosphorylation, and IL-6/STAT3 downstream target (Notch3 and MUC1) expression.	Azoxymethane	86-98	signal transducer and activator of transcription 3	Mus musculus	189-194
25713055-5	2015	We report that intestinally targeted transgenic 15-LOX-1 expression in mice inhibited azoxymethane- and dextran sodium sulfate-induced CAC, IL-6 expression, STAT3 phosphorylation, and IL-6/STAT3 downstream target (Notch3 and MUC1) expression.	Azoxymethane	86-98	notch 3	Mus musculus	214-220
25713055-5	2015	We report that intestinally targeted transgenic 15-LOX-1 expression in mice inhibited azoxymethane- and dextran sodium sulfate-induced CAC, IL-6 expression, STAT3 phosphorylation, and IL-6/STAT3 downstream target (Notch3 and MUC1) expression.	Azoxymethane	86-98	mucin 1, transmembrane	Mus musculus	225-229
25712056-0	2015	Nrf2-dependent suppression of azoxymethane/dextran sulfate sodium-induced colon carcinogenesis by the cinnamon-derived dietary factor cinnamaldehyde.	Azoxymethane	30-42	nuclear factor, erythroid derived 2, like 2	Mus musculus	0-4
25521828-7	2015	The azoxymethane (AOM)-induced colon carcinogenesis model in Erbin(DeltaC) (/) (DeltaC) mice, with the PDZ domain of Erbin deleted, demonstrated that the PDZ domain of Erbin and its regulation of EGFR signalling are necessary for the tumourigenesis and tumour growth of CRC.	Azoxymethane	4-16	Erbb2 interacting protein	Mus musculus	61-66
25521828-7	2015	The azoxymethane (AOM)-induced colon carcinogenesis model in Erbin(DeltaC) (/) (DeltaC) mice, with the PDZ domain of Erbin deleted, demonstrated that the PDZ domain of Erbin and its regulation of EGFR signalling are necessary for the tumourigenesis and tumour growth of CRC.	Azoxymethane	4-16	Erbb2 interacting protein	Mus musculus	117-122
25521828-7	2015	The azoxymethane (AOM)-induced colon carcinogenesis model in Erbin(DeltaC) (/) (DeltaC) mice, with the PDZ domain of Erbin deleted, demonstrated that the PDZ domain of Erbin and its regulation of EGFR signalling are necessary for the tumourigenesis and tumour growth of CRC.	Azoxymethane	4-16	Erbb2 interacting protein	Mus musculus	117-122
25521828-7	2015	The azoxymethane (AOM)-induced colon carcinogenesis model in Erbin(DeltaC) (/) (DeltaC) mice, with the PDZ domain of Erbin deleted, demonstrated that the PDZ domain of Erbin and its regulation of EGFR signalling are necessary for the tumourigenesis and tumour growth of CRC.	Azoxymethane	4-16	epidermal growth factor receptor	Mus musculus	196-200
25521828-7	2015	The azoxymethane (AOM)-induced colon carcinogenesis model in Erbin(DeltaC) (/) (DeltaC) mice, with the PDZ domain of Erbin deleted, demonstrated that the PDZ domain of Erbin and its regulation of EGFR signalling are necessary for the tumourigenesis and tumour growth of CRC.	Azoxymethane	18-21	Erbb2 interacting protein	Mus musculus	61-66
25521828-7	2015	The azoxymethane (AOM)-induced colon carcinogenesis model in Erbin(DeltaC) (/) (DeltaC) mice, with the PDZ domain of Erbin deleted, demonstrated that the PDZ domain of Erbin and its regulation of EGFR signalling are necessary for the tumourigenesis and tumour growth of CRC.	Azoxymethane	18-21	Erbb2 interacting protein	Mus musculus	117-122
25521828-7	2015	The azoxymethane (AOM)-induced colon carcinogenesis model in Erbin(DeltaC) (/) (DeltaC) mice, with the PDZ domain of Erbin deleted, demonstrated that the PDZ domain of Erbin and its regulation of EGFR signalling are necessary for the tumourigenesis and tumour growth of CRC.	Azoxymethane	18-21	Erbb2 interacting protein	Mus musculus	117-122
25521828-7	2015	The azoxymethane (AOM)-induced colon carcinogenesis model in Erbin(DeltaC) (/) (DeltaC) mice, with the PDZ domain of Erbin deleted, demonstrated that the PDZ domain of Erbin and its regulation of EGFR signalling are necessary for the tumourigenesis and tumour growth of CRC.	Azoxymethane	18-21	epidermal growth factor receptor	Mus musculus	196-200
25263446-8	2015	Besides that, knockout of AIB1 in mice inhibited colon carcinogenesis induced by azoxymethane/dextran sodium sulfate treatment.	Azoxymethane	81-93	brain enriched myelin associated protein 1	Mus musculus	26-30
25909160-4	2015	In IL-32alpha-Tg mice, azoxymethane (AOM)-induced colon cancer incidence was decreased, whereas expression of TNFR1 and TNFR1-mediated apoptosis was increased.	Azoxymethane	37-40	interleukin 32	Homo sapiens	3-13
25803810-2	2015	Its up-regulation is also important for promotion of the stage of colorectal carcinogenesis in vivo in human NEU3 transgenic mice treated with azoxymethane for the induction of aberrant crypt foci in the colon mucosa, accompanied by enhanced phosphorylation of EGF receptor (EGFR).	Azoxymethane	143-155	neuraminidase 3	Homo sapiens	109-113
25881076-5	2015	METHODS: Wild-type mice and NPC1L1(-/-) (NPC1L1 knockout) mice were treated with azoxymethane (AOM)-dextran sodium sulfate (DSS) to induce colitis-associated colorectal tumorigenesis.	Azoxymethane	81-93	NPC1 like intracellular cholesterol transporter 1	Mus musculus	41-47
25909160-4	2015	In IL-32alpha-Tg mice, azoxymethane (AOM)-induced colon cancer incidence was decreased, whereas expression of TNFR1 and TNFR1-mediated apoptosis was increased.	Azoxymethane	23-35	interleukin 32	Homo sapiens	3-13
25740822-6	2015	Treatment with the carcinogen azoxymethane caused Sgo1(-/+) ME-CIN model mice to develop HCCs within 6 months, whereas control mice developed no HCC (P &lt; 0.003).	Azoxymethane	30-42	shugoshin 1	Mus musculus	50-54
25803810-2	2015	Its up-regulation is also important for promotion of the stage of colorectal carcinogenesis in vivo in human NEU3 transgenic mice treated with azoxymethane for the induction of aberrant crypt foci in the colon mucosa, accompanied by enhanced phosphorylation of EGF receptor (EGFR).	Azoxymethane	143-155	epidermal growth factor receptor	Mus musculus	261-273
25803810-2	2015	Its up-regulation is also important for promotion of the stage of colorectal carcinogenesis in vivo in human NEU3 transgenic mice treated with azoxymethane for the induction of aberrant crypt foci in the colon mucosa, accompanied by enhanced phosphorylation of EGF receptor (EGFR).	Azoxymethane	143-155	epidermal growth factor receptor	Mus musculus	275-279
25581824-3	2015	METHODS: TNF mice were treated with azoxymethane/dextran sulfate sodium to induce inflammation and tumorigenesis.	Azoxymethane	36-48	tumor necrosis factor	Mus musculus	9-12
25781343-4	2015	Arthur and colleagues identified a genotoxic island in Escherichia coli NC101 that appeared to be responsible for causing neoplastic lesions in inflammation-induced IL10-/- mice treated with azoxymethane.	Azoxymethane	191-203	interleukin 10	Mus musculus	165-169
25763529-0	2015	Strawberry phytochemicals inhibit azoxymethane/dextran sodium sulfate-induced colorectal carcinogenesis in Crj: CD-1 mice.	Azoxymethane	34-46	CD1 antigen complex	Mus musculus	112-116
25503930-3	2015	Murine knockout of 15-PGDH increases susceptibility to azoxymethane-induced colon tumors.	Azoxymethane	55-67	hydroxyprostaglandin dehydrogenase 15 (NAD)	Mus musculus	19-26
26137415-3	2015	Formation of Azoxymethane/Dextransulfate (AOM/DSS)-induced CRCs was strongly suppressed in STAT3Deltam mice.	Azoxymethane	13-25	signal transducer and activator of transcription 3	Mus musculus	91-96
26137415-3	2015	Formation of Azoxymethane/Dextransulfate (AOM/DSS)-induced CRCs was strongly suppressed in STAT3Deltam mice.	Azoxymethane	42-45	signal transducer and activator of transcription 3	Mus musculus	91-96